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ABSTRACT 
 
COMPUTATIONAL APPROACHES FOR UNDERSTANDING ONE-
CARBON METABOLISM IN CANCER 
 
 
Mahya Mehrmohamadi, Ph. D. 
Cornell University 2017 
 
 
 Cancer metabolism is an emerging research area in cancer biology and 
therapeutics. One of the major metabolic pathways known to play important roles in 
the pathogenesis of cancer is one-carbon (1-C) metabolism. 1-C metabolism integrates 
the status of many dietary nutrients as inputs, and in turn regulates a variety of cellular 
processes including de novo nucleotide synthesis, lipid metabolism, protein 
biosynthesis, redox metabolism, transsulfuration, and epigenetics. As the regulation of 
these cellular processes is critical to cells, the tuning of the activity of 1-C metabolism 
plays important roles in cancer. Previous studies have established implications of 
genetic and dietary perturbations of multiple components of 1-C metabolism in human 
cancers. However, the heterogeneity among cancer types and subtypes with respect to 
the usage and flux distribution of 1-C metabolism has not been systematically 
quantified. There remain great potentials in deciphering how 1-C metabolism plays 
different roles in different human cancers, especially since this metabolic pathway is 
targeted by a number of the existing antimetabolite chemotherapeutic agents.  
 In this dissertation, I quantitatively characterize various aspects of 1-C 
metabolism across human cancers. I first investigate the between-cancer-type variation 
in the usage of serine by 1-C metabolism using flux distribution analyses and find 
substantial heterogeneity. I also show that a common feature across cancers is 
correlated activation of nucleotide and redox metabolism. Next I assess the link 
between 1-C metabolism and DNA methylation using computational modeling and 
machine-learning. I find significant contribution from particular enzymes within 1-C 
metabolism— such as methionine adenosyltransferases— in explaining the within- 
cancer-type (inter-individual) variation in DNA methylation. My results provide 
evidence that misregulation of 1-C metabolism is at least in part responsible for 
disrupted DNA methylation profiles in tumors leading to epigenetic instability and 
higher malignancy. Given evidence for the role of 1-C metabolism and the methionine 
cycle in methylation dynamics, I next evaluate the potential for dietary intervention 
using the amino acid methionine. To this end, I model human serum methionine levels 
and quantify the contribution of various factors in determining the concentration of 
methionine. I discover that dietary factors could together explain nearly 30% of 
overall variation in methionine concentrations, and also provide evidence that the 
relationship between 1-C metabolism and methylation exists at physiological 
concentrations of methionine. Finally, I use a novel approach to identify gene 
expression markers of tumor response to 5-FU and Gemcitabine —two of the 
commonly used antimetabolite chemotherapies that target enzymes in 1-C 
metabolism. I discover that response to these agents is to a large degree determined by 
the metabolic state of tumors and the expression levels of specific target pathways of 
each of these agents. Together, my findings provide quantitative information about the 
heterogeneity among tumors with respect to the usage of 1-C metabolism, and 
delineate some of the ways this information can be translated into clinical decision- 
making.  
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CHAPTER 1: INTRODUCTION1 
1.1. Cancer metabolism 
 
Cancer cells alter the usage of their metabolic network by adjusting the flux 
distribution through the network to accommodate their special needs (Locasale, 2013). 
This phenomenon is known as “reprogramming” or “rewiring” of metabolism and is 
one of the recently appreciated hallmarks of cancer (Pavlova and Thompson, 2016) 
(Hanahan and Weinberg, 2011). Since cancerous cells differ from their normal 
counterparts with respect to various characteristics, major metabolic shifts are required 
to equip them with cellular components necessary for proliferation, biosynthesis, 
stress protection, and survival. The most well-known example of a cancer-specific 
metabolic program is the famous “Warburg effect” (Vander Heiden et al., 2009) that 
refers to aerobic glycolysis associated with increased glucose uptake and lactate 
secretion by cancer cells (Liberti and Locasale, 2016).  
Importantly, many metabolic pathways are readily manipulable through 
enzyme targeting or dietary intervention (Locasale, 2013). Thus, targeting cancer 
metabolism is an attractive route toward improving cancer therapeutics in more 
feasible and cost effective ways than most alternative drug development options. To 
this end, a deeper understanding of metabolic features that distinguish cancers from 
normal tissues as well as from other cancer types is needed. The increase in the 
availability of genomics data with the rapid reduction of costs associated with high-
																																								 																				
1 Some of the text in this section has been published in: Mehrmohamadi M, Locasale JW, 
Context-dependent utilization of serine in cancer. Molecular and Cellular Oncology, 2:4, 
e996418 (2015). 
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throughput sequencing has made quantitative analyses of tumor metabolism more 
feasible today than ever before.  These valuable technologies facilitate the study of 
tumor heterogeneity from molecular profiles of tumors.  
1.2 One-carbon metabolism in cancer 
 
One-carbon (1-C) metabolism is a metabolic pathway commonly implicated in 
cancer (Yang and Vousden, 2016) (Locasale, 2013). 1-C metabolism consists of the 
folate and the methionine cycles that work in concert to integrate nutrient status and 
availability into cellular metabolism (Figure 1.1). Many dietary factors provide inputs 
to 1-C metabolism, including folates, amino acids (serine, glycine, and methionine), 
betaine and vitamin B-12. Thus, the activity of 1-C network is dependent on the levels 
of these input metabolites, and this network can be thought of as a sensor of the 
availability of these nutrients (Locasale, 2013). 1-C metabolism in turn regulates the 
activity of many downstream pathways by producing metabolites that serve as inputs 
to those downstream pathways (Figure 1.1). Purine and pyrimidine nucleotide 
synthesis, protein biosynthesis, lipid synthesis, redox metabolism, transsulfuration, 
and methylation are all critical cellular processes where one or more of the input 
metabolites are generated through the activity of 1-C metabolism (Locasale, 2013).   
		 3	
 
Figure 1. 1— Schematic of the 1-C metabolic pathway.  
The Methionine cycle components are shown on the right and the folate cycle on the left. Input 
metabolites are drawn with blue arrows while the green arrows point to output processes. 
(Abbreviations: THF= tetrahydrofolate; m-THF= methyl-THF; me-THF= methylene-THF; 
SAM= S-adenosyl methionine; SAH= S-adenosyl homocysteine).  
 
One-carbon metabolism is highly implicated in cancer (Locasale, 2013). Since 
2009 when there was a surge of interest in studying 1-C metabolism in human stem 
cells as well as cancers (Labuschagne et al., 2014; Locasale et al., 2011; Maddocks et 
al., 2013; Nilsson et al., 2014; Possemato et al., 2011; Vazquez et al., 2011), numerous 
studies have provided molecular and epidemiological evidence showing alterations in 
components of this pathway can play important roles in pathogenesis of multiple 
human cancers (Locasale, 2013).  
1.2.1 Serine metabolism  
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Serine and glycine donate single carbon units and fuel the 1-C metabolic 
network. Through the action of the 1-C network, these nutrients support a wide variety 
of downstream cellular processes such as nucleotide synthesis, methylation 
metabolism, sulfur metabolism, polyamine metabolism, lipid and protein synthesis and 
redox balance (Locasale, 2013). In recent years, cancer researchers have reported 
multiple instances where serine uptake or its de novo synthesis was significantly 
elevated in tumor cells (Jain et al., 2012; Maddocks et al., 2013) (Locasale et al., 2011; 
Possemato et al., 2011). It was shown that several human cancer types including breast 
and colorectal cancers rely on serine for proliferation and survival and that 
hyperactivity in the network can drive the development of cancer. The utilization of 
serine for increasing de novo nucleotide synthesis rates in highly proliferative cells has 
been the main proposed explanation for this observation. However, serine and glycine 
feed into numerous other metabolic pathways as well. Recent studies have shown that 
serine is also used for production of NADPH and that the role of serine in the 
regulation of the redox status could be very critical to cell proliferation (Fan et al., 
2014; Lewis et al., 2014; Nilsson et al., 2014; Ye et al., 2014).  Intermediates in 1-C 
metabolism including folate, betaine, and cystathionine in the serum have all been 
linked to proliferation of cancer cells (Locasale, 2013). Together, evidence supports 
the importance of serine metabolism in many instances of human cancers (Yang and 
Vousden, 2016). 
1.2.2 The methionine cycle 
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Methylation is a key biochemical reaction and many molecules in cells 
undergo this modification. Misregulated methylation of proteins, nucleic acids, and 
metabolites contribute to many human conditions (Bergman and Cedar, 2013; Greer 
and Shi, 2012; Kraus et al., 2014).  When methylation occurs at histones and DNA 
that determine the epigenetic status in cells, it can affect gene expression programs 
(Barth and Imhof, 2010).  Previous studies provide evidence that compared to normal 
counterparts, cancer cells exhibit elevated disordered variation in their DNA 
methylation patterns (Timp and Feinberg, 2013).  This suggests a model of cancer as a 
dysregulated epigenome that provides tumor cells with epigenetic plasticity, acting in 
parallel with genetic instability to assure higher adaptive potential in cancer compared 
to normal cells.  Methylation levels can be altered due to dysregulated expression or 
activity of methyltransferase and demethylase enzymes in cancer (Chi et al., 2010; 
Dawson and Kouzarides, 2012).  It has also been long established that S-
adenosylmethionine (SAM) is the universal methyl substrate for these enzymes that 
transfer its methyl group to yield a methylated product, and is itself converted to S-
adenosylhomocysteine (SAH) (Finkelstein, 1990).  This provides a link between SAM 
production and the epigenetic status of cells (Gut and Verdin, 2013; Katada et al., 
2012; Teperino et al., 2010). A study from our research group provided direct 
evidence for the importance of the methionine cycle in regulating histone methylation 
in both healthy and cancerous tissues (Mentch et al., 2015). Together, previous studies 
have illustrated an important regulatory link between 1-C metabolism and cellular 
epigenetics suggesting great potential for metabolic manipulation of cellular gene 
expression dynamics.  
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1.2.3 Chemotherapies that target 1-C metabolism  
 
Many widely used chemotherapeutic agents that are approved by the U.S. Food 
and Drug Administration (FDA), usually classified as cytotoxic and non-specific, in 
fact target specific enzymes within 1-C metabolism (Locasale, 2013). A few of the 
well-known examples include the anti-folate Methotrexate which targets dihydrofolate 
reductase (DHFR), and nucleotide analogs 5-fluorouracil (5-FU) and Gemcitabine 
which interfere with nucleotide biosynthesis though inhibiting 1-C metabolic enzymes 
thymidylate synthetase (TYMS) and ribonucleotide reductase (RRM), respectively 
(Amelio et al., 2014). These agents can often be tolerated and can achieve remarkable 
responses in advanced stage cancers leading to complete remission in many cases.  
However, the clinical responses to these agents are heterogeneous with some patients 
exhibiting complete resistance. Thus, a better characterization of 1-C metabolism has 
great potential for improving and personalizing the administration of currently existing 
antimetabolite drugs. Results from previous analyses of the power of 1-C metabolic 
genes in predicting patient response to antimetabolites are largely controversial 
(Etienne-Grimaldi et al., 2010; Vazquez et al., 2013; Zhao et al., 2016). Despite 
numerous studies on cancer cell lines as well as cancer patients, the clinical 
administration of antimetabolite agents remains mainly non-specific (Audet-Walsh et 
al., 2016; Iorio et al., 2016; Ser et al., 2016). No metabolic biomarkers are currently 
used in practice for stratifying patients based on whether or not they are likely to 
benefit from these agents. With the increased availability of molecular data on human 
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tumors, there is considerable potential in computational assessment of tumor genomic 
data in search for determinants of response to antimetabolite chemotherapies.  
1.3 Metabolic heterogeneity in cancer 
 
Numerous molecular studies have illustrated roles for components of 1-C 
metabolism in cancer (Amelio et al., 2014), however, the heterogeneity among 
different human cancer types and subtypes with respect to the usage and 
reprogramming of 1-C metabolism remains largely uncharacterized. It is well 
established that cancer is a complex disease and populations of tumor cells show 
substantial levels of both inter- and intra-tumor variation that makes cancer treatment 
highly challenging (McGranahan and Swanton, 2015). In recent years, many studies 
have quantified aspects of tumor heterogeneity by capitalizing on the availability of 
genome-scale information on tumors leading to interesting clinical findings (Andor et 
al., 2016). Knowledge provided by studies of this kind can guide clinicians in making 
more informed decisions in cancer diagnostics, choice of therapy regimens, 
personalizing chemotherapies, and predicting cancer outcome. Similar to other 
molecular features of cancer, 1-C metabolism is also highly variable among different 
cancer types and subtypes (Hu et al., 2013). The heterogeneity of cancer cells with 
respect to 1-C metabolism has not been systematically characterized and quantified to 
date.  Important questions that remain to be further investigated include heterogeneity 
in the usage of different metabolic inputs, the contribution from 1-C metabolism in 
regulating methylation dynamics, and flux distribution through 1-C metabolism in 
different human cancers.  
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1.4 In this dissertation 
 
In this work, I focus on characterizing the variability among human cancers 
with respect to 1-C metabolism. More specifically, I quantify differences between 
individual tumors with respect to flux distribution, amino acid utilization, epigenetic 
regulation, drug response, and patient survival based on 1-C activity in tumors.  
In chapter two, I use gene expression profiles of hundreds of human tumors to 
predict serine flux distribution through 1-C metabolism and find considerable 
heterogeneity in the usage of serine across human cancers. Notably, I find that 
nucleotide synthesis and redox metabolism are co-regulated in cancers. I then assess 
the validity of these expression-based flux predictions using experimental serine 
tracing and metabolomics in cancer cell lines and confirm that fluxes can be predicted 
from pathway-level gene expression data.  
In chapter three, I study the link between 1-C metabolism and epigenetic 
regulation in cancer. I build computational models of DNA methylation using 
hundreds of molecular features across thousands of human tumors. I then quantify the 
contribution of 1-C metabolism in explaining variation in DNA methylation at 
multiple levels and find a surprisingly large contribution for 1-C metabolic genes—
especially for enzymes in the methionine cycle. Finally, I assess the clinical 
implications of these results by performing survival analysis and find that tumors in 
which DNA methylation is regulated by 1-C metabolism tend to be less malignant 
than tumors in which this link appears to be disrupted.  
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In chapter four, I study the variability of the amino-acid methionine —which 
provides the chemical link between 1-C metabolism and epigenetics— in the human 
serum using metabolomics and computational modeling. This study finds substantial 
variability among individuals in their serum methionine levels that could potentially 
impact methylation and epigenetics. Results confirm the validity of dietary 
interventions for manipulating methionine levels in the human serum. Finally, using 
predictive modeling and analysis of variance, I quantify the clinical, dietary, and 
physiological determinants of methionine levels in the serum. 
Lastly in chapter five, I investigate the extent of specificity in the action of 
antimetabolite chemotherapies that target 1-C metabolism, and introduce a framework 
for identifying gene expression markers of patient response to a number of these 
agents. I show that this approach is more powerful than individual gene expression 
markers in identifying responder and non-responder sub-groups of patients. I also find 
sets of metabolic pathways that proved valuable in stratifying patient subgroups with 
respect to response to 5-FU and Gemcitabine. Together, my results illustrate that 
antimetabolite agents act more specifically than previously appreciated, and there is 
great unexplored potential in further searching for biomarkers within the specific 
metabolic pathways that these agents target, using novel approaches such as the one 
applied to gene expressions in the current work.  
 Overall, this dissertation aims at systematic and quantitative analyses of major 
roles of 1-C metabolism in cancer, with a focus on heterogeneity among and within 
cancer types. Results provide valuable insights into clinical applicability of uncovering 
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such variability in cancer, and also introduce computational strategies for tackling 
such complex questions using high-dimensional genomic data.   
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CHAPTER 2: CHARACTERIZATION OF THE USAGE OF SERINE IN 
HUMAN CANCER2 
 
2.1 Abstract 
 
The serine, glycine, one carbon (SGOC) metabolic network is implicated in 
cancer pathogenesis but its general functions are unknown.  I carried out a 
computational reconstruction of the SGOC network and then characterized its 
expression across thousands of cancer tissues. Pathways including methylation and 
redox metabolism exhibited heterogeneous expression indicating a strong context 
dependency of their usage in tumors.  From an analysis of coexpression, simultaneous 
up- or down-regulation of nucleotide synthesis, NADPH and glutathione synthesis 
was found to be a common occurrence in all cancers.  Finally, my collaborators and I 
developed a method to trace the metabolic fate of serine using stable isotopes, high-
resolution mass spectrometry and a mathematical model.  Although the expression of 
single genes did not appear indicative of flux, the collective expression of several 
genes in a given pathway allowed for successful flux prediction. Together these 
findings identify expansive and heterogeneous functions for the SGOC metabolic 
network in human cancer.    
 
  
																																								 																				
2 Mehrmohamadi, M., Liu, X., Shestov, A.A. & Locasale, J.W. Characterization of the usage 
of the serine metabolic network in human cancer. Cell Reports 9, 1507-1519 (2014). 
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2.2 Introduction 
 
Serine and glycine are nutrients that fuel metabolic pathways including one 
carbon metabolism and sulfur metabolism.  This metabolic unit referred to as the 
serine, glycine and one carbon (SGOC) network provides an integration point in 
cellular metabolism that allows for cells to achieve diverse biological functions by 
converting serine and glycine into several metabolic outputs.  These outputs include 
building blocks for nucleotide, lipid, and protein synthesis.  They also include 
polyamine synthesis and work in the maintenance of redox status as determined by 
glutathione biosynthesis and NADPH production (Circu and Aw, 2010; Fan et al., 
2014; Lewis et al., 2014a, b; Murphy et al., 2011; Tedeschi et al., 2013).  The network 
also provides the substrates for methylation reactions that may have relevance to 
maintaining cellular epigenetic status (Gut and Verdin, 2013; Teperino et al., 2010).   
Recent work has pointed to new roles of the SGOC network in cancer 
pathogenesis (Chaneton et al., 2012; Jain et al., 2012; Ma et al., 2013; Maddocks et al., 
2013; Scuoppo et al., 2012; Zhang et al., 2012).  Whereas a subset of cancer cells 
increase de-novo serine biosynthesis (Locasale et al., 2011; Possemato et al., 2011), 
other cancers benefit from an increased serine and glycine uptake rate which allows 
them to metabolize these amino acids for their biosynthetic needs (Jain et al., 2012; 
Maddocks et al., 2013). Importantly, a recent study showed that serine but not glycine 
is critical in providing the one-carbon units required for biosynthesis of nucleotides in 
some cancer cells (Labuschagne et al., 2014).  A critical role for the mitochondrial 
folate pathway in rapidly proliferating cancer cells has also been recently elucidated 
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(Nilsson et al., 2014).  Furthermore, the importance of one-carbon metabolism in 
NADPH production through the oxidation of folates was demonstrated in cancer cells 
in a number of recent studies (Fan et al., 2014; Lewis et al., 2014a, b; Tedeschi et al., 
2013; Vazquez et al., 2011).  These studies showed that in addition to providing cells 
with nucleotide units, one-carbon metabolism has an important role in redox balance.  
Despite these advances, the general coordinated usages and different contexts in which 
serine and glycine flux contributes to different metabolic functions within and across 
cancer types and normal tissues remain largely unknown. 
Previous studies have analyzed the expression levels of metabolic pathways 
across a variety of cancer types using meta-analysis approaches (Hu et al., 2013; 
Nilsson et al., 2014; Tedeschi et al., 2013; Vazquez et al., 2013).  These studies have 
identified tumor-associated changes in gene expression across human metabolism 
including one carbon metabolism.  Whereas previous work has characterized 
expression of the SGOC network effectively as a pathway (Hu et al., 2013) and thus 
one or two data points or as a single series of individual genes (Nilsson et al., 2014), I 
attempted to carefully examine with higher resolution the coordination and context-
dependence of functionally distinct pathways of serine utilization.  I further investigate 
my computational findings experimentally by tracing the metabolic fate of serine and 
connecting these observations to expression patterns in the network.  Together I 
identify several novel context dependent utilizations of serine in human cancers. 
2.3 Results  
2.3.1 Reconstruction of the human SGOC network  
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I constructed a network that represents the metabolism of serine and glycine 
through one carbon metabolism and other immediate pathways including the 
transsulfuration pathway that together lead to defined cellular outputs.  This network, 
collectively referred to the SGOC network, was generated first by curating all human 
metabolic genes from the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
(Kanehisa and Goto, 2000).  Each gene involved in the KEGG-defined pathways, 
Glycine - Serine and Threonine metabolism, Cysteine and Methionine metabolism, 
and Folate biosynthesis was then selected.  I subsequently included genes involved in 
adjacent chemical reactions (edges) of the selected genes (nodes), and these nodes 
were then connected to the selected edges to allow for a contiguous sequence of 
chemical reactions.  Finally, I pruned this network to exclude each isolated node as 
well as enzymes that carry out chemical reactions involved in other pathways that I 
concluded to be non-specific to SGOC metabolism (Figure 2.1A, Methods).   
As a result, the network comprises of a set of sixty-four genes involving core 
metabolic reactions and enzymes and isoenzymes (Figure 2.1B).  Inputs of the 
network include de novo serine and glycine metabolism from glucose and the import 
of serine and glycine from the extracellular space.  Outputs of the network include 
purine, pyrimidine, lipid, glutathione, redox, taurine, and methylation metabolism. In 
practice the network is compartmentalized into cytosolic/nuclear and mitochondrial 
components that can be to some extent captured in these reaction sequences when 
metabolites are shuttled in and out of the mitochondria.   
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Figure 2.1 – Reconstruction of the functional SGOC network. 
A) The entirety of the human metabolic network is first considered using a list of all metabolic 
genes from KEGG.  A sub network involving all human serine, glycine, and one carbon 
metabolism related genes are considered obtained from KEGG.  Reaction paths from this 
network were used to create the final SGOC network.  
B) Schematic of resulting network and its decomposition into functional outputs 
(mitochondrial isoforms are shown in yellow).  
C) Expression patterns of SGOC network genes across four cancer types (ovarian, lung, 
colorectal, and breast) visualized with unsupervised hierarchical clustering (100 randomly 
chosen samples from each cancer type from TCGA were used). (See also Figure A1.S1). 
D) Cumulative density plots showing the distribution of SGOC expression levels across four 
tumor types and their corresponding normal tissues (GENT).  
 
2.3.2 Expression of the SGOC network in human cancers and normal tissues 
 
Having constructed this network, I then investigated its expression in several 
cancer types and corresponding normal tissues.  I considered both The Cancer 
Genome Atlas (TCGA) data across Breast, Ovarian, Lung, and Colorectal cancers 
(Cancer Genome Atlas, 2012a, b; Cancer Genome Atlas Research, 2011, 2012) and 
the Gene Expression in Normal and Tumor (GENT) database (Shin et al., 2011) that 
contains larger numbers of normal tissue samples.  I chose these cancer types for two 
reasons:  1) The three major types Breast, Lung, and Colon represent major sources of 
cancer mortality with ovarian cancer exhibiting expression patterns similar to that of 
subtypes of breast cancer observed to have enhanced requirements for serine 
metabolism (Locasale et al., 2011; Possemato et al., 2011) and 2)  Each of the three 
major cancer types considered has been shown to exhibit clinical response to 
chemotherapies that target nodes within the one carbon metabolism network (Chabner 
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and Longo, 2011).  For each tumor type, expression data are available across hundreds 
of tumors allowing for extensive statistical characterization.  
I first assessed the global expression of the genes in the network (Table 2.1).  
A hierarchical clustering across the cancer types revealed clustering based largely on 
tissue type (Figure 2.1C) consistent with the results of principal component analysis 
(PCA) (Figure A1.S1).  Major exceptions were observed for lung cancer samples as 
well as a subset of breast cancers that clustered with ovarian cancer in which case 
breast cancers lacking estrogen receptor exhibited expression patterns 
indistinguishable from those of ovarian cancer.  Next, an analysis of the global 
properties of the network was considered.  In ovarian, colon, and lung cancers, the 
overall distribution of SGOC network gene expression is shifted toward higher 
expression levels compared to the levels in corresponding normal tissue (Figure 2.1D).  
However, in breast cancer, the broad range of the cumulative density plot shows a 
higher variability in the expression levels of SGOC genes compared to normal breast 
tissue (Figure 2.1D).  In all cancer types, the distribution of SGOC expression differed 
between tumor and normal (Kolmogorov-Smirnov p-value < 2.2e-16).  I next 
considered the variability between and within cancer types to further identify cancer 
contexts of the network (Table 2.1).  These contexts include high expression in one 
tumor type relative to others, large variation in a single tumor type, high expression in 
tumor versus corresponding normal tissue, and high variability in tumor vs. normal.  
The resulting calculations revealed that genes predominantly involved in de novo 
nucleotide synthesis pathways are over-expressed in all four cancer types compared to 
the corresponding normal tissues (Table 2.1). This result is in agreement with the 
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previous literature emphasizing the importance of nucleotide biosynthesis to rapidly 
proliferating cells (Hu et al., 2012; Wilson et al., 2012).  Furthermore, consistent with 
a recent observation (Nilsson et al., 2014) I also observed methylenetetrahydrofolate 
dehydrogenase 2 (NADP+ dependent)  (MTHFD2) and serine 
hydroxymethyltransferase 2 (SHMT2), two mitochondrial enzymes that contribute to 
nucleotide metabolism, to be consistently overexpressed in cancers compared to 
corresponding normal tissues (Table 2.1).  Furthermore, when SGOC enzymes with a 
mitochondrial isoform were compared to their cytosolic isoforms, the mitochondrial 
isoforms showed stronger up-regulation in tumors (Fisher’s exact test p-value= 0.02), 
demonstrating the importance of mitochondrial compartment in tumor metabolism 
(Supplementary Methods).  However, some cancer type-specific expression patterns 
were also observed.  For instance, cystathionine beta-synthase (CBS), serine 
dehydratase (SDS), and glutathione synthetase (GSS) were expressed more highly in 
ovarian, breast, and colon tumors, respectively (Table 2.1). These three genes also 
showed very little within-cancer type variation in contrast to other genes.  Cross 
normal tissue comparisons revealed high expression of thymidylate synthetase 
(TYMS) in normal colon and alanine-glyoxylate aminotransferase (AGXT) in normal 
breast (Table 2.1).  Together, the variation in genes within tumor types and in 
comparison to corresponding normal tissues suggested many newly identified context 
dependent expression patterns in the network.  
Table 2.1. SGOC expression analysis across tissues. 
Name T-T 
highes
T-T 
significa
N-N 
highes
N-N 
significa
T-N overexp. T-N 
significa
		 21	
t nce t nce (pvalue<2.8e10-6)  nce 
ADC breast x+ breast x+ breast,ovary,lung  -,-,- 
AGXT1 colon x+ breast x+ Lung  - 
AGXT2(m
) 
breast x+ breast x+ colon,lung  -,- 
AHCY colon x colon x+ breast, colon, lung  -,+,+ 
AHCYL1 ovary x+ breast x+ ovary,colon  -,- 
ALAS1(m) colon x colon x+ Ovary  - 
ALAS2(m) lung x breast x+ Colon  - 
AMT(m) colon x ovary x  -   
ANPEP colon  + breast x+ Ovary  - 
ATIC colon x colon x+ breast, colon, lung  +,+,+ 
BHMT lung x breast x+ ovary,lung  -,- 
BHMT2 breast x+ breast x+ ovary,lung  -,- 
CBS ovary x+ ovary   breast, ovary,lung  -,-,+ 
CDO1 breast x+ breast x+ Colon  - 
CHDH(m) colon x breast x+ ovary,colon, lung  -,-,+ 
CP ovary x lung x ovary,lung  -,+ 
CSAD breast x+ breast x+  -   
CTH colon x+ colon x+ lung  + 
DHFR colon x colon x+ breast,ovary,colon
,lung 
 -,-,+,+ 
DLD(m) colon x+ colon x+ breast, ovary  -.- 
DMGDH(
m) 
ovary x+ breast x+ colon  - 
FPGS(m) ovary  + breast x+ ovary,colon,lung  -,+, - 
FTCD ovary x breast x+ ovary,colon,lung  -,-,- 
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GAD1 lung x breast x+ colon, lung  +,+ 
GAD2 lung   breast x+ colon,lung  -,- 
GAMT breast x breast x+ ovary,lung  -,+ 
GART colon x breast x breast,ovary,colon
,lung 
 -,+,+,+ 
GATM breast x+ breast x+ lung  - 
GCAT(m) lung   colon x breast,colon,lung  -,-,+ 
GGH colon x colon x+ breast,ovary,colon
,lung 
 -,-,-,+ 
GLDC(m) ovary x+ breast x+ ovary,lung  -,+ 
GNMT breast x breast    -   
GOT1 colon x+ colon x+ breast  - 
GOT2(m) colon x+ ovary x breast, colon, lung  -,-,- 
GPT colon x+ colon x+  -   
GPT2 ovary x breast x+ colon, lung  +,+ 
GSS colon x+ colon x+ breast, colon, lung  -,-,+ 
IL4I1 ovary x ovary   breast,ovary,colon
,lung 
 -,-,-,+ 
MAT1A ovary x+ ovary x colon  - 
MAT2A ovary x+ lung   ovary,colon  +,- 
MAT2B colon x breast x  -   
MPST(m) colon x colon x+ ovary  - 
MTFMT 
(m) 
colon x ovary    -   
MTHFD1 colon x+ breast x+ colon,lung  -,+ 
MTHFD1L 
(m) 
lung x ovary x colon, lung  +,+ 
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MTHFD2 
(m) 
lung x colon x breast,ovary,colon
,lung 
 +,+,+,+ 
MTHFR ovary x+ breast x  -   
MTHFS lung x ovary   breast, colon, lung  -,-,- 
MTR ovary x+ ovary x+ colon  + 
NAGS(m) colon x colon   lung  - 
PDPR(m) ovary x+ breast x+ ovary,colon  -,- 
PHGDH ovary x breast x+ colon,lung  +,- 
PIPOX ovary x ovary x+ colon, lung  +,+ 
PPCS lung   ovary x breast,lung  -,+ 
PPIG ovary x+ ovary x  -   
PSAT1 ovary x breast x+ ovary,colon,lung  +,+,+ 
PSPH lung   ovary x breast,colon  -,+ 
SARDH(m
) 
breast x+ breast x+ lung  - 
SDS breast x+ breast x+ breast,ovary,colon
,lung 
 -,-,-,+ 
SHMT1 ovary x breast x+ lung  - 
SHMT2(m
) 
ovary x+ ovary x breast,ovary, 
colon, lung 
 +,-,+,+ 
TYMS colon   colon x+ breast,colon, lung  +,-,+ 
ALDH1L1 colon x breast x+ ovary,colon,lung -,+,+ 
ALDH1L2
(m) 
NA NA breast x+ ovary,colon,lung +,+,+ 
The SGOC genes are listed in the first column with mitochondrial enzymes denoted by “m”. 
The second column shows the cancer type with the highest average expression across the 4 
cancers in the study. In the significance column, Mann-Whitney-Wilcoxon p-values smaller 
than the genome-level Bonferroni threshold (2.8 e 10-6) are denoted by an “x” and effect 
sizes larger than 0.3 are denoted by a “+” sign.  The fourth and fifth columns summarize 
similar analysis across the 4 normal tissue types.  The sixth and seventh columns summarize 
the results of tumor vs. normal comparisons.  In the sixth column, tissue types in which a 
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significant over-expression (p-value < 2.8 e 10-6) was detected in tumors are listed.  The fifth 
column specifies corresponding effect sizes by a “+” if larger than 0.3 and a “-” otherwise. 
“NA” denotes missing data. 
 
2.3.3 Serine utilization in the SGOC network  
 
After analyzing the expression of individual genes, I considered a functional 
analysis of the metabolic outputs of the network.  I first introduced a framework for 
understanding the different metabolic fates of serine.  I decomposed the SGOC 
network into pathways that utilize serine as an input and achieve a distinct biological 
function as an output (Methods).  I also added de novo serine biosynthesis as an 
additional pathway due to its implications in cancer (Locasale, 2013).  For each 
pathway, I analyzed the overall range of expression (Figure 2.2A).  It was observed 
that there is large within-cancer variability in expression of pathways especially across 
different breast tumors (Figure 2.2A).  Furthermore, mean pathway expression was 
similar across cancer types for some pathways such as methylation, whereas there 
were significant differences in other pathways including de novo serine biosynthesis 
(Figure 2.2A).  Next I developed an algorithm to evaluate the expression along each 
functional pathway (Figure 2.2B).  I first decomposed each biologically distinct unit of 
the network into a set of genes.  Then, the mean, median, and variation of expression 
for each gene comprising each pathway was computed and statistics were evaluated 
across the population of tumors (Methods).  Since the pathways varied in length, I 
normalized the obtained values to the number of genes contained in the pathway.   
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I considered this pathway analysis with several contrasts: expression levels in 
one cancer relative to other tumor types (T-T), variability in individual tumor (T) 
types, over-expression of the pathway in tumor relative to normal tissue (T-N), 
expression of the pathway in one normal tissue relative to other tissue types (N-N), 
variability in tumor vs. corresponding normal tissue (T-N CV).   Each of these 
analyses provides unique information relevant to cancer.  For example, high 
expression in the normal tissue may indicate a predisposition for the usage of the 
pathway in a particular cancer type.  Furthermore, a high variability indicates possible 
selective usage or overexpression in some context of tumorigenesis such as a 
particular mutational event.  Due to the tremendous heterogeneity within cancer types, 
a high within-cancer-type variability is important to know since it implies that 
different sub-populations of samples behave differentially with respect to a certain 
pathway, which suggests their potential use as biomarkers, provides further context for 
the use of the pathway, and finally possibly yields some predictive capacity for 
evaluating the response to agents that target the pathway.  A comparison across tumor 
tissues shows that several pathways are overexpressed relative to other tumors with 
breast and ovarian cancer exhibiting higher expression of specific components of 
sulfur related metabolism (Figure 2.2C).  High variability across each cancer type was 
observed throughout the network but the taurine, methylation, and NADPH pathways 
showed highest variability compared to other pathways (Figure 2.2D).  However, 
when comparing expression in normal and tumor tissue, only routes related to 
nucleotide and redox metabolism were commonly upregulated in tumors consistent 
with previous analysis of individual genes (Figure 2.2E).  Interestingly, in comparing 
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individual genes and pathways, I found that high relative levels of expression in one 
normal tissue did not necessarily overlap with high relative levels of expression in 
tumor tissue, indicating shifts in metabolism that are not directly due to differences in 
tissues of origin (Figure 2.2F).  This observation is also apparent in comparing the 
variability in expression of tumor and normal cancer types (Figure 2.2G).  Together 
these findings identify novel relationships of context dependent utilizations of the 
SGOC network.     
 
Figure 2.2 – Functional SGOC pathway utilization across four cancer types.   
A) Boxplots showing average pathway expression across four cancer types (TCGA).  
B) Summary for quantification of pathway utilization analyses.   
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C-G) Bar-plots denoting the collective expression of a given pathway route in the SGOC 
network.  C) Pathways hyper-utilized in a single cancer type relative to others.  D) Pathways 
exhibiting high variation within cancer types.  E) Pathways overexpressed in tumor versus 
corresponding normal tissue.  F) Pathways highly expressed in one normal tissue relative to 
others.  G) Pathways with high variation in tumor versus normal tissue.  
 
2.3.4 Co-occurrence of pathway utilization within the network   
 
Since in metabolism, the output of one branch of the network is coupled to the 
output of all other branches, I hypothesized that there could exist correlations in the 
expression of sets of genes leading to metabolic outputs of the network.  To 
investigate this possibility I computed a similarity matrix for each of the cancer types.  
Clustering of each similarity matrix revealed co-occurring expression patterns in each 
cancer type suggesting coordinated utilization of certain enzymes (Figure 2.3A).  A 
global analysis of these pairwise correlations revealed that the genes in the SGOC 
network were significantly more correlated compared to randomly chosen genes as 
revealed by quantile-quantile (QQ) plots (Figure 2.3B).  To my knowledge this is the 
first systematic demonstration of coordinated expression of metabolic genes in a 
defined metabolic pathway in humans.     
Next, I considered the normalized mean expression of the pathway routes that 
illustrated the extent of co-occurrence in the network (Figure 2.3C).  When assessed 
across the four cancer types, it was found that correlations emerge along specific 
pathways.  Surprisingly many of these correlations were largely found to be 
independent of tissue type demonstrating the existence unique metabolic programs 
within each tissue.  A core group of pathways involving glutathione, NADPH, and 
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nucleotide metabolism show correlations in their expression suggesting that a coupling 
between de novo nucleotide and redox metabolism occurs.  De novo serine synthesis 
correlated only with cysteine metabolism in some cancer types indicating that the 
condensation of serine and entry into the transsulfuration pathway is a major usage of 
serine in cells with enhanced de novo serine biosynthesis.  Also in all cancer types, 
taurine and nucleotide metabolism anti-correlated with one another indicating that 
their usages are orthogonal in cancers.    
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Figure 2. 3 – Correlations across reaction paths in the SGOC network.  
A) Hierarchically-clustered similarity matrices for four cancer types based on pairwise 
Spearman correlations.  Modularity in the co-expression network is apparent.  
B) Overview of algorithm that collapses co-regulated genes into reaction paths.   
C) Quantile-Quantile (QQ) plots showing p-values from gene-gene Spearman correlations in 
SGOC compared to randomly chosen pair of genes.  
D) Correlations in expression of transcripts in one pathway in reference to another.  Results 
are organized by hierarchical clustering using Spearman correlations in linkage similarities.      
  
2.3.5 Serine-derived metabolic fluxes in the network  
 
Gene expression in human clinical samples offers an unbiased assessment of 
the expression of the network in cancer.  However, gene expression does not 
necessarily determine metabolic phenotype that ultimately involves metabolic flux or 
the rate of flow of a metabolite from one point in the network to another.  To 
investigate the relationship of metabolic flux with gene expression, my collaborator 
Xiaojing Liu first developed a 13C-serine-based isotopomer mass spectrometry 
method.  We incubated a panel of cancer cells with 13C labeled serine and measured 
relative abundances of all mass isotopomers (molecules differing only in the extent of 
their isotopic composition) of each metabolite from the integrated ion current.  
Uniformly labeled serine (U-13C Serine) was present in the media in a 1:1 proportion 
with respect to unlabeled serine in the culture medium. Therefore, at steady state, as 
expected a substantial portion of the serine is unlabeled (Figure A1.S2).  Furthermore, 
M+1 glycine was detected near the natural abundance level in my experiment (Figure 
A1.S2), suggesting that glycine cleavage does not happen in reverse at a substantial 
rate.  The eight human colon cancer cell lines used in this study consistently showed 
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labeling of glutathione and de novo purine and thymidine synthesis intermediates, 
while little or no label was detected on methionine, pyruvate, alanine, betaine and 
taurine (Figure 2.4A, Figure A1.S3).  Since gene expression is available for each of 
these cell lines, I could then ask to what extent patterns in gene expression could be 
related to these isotope patterns.  Using abundance ratios of mass isotopomers as 
surrogates for the corresponding fluxes, I studied correlations between labeling 
patterns and gene expression first at the single gene level and then at the level of 
pathways (Figure 2.4B).  I asked whether gene expression within the network could 
predict isotope-labeling patterns. I found that the expression of individual genes in the 
SGOC network could to some extent predict fluxes (Figure 2.4C, FDR q-value 0.15).  
Notably, results from a Fisher’s exact test indicate that gene expression at the pathway 
level is more strongly correlated with fluxes compared to single gene level (Figure 
2.4D).  In summary, results from these data indicate that fluxes can be determined 
directly to an extent from gene expression in cancer cells but this requires knowledge 
of the overall expression of the pathway.  To my knowledge this is the first study in a 
mammalian system that provides an example of the relationship between gene 
expression and flux.  
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Figure 2.4 – Flux analysis of serine metabolism. 
A) Abundance ratios for labeled isotopomers detected across the 8 colon cancer cell lines.  
B) Overview of mass isotopomer analyses.  
C) Histogram of the number of significant correlations between labeled SGOC metabolite 
isotopomers and expression of randomly selected networks of genes. Expression of SGOC 
genes shows a higher than random correlation (FDR=0.15).  
D) Quantification of the frequency of significant correlations between SGOC expression and 
isotopomer labeling at single genes level vs. pathway level using a Fisher’s exact test. (See 
also Figure A1.S3). 
 
2.3.6 Interaction between de novo nucleotide and glutathione biosynthesis  
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Next, I further investigated the relationship between de novo nucleotide 
metabolism and glutathione synthesis (Figure 2.5A) in colorectal cancer cells.  I 
considered the relationship between thymidine and glutathione synthesis, purine and 
glutathione synthesis, and purine and thymidine synthesis (Figure 2.5A).  In each case, 
the expression levels of key genes in the pathway provided little information about the 
pathway relationships.  However, when comparing pathway expression, strong 
correlations in nucleotide synthesis and glutathione biosynthesis exist. This 
phenomenon was observed both in TCGA colon cancer data as well as in gene 
expression data from the 8 colon cancer cell lines in the study.  Experimentally, this 
result is also apparent in that labeling of de novo nucleotide synthesis intermediates 
was highly correlated with glutathione labeling (Figure 2.5A).  Together these findings 
point to a model where increases in nucleotide biosynthesis are coupled to flux to 
glutathione synthesis whereas other pathway routes from serine are not correlated with 
nucleotide synthesis (Figure 2.5B).  Since NADPH synthesis is coupled to the redox 
balance of oxidized and reduced glutathione, this finding provides a possible 
connection to a recent finding indicating that one carbon metabolism is a major source 
of NADPH in cells (Fan et al., 2014).  In fact, I also observe a positive association 
between NADPH synthesis with nucleotide and glutathione synthesis at the pathway 
level (Figure A1.S4).    
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Figure 2.5 – Interaction between de novo nucleotide and glutathione synthesis.    
A) Thymidine and Glutathione (top panel): The left plot shows weak association between 
TYMS and GSS expression (R-squared=0.094). The middle plot shows significantly higher 
correlation between thymidine and glutathione at average pathway expression level (R-
squared= 0.53). The right plot shows association between glutathione and thymine label 
ratios (R-squared=0.35).  Purine and Glutathione (middle panel): The left plot shows weak 
association between phosphoribosylglycinamide formyltransferase (GART) and GSS 
expression at single gene level (R-squared=0.01). The middle plot shows significantly higher 
correlation between purine and glutathione at average pathway expression level (R-
squared=0.54). The right plot shows association between glutathione and S-adenosyl-
methionine (SAM) - a purine intermediate- label ratios (R-squared=0.44).  Thymidine and 
Purine (bottom panel): The left plot shows weak association between TYMS and IMP 
cyclohydrolase (ATIC) expression at single gene level (R-squared=0.001). The middle plot 
shows significantly higher correlation between thymidine and purine at average pathway 
expression level (R-squared=0.55). The right plot shows association between inosine-
monophosphate (IMP) -a purine intermediate- and thymine label ratios (R-squared=0.67). 
B) Schematic showing serine metabolic outputs. Results from tracing serine in vitro suggest a 
simultaneous flux going through de novo nucleotide and glutathione synthesis pathways 
(green arrows) in the colon cancer cell lines studied when little or no flux goes from serine to 
the other pathways. NADPH labeling could not be assayed in my experimental set-up using 
13C-serine.  
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2.3.7 Mathematical modeling of pathway fluxes 
 
Although labeling patterns can sometimes be used to infer the extent of flux 
through a pathway, in general this is not always the case.  Fluxes ultimately are 
required to be estimated from network models that account for the isotope patterns.  I 
therefore considered a mathematical model of the Mass Isotopomer Distributions 
(MIDs) to estimate quantitative values for the fluxes in the network (Figure 2.6A, 
Methods).  A two-compartment Serine-Glycine-Methylenetetrahydrofolate (Ser-Gly-
meTHF) metabolic model was built by my collaborator Alexander Shestov, to fit 
experimental 13C MIDs of the SGOC network to determine metabolic fluxes involving 
transport and exchange relative to extracellular serine transport (Ftr-ser=1).  The 
metabolic network includes cellular serine production via de novo synthesis from 3-
phosphoglycerate, extracellular serine uptake, reversible cytosolic SHMT1 and 
mitochondrial SHMT2 fluxes, mitochondrial glycine cleavage system activity (GCS), 
serine, glycine and meTHF exchange fluxes between cytosolic and mitochondrial 
compartments, dilution fluxes for cytosolic and mitochondrial one-carbon metabolite 
pool represented in the model by meTHF, de novo and salvage formation pathways for 
adenine (Ade representing purines) and thymidine (Thd representing pyrimidines), and 
glutathione production flux. An analysis of the fluxes across each cell line provided 
direct quantitative information about the distribution of fluxes across the network 
(Figure 2.6B).  For example, flux from glycine to serine varied over an order of 
magnitude suggesting that some cells may be able to compensate for differences in 
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serine availability through the uptake of glycine.  Across the cell lines, results from the 
analyses of estimated fluxes show a positive relationship between the de novo purine 
and thymidine pathway fluxes consistent with the pathway expression levels across the 
8 cell lines (Figure 2.6C).  Furthermore, using estimated flux through SHMT1 as a 
surrogate for glutathione production flux, a positive relationship is detected between 
glutathione and thymidine synthesis both at the flux level as well as the pathway 
expression level (Figure 2.6D). Similarly, purine biosynthesis shows a positive 
association with glutathione production (Figure 2.6E). Together these findings both 
identify the heterogeneity of pathway fluxes across the network in a set of cell lines 
and provide confirmation of correlations that exist in the utilization of serine for 
specific metabolic functions.    
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Figure 2.6 – Mathematical modeling estimates fluxes in purine and pyrimidine synthesis 
pathways. 
A) Schematic of the model that was used for flux estimation.  Serine, glycine, and formate are 
shuttled in and out of the mitochondria whereas folate is not.  Plots show mass isotopomer 
distributions (MID) for metabolites that were detected experimentally. Fluxes that were 
estimated are labeled by green rectangles.  
B) Barplots of estimated fluxes with respect to the serine transport flux (Ftr-ser=1) across the 
8 cell lines. (Fshmt1+: forward flux through SHMT1; Fshmt1-: reverse flux through SHMT1; 
Ftr-gly: Glycine transport flux; Fx-ser+: serine exchange flux; Fphgdh: de novo serine 
synthesis flux; Fshmt2+: forward flux through SHMT2; Fx-methf+: meTHF exchange flux 
through formate; Fthd-dn: de novo thymidine synthesis flux; Fade-dn: de novo adenine 
synthesis flux) 
C) Purine and thymidine pathways are correlated. Estimated fluxes for de novo thymidine and 
adenine synthesis are positively associated (R-squared=0.14) (left). Expression of the purine 
pathway is positively correlated with that of the de novo thymidine pathway (R-squared=0.4) 
across the 8 colon cancer cell lines (right). 
D) Glutathione and thymidine pathways are correlated. Estimated fluxes for de novo 
thymidine and glutathione synthesis (SHMT1+) are positively associated (R-squared=0.39) 
(left). Expression of the glutathione pathway is positively correlated with that of the de novo 
thymidine pathway (R-squared=0.7) across the 8 colon cancer cell lines (right). 
E) Glutathione and purine pathway correlations. Estimated fluxes for de novo adenine and 
glutathione synthesis (SHMT1+) are positively associated (R-squared=0.42) (left). Expression 
of the glutathione pathway is positively correlated with that of the de novo purine pathway (R-
squared=0.28) across the 8 colon cancer cell lines (right). 
 
2.4 Discussion 
 
My findings present the first comprehensive systems-level analysis of the 
expressions patterns, metabolic fluxes, and interrelationships of serine metabolizing 
pathways in numerous cancer contexts and together delineate the likely roles of the 
SGOC network in several cancer types.  While there is no general global 
overexpression of the entire network in cancer as found in other pathways such as 
glycolysis, the expression of the network differs in more complex ways.  
Heterogeneity is strikingly apparent with for example breast cancers showing both 
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overall under- and over- expression of multiple pathway components.  Components 
contributing to nucleotide synthesis are commonly upregulated as previously reported 
(Hu et al., 2013; Jain et al., 2012), but other pathways exhibit no general features of 
over- and under- expression across cancer types.  In normal tissues, many of these 
components are constituently expressed with variability suggesting that the usage of a 
particular component in the normal tissue may confer predisposition of its usage in 
cancer.   
  When considering co-expression of the network, strong correlations in 
individual genes and expression of the pathways were observed.  The most common 
co-existence was the expression of genes contributing to nucleotide metabolism, 
glutathione and NADPH synthesis.  This was also observed in direct measurements of 
pathway fluxes for glutathione and nucleotides.  Since glutathione is the essential 
component of cellular redox maintenance, concomitant synthesis of glutathione and 
nucleotides likely provides a redox environment necessary for nucleotide synthesis 
and repair.  In fact, several studies in plants have demonstrated that redox regulation 
by glutathione has an important role during nucleotide synthesis and cell division 
(Belmonte et al., 2003; Belmonte et al., 2005; Stasolla, 2010).  By performing co-
expression analyses on the serine pathways, I provided new insights into the biology 
of the SGOC network in cancer.  In fact, my finding that glutathione synthesis is 
associated with nucleotide synthesis appears novel in the context of human cancer, and 
could suggest that cancer cells utilize a redox balance mechanism in parallel to the up-
regulation of biosynthetic pathways.  
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Gene expression measurements are typically thought to not be useful 
surrogates in cells for flux measurements that are the ultimate phenotypes of interest in 
studying metabolism.  However, I show that pathway-level gene expression to a large 
extent in the SGOC network can be used as a predictor of experimentally measured 
fluxes.  This is a very important finding in general given the wealth of publically 
available gene expression data, and the technical limitations associated with 
performing large-scale metabolomics analyses on human tumor samples.  Therefore 
this work hopefully provides motivation for further comparative analysis of gene 
expression and flux distributions in biological samples.     
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2.5 Methods  
2.5.1 Cell culture and metabolite extraction  
 
Colon cancer cells (SW620, SW480, HCT8, HT29, HCT116, NCI-H508, 
SW48, and SW948) were cultured as previously described (Liu et al., 2014).  For 13C-
serine tracing experiments, cells were seeded in 6-well plate at a density of 2×105 to 
5×105 cells per well. After overnight incubation in 37 °C with 5% CO2, full growth 
media were removed, and cells were washed with 2 ml PBS before the addition of 
RPMI media supplemented with 10% dialyzed and heat inactivated FBS, 100 U/ml 
penicillin, 100 mg/ml streptomycin and 13C-U-serine (3 mg/100 ml 
medium, Cambridge Isotope Laboratory) such that in the final medium, 50% of serine 
is 13C labeled.  After a 24 hour incubation, the cells were harvested as previously 
described (Liu et al., 2014). 
2.5.2 Mass spectrometry and Liquid chromatography   
 
The qExactive Mass Spectrometer (QE-MS) coupled to liquid chromatography 
(Ultimate 3000 UHPLC) was used for metabolite separation and detection as 
previously described (Liu et al., 2014).  Raw data collected from LC-Q Exactive MS 
was processed with Sieve 2.0 (Thermo Scientific).  Relevant instrument parameters 
are contained in a previous work (Liu et al., 2014).  
2.5.3 Network construction and gene expression analyses 
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The network reconstruction was carried out using the Cytoscape plugin – 
Metscape (Gao et al., 2010).  The SGOC network was generated first by curating all 
human metabolic genes from the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
(Kanehisa and Goto, 2000).  All genes involved in the KEGG-defined pathways 
Glycine, Serine and Threonine metabolism, Cysteine and Methionine metabolism, and 
Folate biosynthesis were selected.  I subsequently included genes involved in adjacent 
chemical reactions (edges) of the selected genes (nodes), and these nodes were then 
connected to the selected edges to allow for a contiguous sequence of chemical 
reactions.  Finally, I manually excluded all genes that involve non pathway-specific 
chemical reactions that thus take part in many metabolic pathways implying that their 
function need not be confined to 1-C metabolism (reactions including: ATP-
dependent; tRNA synthesis; Methylation; Co-A; CO2 and NH3; aldehyde 
dehydrogenases; pyruvate metabolism) (see Table S2 for the complete list of genes 
excluded).   
Gene expression across human tumors was analyzed using level 3 TCGA (The 
Cancer Genome Atlas) mRNA data (Cancer Genome Atlas, 2012a, b; Cancer Genome 
Atlas Research, 2011, 2012).  Data from AgilentG4502A microarray chips were 
collected for all TCGA breast (BRCA), ovarian (OV), colon (COAD), and lung 
(LUSC, LUAD) samples corresponding to four cancer types.  Level 3 data contain 
combined probe signals for each gene and samples were LOESS normalized using a 
reference RNA sample (cy5/cy3)(Yang et al., 2002), therefore, poor probe binding 
was accounted for by reporting the ratio mRNA from sample to that of the standard.  
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Mean and median expression levels were calculated for each of the 64 genes in the 
SGOC network across each cancer type.   
For evaluating high expression of one cancer type relative to other cancer 
types, I considered the following.  For each gene, the cancer type that had the highest 
median expression was grouped (“high expression”) and all samples from the other 
three cancer types were pooled into one group (“low expression”).  The Mann-
Whitney Wilcoxon (Wilcoxon) test was then performed to compare gene expression 
between the “high expression” vs. “low expression” groups.  The Bonferroni method 
for multiple hypothesis correction was then applied to determine the significant p-
values.  Effect sizes for the Wilcoxon test are calculated as r=Z/sqrt(N) where N is the 
total number of samples and Z is the Z-score for the Wilcoxon test.  Genes with a 
significant p-value but a small effect size (r < 0.3) were also considered insignificant.  
The result of this analysis is a set of genes highly expressed in one cancer type.    
For tumor vs. normal comparisons, Affymetrix U133Plus2 expression data 
from the GENT (Gene Expression across Normal and Tumor tissues) dataset were 
used for breast, ovarian, colon, and lung cancer as well as normal tissue samples.  The 
data were preprocessed using the MAS5 algorithm and then normalized to a target 
density of 500 to correct for batch effects according to GENT specifications (Shin et 
al., 2011).  Each cancer type was compared to its corresponding normal tissue using 
the same statistical approach (Wilcoxon test with Bonferroni and effect size 
corrections).  Comparisons of expression in one normal tissue type relative to other 
normal tissue types were conducted on these data using the same statistical criterion.      
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For an analysis of variability in expression, the coefficient of variation (CV) 
was calculated for each gene across each tissue type.  CV comparisons for each case 
were carried out using the same criteria starting with the Wilcoxon test.    
2.5.4 Pathway definitions and analysis 
 
I considered the amino acid serine as the input source of one-carbon units to 
the SGOC network and decomposed the network into biochemical pathways that 
consume serine in different reactions and result in a distinct biological output.  The 
enzymes in each of the pathways from serine metabolism are as follows 
(mitochondrial isoforms are denoted by “m”): 
Methylation: SHMT1/SHMT2 (m) – MTHFR- MTR/BHMT/BHMT2- 
MAT1A/MAT2A/MAT2B 
Thymidine: SHMT1/SHMT2(m)  – AMT(m) -TYMS- DHFR 
Purine: SHMT1/SHMT2(m) - MTHFD1/MTHFD2(m) /MTHFD1L(m) - ATIC/GART 
NADPH: SHMT1/SHMT2(m) - MTHFD1/MTHFD2(m) /MTHFD1L(m) - 
ALDH1L1/ALDH1L2(m) 
Alanine: AGXT1/AGXT2(m) 
Glutathione: SHMT1/SHMT2(m)  - GSS 
Cysteine: CBS- CTH 
Taurine: CBS- CTH- CDO1- CSAD 
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Betaine/Choline: SHMT1/SHMT2(m) - CHDH(m) 
Pyruvate: SDS 
To compare these pathways in reference to the statistical analysis that I 
conducted for each gene, I considered an overall pathway score (frequency of 
occurrences).  For each pathway, the number of significant genes, normalized to the 
number of genes in that pathway, was computed for each of the statistical analyses that 
I performed.  Results are reported in Figure 2.2.      
For the analysis of network covariance, similarity matrices were constructed 
based on pairwise Spearman correlations between expression levels of the 64 SGOC 
metabolic genes across each one of the four cancer types (Lung, Breast, Colon, and 
Ovarian) in the study.  In order to visualize these correlations in the context of serine-
fate pathways, average pathway expression levels were measured for all tumor 
samples in study, and similarity matrices were made based on Spearman correlations 
between average pathway expressions separately in each cancer type.  All clustering 
calculations were carried out using the Gene-E package (Broad Institute 
www.broadinstitute.org/cancer/software/GENE-E/).  
For comparison of pairwise correlations between expression levels of SGOC 
genes to that expected by chance, I used a randomization method.  I randomly picked 
64 genes from the genome and calculated pairwise correlations of those genes and 
repeated this for 100 iterations.  Finally, I used the average of sorted p-values from the 
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100 iterations and plotted the results against the sorted p-values from SGOC pairwise 
correlations separately for each cancer type (quantile-quantile plots).  
Finally, mRNA expression data for the 8 colon cancer cell lines in study were 
obtained from Broad Institute Cancer Cell Line Encyclopedia (Barretina et al., 2012) 
and similar SGOC pathway expression analyses were performed on the data for 
comparisons with isotope labeling and flux data.  Correlation between expression 
levels of SGOC genes with label ratios in Serine, Glycine, Thymidine, Glutathione, 
and IMP (representing purines) were calculated across the eight cell lines. As a 
control, label ratios were also correlated with expression of same-size sets of genes 
randomly picked from the genome. A histogram of all significant p-values 
(p<0.05) was generated from the results of the 500 simulations.  Furthermore, gene 
expression at the pathway level (average across pathways shown) was also correlated 
with detected isotope enrichments. Single-genes and pathways were associated with 
fluxes by plotting the percent of significant correlations (p-value< 0.05) between gene 
expression and label ratios for each case. All calculations were carried out using R. 
(http://www.R-project.org/) 
2.5.5  13C Mass-isotopomer distribution model  
 
A two-compartment (mitochondria and cytosol) Serine-Glycine-
Methylenetetrahydrofolate (Ser-Gly-meTHF) flux model was used to fit experimental 
13C mass isotopomer distributions (MIDs) of the SGOC associated metabolites to 
determine intercellular metabolic fluxes, transport and exchange fluxes relative to 
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extracellular serine transport flux.  The model was formalized using two types of mass 
balance equations: 1) mass balance for total metabolite concentration; and 2) 13C mass-
isotopomer mass balance for labeled metabolites based on the network depicted in 
Figure 2.6A and corresponding atom distribution matrices.  MID equations were 
derived in the similar manner as equations for bonded cumulative isotopomers as 
described previously (Shestov et al., 2012). In terms of the ordinary differential 
equations, the model describes the rates of loss and creation of particular labeled and 
unlabeled metabolite that forms after incubation of labeled serine in extracellular 
media. Those equations are based on the flux balance of metabolites and take the 
general form (e.g. for parallel unimolecular reactions): 
𝑴 𝒅𝝁 𝒊𝒅𝒕 = 𝑭𝒋𝝈𝒋(𝒊)𝒋 − 𝑭𝒌𝒌 𝝁 𝒊  
where metabolite M is downstream of another metabolites Sj. The total outflux ∑Fk 
balances total influx ∑Fj. [M] represents the total pool size of metabolite M, while  μ(i) 
and σj(i) represent the I mass-isotopomer fraction of metabolite M (M+I mass-
isotopomer) and metabolite Sj (S+I mass-isotopomer), respectively.  The number of 
labeled C atoms in M molecule, I, changes between 0 and N, where N is the total 
number of C atoms in metabolites.  At steady state the left term of equation (1) is 
equal to zero resulting in a set of algebraic equations.  For labeled [U-13C] serine 
experiments in RPMI medium, the fitted experimental steady state mass-isotopomers 
(combined cytosolic and mitochondrial) were four isotopomer forms of serine, three 
forms of glycine, four forms of glutathione which serves as a readout for cytosolic 
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glycine patterns, three forms of thymidine, and six isotopomer forms of adenine 
together making a total of 20 steady state mass-isotopomers.  Thymidine and adenine 
isotopomers reflect pyrimidine and purine metabolism, respectively.  Eleven fluxes 
were determined relative to serine transport flux, which are represented in Table 
A1.S1: de novo serine synthesis, two unidirectional rates for reversible cytosolic and 
mitochondrial SHMT fluxes, unidirectional glycine uptake flux, inter-compartmental 
serine, glycine, and one-carbon pool (meTHF) exchange fluxes, glycine cleavage 
system (GCS) activity, mitochondrial dilution flux for meTHF due to dimethylglycine 
and sarcosine contribution.  Also the fraction of the de novo thymidine and adenine 
production along with salvage contribution was calculated. For each metabolite MIDs, 
13C natural abundance of 13C isotope (1.08%) was taken into account.  There was no 
need to correct for 15N natural abundance (0.38%) due to the mass resolution used 
(70,000) that is able to separate 13C and 15N for the molecules considered. Solving a 
system of non-linear differential equations in terms of whole/fragmented mass-
isotopomers, with the Runge-Kutta 4th order procedure (Matlab, Natick, MA), yields 
time courses for all possible 13C mass-isotopomers (e.g. serine and glycine).  A 
quadratic cost function was used to quantify differences between measurements and 
estimated results for labeled steady state data and to select the corresponding vector of 
fluxes that minimizes the cost function in 13C serine experiments using a simplex 
algorithm. Mean-square convergence was confirmed by verifying that goodness-of-fit 
values were close to expected theoretical values.  To overcome potential local minima, 
we used several sets of initial random fluxes.   
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We estimated errors for the obtained values using a Monte Carlo simulation 
method as previously described (Shestov et al., 2007). Initial values for all parameters 
were chosen close to the HCT116 cell line fluxes as a reference cell line.  13C mass-
isotopomer values for Ser, Gly, GSH, Thd and Ade were then generated by solving 
differential equations describing the model with initial value of fluxes.  For each 
Monte-Carlo run, random Gaussian noise with mean zero and standard deviation σ = 
0.01 was added to the steady-state of these 13C mass-isotopomers.  Finally, the MIDs 
for each metabolite were computed and used for fitting with the SGOC metabolic 
model to obtain the values of relative metabolic fluxes.  This procedure was repeated 
500 times to obtain histograms for each parameter.  Standard deviations are reported 
in Table A1.S1.  
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CHAPTER 3: CONTRIBUTION OF ONE-CARBON METABOLISM TO 
DNA METHYLATION3 
 
3.1 Abstract 
 
Altered DNA methylation is common in cancer and often considered an early 
event in tumorigenesis. However, the sources of heterogeneity of DNA methylation 
among tumors remain poorly defined. Here, I capitalize on the availability of multi-
platform data on thousands of human tumors to build integrative models of DNA 
methylation. I quantify the contribution of clinical and molecular factors in explaining 
within-cancer variability in DNA methylation. I show that a set of metabolic genes 
involved in the methionine cycle is predictive of several features of DNA methylation 
in tumors including the methylation of cancer genes. Finally, I demonstrate that 
patients whose DNA methylation can be predicted from the methionine cycle 
exhibited improved survival over cases where this regulation is disrupted. This study 
represents a comprehensive analysis of the determinants of methylation and 
demonstrates the surprisingly large association between metabolism and DNA 
methylation variation. Together, my results illustrate links between tumor metabolism 
and epigenetics and outline future clinical implications.    
  
																																								 																				
3 Mehrmohamadi, M., Mentch K.L., Clark A.G.,  Locasale, J.W. Integrative modeling of 
tumor DNA methylation quantifies the contribution of metabolism. Nature Communications, 
(2016). 
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3.2 Introduction 
 
DNA methylation is a major epigenetic mechanism that determines cellular 
outcome by regulating gene expression and chromatin organization(Jones, 2012) in a 
fashion more dynamic than previously appreciated (Schubeler, 2015).  Altered DNA 
methylation is frequently observed in cancers compared to corresponding normal cells 
(Hansen et al., 2011; Mack et al., 2014; Timp and Feinberg, 2013).  For example, 
global DNA hypomethylation (Ehrlich and Lacey, 2013) and tumor suppressor 
silencing by DNA hypermethylation are two of the most well characterized cancer 
associated alterations common across many human malignancies (Berman et al., 2012) 
.  In addition to hypo- and hyper-methylation, cancer cells exhibit increased variability 
in DNA methylation across large portions of the genome compared to their 
corresponding normal tissues (Gaidatzis et al., 2014; Landau et al., 2014).  Previous 
studies have shown that, for several cancer types, variation in methylation levels 
among tumor samples is significantly higher than normal samples of the same tissue of 
origin (Hansen et al., 2011; Landau et al., 2014), possibly indicating that deregulated 
epigenetics provides tumor cells with potential adaptive advantages (Timp and 
Feinberg, 2013).  While inter-tissue variability in DNA methylation is mainly 
explained by differentiation and tissue-specific regulatory mechanisms (Lokk et al., 
2014; Ziller et al., 2013), very little is known about the functions and determinants of 
the high inter-individual variation among tumors of the same tissue type.  Notably, a 
recent twin study on the determinants of inter-individual variability in DNA 
methylation reported that genetic difference among individuals account for only 20% 
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of total variance with the remaining variance explained by environmental and 
stochastic factors that are yet to be identified(van Dongen et al., 2016).  
The source of the methyl group for methylation is S-adenosylmethionine 
(SAM) which is generated from the methionine (met) cycle and is coupled to serine, 
glycine, one -carbon (SGOC) metabolism (Locasale, 2013).  A large body of evidence 
indicates numerous roles for one-carbon metabolism in proliferation and survival of 
tumor cells through its roles in biosynthesis and redox metabolism (Gut and Verdin, 
2013; Kaelin and McKnight, 2013; Locasale, 2013; Sahar and Sassone-Corsi, 2009).  
The met cycle also mediates histone and DNA methylation in physiological conditions 
and provides a link between intermediary metabolism and epigenetics (Anderson et 
al., 2012; Mentch et al., 2015; Pfalzer et al., 2014).  Although the network contributes 
methyl units to DNA, whether and to what extent this interaction is apparent in tumors 
and may contribute to cancer biology is unknown.     
 I set out to comprehensively quantify the contribution of various factors in 
explaining variation in DNA methylation.  The advent of standardized genomics and 
other high-dimensional multi-platform ‘omics’ data through The Cancer Genome 
Atlas (TCGA) allows for systematic assessments of molecular features across cancers 
(Cancer Genome Atlas Research et al., 2013).  With combined statistical analysis, 
computational modeling, and machine-learning approaches, I directly evaluated the 
quantitative contributions of molecular and clinical variables that lead to DNA 
methylation.  I found a surprisingly large contribution for the expression of the 
methionine cycle and related SGOC network genes in explaining DNA methylation 
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and identified numerous contexts where this interaction may contribute to cancer 
pathology.         
 
3.3 Results  
3.3.1 Quantification of the determinants of DNA methylation 
 
It has been previously proposed that factors normally regulating the epigenome 
are disrupted in cancer, leading to increased variability of the cancer epigenome (Timp 
and Feinberg, 2013). However, the nature and contributions of such factors are largely 
unknown.  Upon analysis of global and local DNA methylation in tumors as measured 
by the Illumina Infinium HumanMethylation450K BeadChip arrays, I indeed found 
higher variation among tumors from the same tissue vs. between different tissue types 
(Note A2.S1; Figure A2.S1A-D; Methods). Arrays were used over bisulfite 
sequencing because of the higher availability of these data in a standardized format 
allowing for an integrative analysis.  To establish quantitative relationships between 
DNA methylation and molecular and clinical features of tumors, I developed an 
integrative statistical modeling and machine-learning approach with the goal of 
identifying the relative contributions to within-cancer DNA methylation variation 
(Methods).  I incorporated hundreds of variables into comprehensive statistical models 
of DNA methylation (Figure 3.1A). Factors with a known role in DNA methylation 
machinery (chromatin remodeling enzymes and transcription factors), as well as 
factors with a potential biochemical link to DNA methylation (SAM-metabolizing 
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enzymes, met cycle enzymes, and other serine, glycine, one-carbon (other SGOC) 
enzymes that are connected to the met cycle (Mehrmohamadi et al., 2014)) were 
together considered (Figure 3.1A).  I also curated available clinical information such 
as age, gender, and cancer stage in the calculations where appropriate. Furthermore, 
since mutations are known to affect the cancer methylome (Duncan et al., 2012), I 
included all recurrent genetic lesions (somatic mutations and copy number alterations) 
for each cancer type in my models.  Together, over 200 variables were collectively 
analyzed for each cancer type.  My models are therefore not completely agnostic as I 
pre-select classes of biological variables that are known to affect DNA methylation to 
avoid loss of statistical power by including too many features (e.g. expression of all 
genes in the genome). Therefore, to test for potential bias, I also considered the 
expression levels of sets of random genes with functions non-related to DNA 
methylation as additional variables in my models (see Methods).  Subsequently, I 
incorporated all variables into unbiased selection algorithms suitable for dealing with 
large numbers of prediction variables. For this task, I considered two independent 
approaches: a generalized linear model (Elastic Net (Zou and Hastie, 2005)) and a 
machine-learning algorithm (Random Forest (Breiman, 2001)).  A distinct 
computation was carried out for each 10 kilobase (kb) genomic region with variable 
methylation (sd > 0.2) in each cancer type.  Samples of each cancer type were divided 
into three independent test subsets and three training subsets and separate models were 
generated using each subset. The models were then combined resulting in a single 
final model for each 10 kb region of DNA methylation in each cancer. Model 
		 56	
performance was evaluated by measuring mean squared prediction error of test 
samples from Elastic Net and Random Forest separately (Methods).   
 
Figure 3.1—Integrative modeling of local DNA methylation levels. 
A) Schematic summarizing the integrative approach utilized for modeling local DNA 
methylations. DNA methylation at a given 10 kb region was predicted by incorporating 
relevant gene expression, somatic mutation, copy number alteration, and clinical information 
into integrative models.  
B) An example of an Elastic Net model performance in lung cancer. The x-axis shows true 
values of DNA methylation in each sample, and the y-axis shows the value predicted by the 
integrative modeling in the same sample when it was in the test subset.  
C) Summary of overall model performance. For each cancer, the mean squared errors of test 
set predictions by Elastic Net and Random Forest were averaged across all models of local 
DNA methylation.  
D) Comparison of original gene expression variables with randomly selected variance-
matched genes. The y-axis shows the average rank of each gene expression category based on 
average variable usage score across all Elastic Net models (left) and average variable 
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importance score across all Random Forest models (right) of local DNA methylation in brain 
cancer (Error bars show the minimum and maximum value in each group). P-values 
associated with the Mann-Whitney test between the ranks across all models are shown (A 
higher rank corresponds to higher contribution; see Methods).   
 
I observed that my models predicted test set DNA methylation with small 
mean squared error (MSE <0.04) in many regions across the genome (Figure 3.1B). 
Comparison of the performances of the two methods showed that Random Forest and 
Elastic Net algorithms were able to predict DNA methylation with comparable MSEs 
on average (Figure 3.1C; Figure A2.2A). In general, predictability of local DNA 
methylation was largely dependent on cancer type as well as chromatin region in each 
model. For example, I observed that local DNA methylation was most predictable in 
prostate and lung cancers and least predictable in liver and bladder cancers (Figure 
3.1C; Figure A2.2A). Together with the high variation in local DNA methylation 
levels seen in liver and bladder cancers (Figure A2.1D), these results suggest a higher 
stochasticity in the epigenetic signatures for these two cancer types compared to others 
in this study. Upon annotating genomic regions where local DNA methylation could 
be predicted with a low error (MSE < 0.04) in each cancer, I found that the majority of 
the predictable regions lie within 20 kb of the transcriptional start site (TSS) of a gene 
(Figure A2.2B), suggesting that regulation of DNA methylation by the factors 
included in my models is stronger at genic regions. 
I next performed a set of tests to evaluate the robustness of my modeling 
approach. To this end, I compared the original gene expression variables included in 
my models, with a group of variance-matched randomly selected genes from the 
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genome (see Methods) in their ability to predict DNA methylation. In the presence of 
both groups of gene expression variables (original and random), both Elastic Net and 
Random Forest models selected my original variables significantly more frequently 
than random genes (Higher rank corresponds to higher contribution; Mann-Whitney p-
value= 0.0007 for Elastic Net and <0.0001 for Random Forest) (Figure 3.1D; see 
Methods). When the same test was performed in the presence of 5 additional popular 
gene families (Receptor tyrosine kinases (RTK), Receptor serine kinases (RSK), Toll 
like receptors (TLR), MAPK signaling (MAPK) and WNT signaling (WNT)), all but 
RTKs ranked significantly lower (Mann-Whitney p-value<0.0001) than the original 
gene expression variables that I initially included in my models based on biological 
functions (Figure A2.3; Method). Together, these tests validate my models and 
confirm that the Elastic Net and Random Forest algorithms are suitable for 
quantitation of variable contributions in determining DNA methylation. Given that my 
models are not completely agnostic, I do not rule out the possibility of existence of 
potentially highly contributing factors other than the hundreds of variables that I 
considered (e.g. RTKs). As such, the results should be interpreted in the context of 
relative contributions among the variables included in the models and the abilities of 
these variables in predicting DNA methylation. 
3.3.2 Metabolism is a major predictor of DNA methylation in cancer 
 
Using the results of the integrative modeling, I next quantified the relative 
contribution of different functional classes of variables in explaining DNA 
methylation variation within each cancer type. For this, I measured two independent 
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metrics, one using the Random Forest variable importance scores, and the other using 
a binary score for whether or not a variable was selected by the Elastic Net models 
(non-zero co-efficient). For each variable, an overall importance score was calculated 
by averaging its relative importance across all models of 10 kb DNA methylations, 
and an overall usage score was calculated by measuring the fraction of 10 kb regions 
in which Elastic Net models selected the variable (Methods).  To estimate the 
contribution of each functional class of variables in explaining total variation in DNA 
methylation, I pooled all variables in the same functional category and averaged across 
their importance and usage scores separately (Figure A2.4A,B).   
Results from both Random Forest and Elastic Net algorithms identified a 
considerable contribution from the variables within the SGOC metabolic network 
relative to other classes of variables (“Other SGOC enzymes” was the 2nd highest 
scoring among all classes, closely following “Transcription factors” according to both 
methods. “Methionine cycle enzymes” was the 3rd and 4th according to Random Forest 
and Elastic Net, respectively) (Figure 3.2A,B).  Previous studies have shown that 
transcription factor abundance and occupancy strongly mediate dynamic DNA 
methylation turnover in regulatory regions (Feldmann et al., 2013; Stadler et al., 
2011).  Consistent with this observation, my results confirm the “Transcription 
factors” class has the highest contribution to predicting DNA methylation levels across 
human tumors.  Notably, even in the presence of most if not all known variables that 
are thought to mediate the status of DNA methylation, metabolic factors still uniquely 
explained a large part of the variability in methylation (Figure 3.2A,B). 
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Figure 3.2—Contribution of different functional classes of variables to DNA methylation 
variation. 
A-B) Relative contributions of the variable classes according to Random Forest average 
variable importance (A), and Elastic Net average variable usage (B) are shown averaged 
across all cancers (Methods). The y-axis shows the average rank of each class across cancers 
(with higher values corresponding to higher contribution). (Error bars span the range 
between the minimum and maximum values in each class with the exception of individual 
outliers shown).  
C) Diagram summarizing the steps taken toward calculating overall contribution of each of 
the met cycle variables relative to other variables in explaining variability local DNA 
methylations.  
D) Ranking all variables according to their overall selection rate (usage) across all models of 
local DNA methylation in each cancer. The y-axis shows the percent of variables that ranked 
lower than each of the met cycle variables (i.e. made less contribution to DNA methylation) in 
each cancer (BHMT2 was removed from the models of colon and bladder cancers due to low 
expression).  
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Given the contribution of the methionine cycle and its biochemical link to 
DNA methylation, I further explored the variables within the met cycle class 
compared to all other variables in their ability to predict DNA methylation (Figure 
3.2C).  Within the met cycle class, methionine adenosyltransferase 2 beta (MAT2B) 
and betaine-homocysteine S-methyltransferase 2 (BHMT2) exhibited higher predictive 
values than methionine synthase (MTR) and adenosylhomocysteinase (AHCY) on 
average (Figure A2.S4C,D).  Notably, in the presence of the nearly 200 other variables 
in the computations, the met cycle — especially MAT2B— still contributed 
substantially to DNA methylation prediction (MAT2B was ranked among the top 5% 
of highly selected variables in prostate, breast, liver, lung, and brain cancers) (Figure 
3.2D). I observed that the levels of MAT2B contribute to DNA methylation in nearly 
half of the variable regions across the genome even after accounting for various 
factors related to DNA methylation (MAT2B was selected by 42% of all Elastic Net 
models with MSE <0.04 on average) (Figure A2.S4C). Together, my results confirm 
that metabolism contributes to DNA methylation in many cases of human cancer and 
the association between metabolism and DNA methylation is stronger in some 
genomic regions than others.  
3.3.3 Functional annotation of metabolically regulated regions  
 
Results of the integrative modeling across cancers indicate that defined 
regulation of DNA methylation happens in regions where gene expression may be 
affected, thereby suggesting that this regulation could drive essential cancer biology. I 
next set out to characterize all regions across the genome where the association 
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between DNA methylation and the met cycle activity is particularly strong. To identify 
such regions, I designed a scanning algorithm to locate genomic regions spanning 
multiple CpGs with significant peaks of correlation of methylation with expression of 
met cycle enzymes (Figure 3.3A;Methods). I performed this analysis on each of the 
eight cancer types separately and identified distinct peak sets across the genome. To 
assess potential bias toward highly methylated regions and regions where there is 
higher probe density, I analyzed the relationship between average absolute 
methylation of individual CpGs and their correlation with met cycle expression, and 
found no significant association (p-value of correlation=0.62), confirming that the 
identified peaks are distinct from highly methylated regions (Figure 3.3B; Methods).  
Density plots of peak distributions relative to the TSS of the nearest gene were 
concentrated around the TSS in all cancers (Figure A2.S5A), as expected given the 
higher density of probes in gene regulatory regions in the Illumina arrays (Figure 
A2.S5B). However, by further visualizing the distribution of the peaks immediately 
surrounding the TSS, I observed that peak distributions are more diffuse around the 
TSS (Figure A2.S5C) compared to the probe density distribution control (Figure 
A2.S5D). This suggests potential enrichment in areas of the genome overlapping with 
gene body regions and CpG island shores where dysregulated DNA methylation has 
previously been observed in human cancers (Timp and Feinberg, 2013). The peak 
distribution density plots extended up to a few hundred kilobases in distance from the 
nearest TSS, suggesting that DNA methylation at inter-genic parts of the genome may 
also be affected by the activity of met cycle.  
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I next tested the met cycle specificity of the identified peaks by correlating 
them with expression of randomly selected genes in the genome (Methods; Figure 
A2.S6A). For the majority (>83%) of the identified peaks, the met cycle’s correlation 
with DNA methylation was significantly non-random (p-value<0.05) (Figure 
A2.S6B). These results show that my approach was able to identify genomic regions 
where DNA methylation levels are specifically affected by the met cycle activity.  
I next set out to identify genes that overlap with the identified peaks in each 
cancer type. Functional annotation of genes overlapping these peaks by means of 
pathway enrichment analyses across a comprehensive collection of more than 70 gene-
set libraries (Chen et al., 2013) showed enrichment of epigenetic features in these 
regions consistently across all cancers. Strikingly, many of my peaks overlapped with 
peaks of histone-3 lysine-27 tri-methylation (H3K27me3) (Figure 3.3C-F; Figure 
A2.S7A-D) as reported by both the encyclopedia of DNA elements (ENCODE) 
human project(Consortium, 2012) and the RoadMap epigenomics project (Roadmap 
Epigenomics et al., 2015). In cancers of the lung and bladder, histone-3 lysine-9 tri-
methylation (H3K9me3) peaks were also significantly enriched (Figure 3.3F; Figure 
A2.S7C). H3K27me3 and H3K9me3 are both associated with repression of gene 
expression (Cedar and Bergman, 2009). My findings therefore suggest that variation in 
the met cycle’s activity may contribute to aberrant expression from normally silenced 
loci and heterochromatin instability in cancer.  
In addition to histone marks, tissue-specific and cell identity gene sets were 
also enriched in relevant cancer types, including “breast and ovarian cancer genes” in 
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breast cancer (Figure A2.S7A); “abnormal nervous system” and “abnormal neuron 
morphology” in brain cancer (Figure 3.3D); “asthma” and “lung carcinoma” gene sets 
in lung cancer (Figure 3.3F); “kidney-specific” gene set in kidney cancer (Figure 
A2.S7B); and “large intestinal genes”, “inflammatory bowel disease”, and “colorectal 
carcinoma” gene sets in colon cancer (Figure 3.3E).  Finally, a number of 
developmental and signaling pathways were among the enriched pathways including 
“TGF-beta signaling” in kidney (Figure A2.S7B), “cell communication” pathway in 
liver (Figure 3.3C), and “G-protein coupled signaling” in bladder cancer (Figure 
A2.S7C). Organ and embryonic morphogenesis pathways were enriched in breast 
(Figure A2.S7A), bladder (Figure A2.S7C), and prostate (Figure A2.S7D), all of 
which are hormonally driven cancers. Interestingly, a previous study in breast cancer 
showed that embryonic developmental genes are enriched in regions of DNA 
hypomethylation compared to normal breast (Hon et al., 2012). Together, these results 
illustrate the functional importance of the relationship between met cycle and DNA 
methylation across cancers.  
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Figure 3.3— Genome-wide screening for metabolically regulated regions.  
A) Schematic describing the algorithm used for finding genomic regions where DNA 
methylation might be regulated by the met cycle (see Methods).  
B) Assessment of the relationship between met cycle correlation and absolute methylation. 
The y-axis shows the Spearman rho for correlation of 2000 randomly selected probes with the 
expression of AHCY in colon cancer. The x-axis shows the average methylation level of the 
same probes across the colon cancer samples in the study (see Methods).  
C-F) Pathway enrichment analyses of genes overlapping peaks. Results are depicted by 
functional annotation of genes located within peaks of correlation between met cycle and 
DNA methylation (see Methods for description of gene sets and enrichment scores; see Figure 
A2.S7 for additional cancer types).  
 
3.3.4 Contribution of metabolism to DNA methylation at cancer genes 
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So far, I have shown that there is a surprising enrichment of peak regions of 
metabolically regulated DNA methylation at loci that link to essential aspects of cell 
identity and chromatin structure. I next questioned whether cancer-specific loci might 
also exhibit this interaction. I chose 19 well-characterized cancer-related genes such as 
TP53, PTEN, and ESR1, as well as 4 genes frequently differentially methylated in 
cancer APC, RASSF1, GSTP1, and MGMT (Methods). A recent study showed that 
DNA methylation for any given gene has two major principal components: one 
representing the promoter region and the other representing the coding sequence (Ho 
et al., 2015). Furthermore, CpG methylation at promoter regions of genes is typically 
associated with repression, while gene body methylation is thought to increase 
expression (Yang et al., 2014). I therefore applied my integrative modeling to DNA 
methylation at promoter and gene body regions of each cancer gene separately. In 
addition to the integrative approach, I also generated models using only the met cycle 
genes as prediction variables to quantify the predictive ability of met cycle in the 
absence of other factors.  Thus, each cancer gene locus was analyzed once using the 
integrative approach and once using met cycle alone and 3-fold cross validation was 
performed in each case as previously described (Methods). Model performance was 
evaluated by calculating the error of prediction of test set methylation, as shown for 
two examples in Figure 3.4: estrogen receptor (ESR1) promoter in breast cancer 
(MSE=0.004) (Figure 3.4A), and androgen receptor (AR) promoter in prostate cancer 
(MSE= 0.001) (Figure 3.4B). ESR1 promoter methylation in breast cancer and AR 
promoter methylation in prostate cancer are two examples of events that are known to 
contribute to the pathogenesis and prognosis of the corresponding tumor types (Heyn 
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and Esteller, 2012; Nakayama et al., 2000; Yang and Park, 2012). I further assessed 
the integrative models of promoter methylation at these two loci, and found many 
SGOC (including met cycle) variables among the top predictive variables of promoter 
methylation according to the variable importance measures (Figure 3.4C,D; Methods).  
Notably, the models across all cancers in the study were able to predict cancer 
gene methylation with high accuracy even using the met cycle variables in the absence 
of all other variables (85% of the predictions were made with MSE<0.01) (Figure 
A2.S8A,B). As in the case of local methylation, cancer gene methylation was also 
more strongly explained by the expression of MAT2B compared with other met cycle 
variables on average (selected by 24% of all integrative models) (Figure A2.S8C), 
consistent with the function of this enzyme that directly affects SAM levels. Relative 
variable class comparisons confirmed considerable contribution from the “Methionine 
cycle enzymes” and “Other SGOC enzymes” among other classes of variables (highest 
after “Transcription factors” and “Mutations”) (Figure A2.S8D,E).   
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Figure 3.4— Contribution of metabolism to DNA methylation at cancer loci. 
A) Prediction of ESR1 promoter methylation in test samples of breast cancer. The x-axis 
shows the methylation value at ESR1 promoter, while the y-axis shows the corresponding 
predicted values by Elastic Net.  
B) Prediction of AR promoter methylation in test samples in prostate cancer. The axes are 
similar to a.  
C-D) Top 20 variables as ranked based on the variable importance score from Random Forest 
model of ESR1 promoter methylation in breast cancer (C), and AR promoter methylation in 
prostate cancer (D). Variables in the SGOC network (including the met cycle enzymes and 
other SGOC enzymes) are shown in red and all other variables are shown in black.   
E) Schematic depicting the ranking of all variables based on combined results of promoter 
and gene body methylation at cancer loci.      
F-G) Variables that were most predictive of cancer gene methylation on average (top 15%) 
are ranked in order of increasing contribution (variable score= percent usage by Elastic Net). 
Green arrows point to previously published factors associated with variations in DNA 
methylation (positive controls). (Variable names: official gene symbols are used to show gene 
expression variables (“Methionine cycle enzymes”, “Other SGOC enzymes”, “Transcription 
factors”, “Chromatin remodeling factors”, and “ SAM metabolizing enzymes”), while 
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“_mut” and “_cn” suffixes following gene symbols denote “Mutations” and “Copy number 
variations”, respectively. For “Clinical factors”, variable names match the descriptors used 
in the TCGA data files) (see Figure A2.S11 for additional cancer types).  
H) Sub-network of SGOC genes contributing to DNA methylation in multiple cancer types (at 
least 4 and 3 cancers based on Elastic Net and Random Forests models, respectively). Red 
and white nodes represent genes and metabolite, respectively. Solid edges denote direct 
biochemical links and dashed edges denote indirect biochemical links through enzymatic 
reactions not shown. Node sizes for the gene nodes correspond to the number of cancer types 
wherein each enzyme contributed significantly to cancer gene methylation. (Phosphoglycerate 
dehydrogenase (PHGDH)=6, MAT (MAT2B and MAT2A) =5, glycine amidinotransferase 
(GATM)=5, serine hydroxymethyltransferase 1 and 2 (SHMT1 and SHMT2)= 4, sarcosine 
dehydrogenase (SARDH)= 4, alanyl aminopeptidase (ANPEP)= 4, L-amino acid oxidase 
(IL4I1)=4, gamma-glutamyl hydrolase (GGH)=4). 
 
I independently evaluated these findings by applying the same models to both 
permuted cancer gene methylation values and also randomly generated methylation 
values (Figure A2.S9A). In all tests, met cycle contribution was significantly (p-
value< 10e-16) higher when applied to cancer gene methylation vs. permutations or 
random numbers (Methods; Figure A2.S9B), confirming the specificity of signals 
contained in the true DNA methylation values at cancer loci. Furthermore, my 
collaborator Lucas Mentch tested the performance of the machine-learning algorithm 
using randomly generated variables for prediction of cancer gene methylation 
(Methods) and found in each of the cases tested, that the predictions made with the 
original variables are uniformly more accurate than what is made using simulated 
random variables (original model MSE smaller by 1.4-2 fold than random model MSE 
on average) (Figure A2.S10A-D). He also simulated a dataset where prediction 
variables and the response are related via linear relationships and compared the 
accuracy of predictions in this simulated linear dataset with the original dataset 
(Methods). He saw in all cases that the improvement in MSE from my dataset (MSE 
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1.4-2 fold smaller than random MSE) is even more than what we observed with data 
of the same dimension that have a linear relationship (MSE 1.3 fold smaller than 
random MSE)  (Figure A2.S10E,F). These independent tests confirm that machine-
learning using the Random Forest algorithm is able to identity non-random signals in 
the data, and also that it can detect non-linear relationships between prediction 
variables and the response.   
Next, I ranked all of the variables based on their overall usage according to the 
integrative models of cancer gene promoter and body methylations (Figure 3.4E). 
Notably, many SGOC (including met cycle) enzymes were among the most frequently 
selected variables in all cancers (Figure 3.4F,G; Figure A2.S11A-F). Importantly, my 
models highly ranked many clinical and molecular factors previously shown to be 
associated with DNA methylation in the existing literature (green arrows in Figure 
3.4F,G and Figure A2.S11A-F). Examples of such positive controls include DNA 
methyltransferase (DNMT3A or DNMT3B) enzymes (Robertson, 2001) that were 
consistently among the top variables in all cancers (Figure 3.4F,G; Figure A2.S11A-
F), and patient’s age (or age at diagnosis) (Jung and Pfeifer, 2015; van Dongen et al., 
2016) that was highly ranked in prostate, colon, breast, kidney, and brain (Figure 
3.4F,G; Figure A2.S11A-F). I also observed ER-status to be one of the most important 
contributors to DNA methylation variation in breast cancer consistent with previous 
publications (Cancer Genome Atlas, 2012) (Figure A2.S11B). Furthermore, I found 
the mutational status of the histone methyltransferase SET-domain containing-2 
(SETD-2) as a significant contributor in kidney (Figure A2.S11C), smoking in bladder 
and lung (Figure A2.S11D,F), and isocitrate dehydrogenase-1 (IDH1) mutational 
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status in brain cancers (Figure 3.4G). Each of these findings are in agreement with the 
current knowledge about determinants of DNA methylation (Cancer Genome Atlas 
Research, 2013, 2014; Turcan et al., 2012; van Dongen et al., 2016). These results 
further validate my models and also emphasize the importance of the contribution 
observed for the SGOC variables (including the met cycle).  
Previous work has shown that expression of enzymes across different regions 
of the SGOC network is predictive of metabolic flux through the network 
(Mehrmohamadi et al., 2014). Notably, I observed that several SGOC genes are 
consistently among the highly ranked variables by both Random Forest and Elastic 
Net models in multiple cancer types. Therefore, to understand which features of 
SGOC metabolism contribute to the interaction with methylation, I defined a sub-
network that was commonly highly ranked by the models in multiple cancer types 
(Figure 3.4H; Methods). This SGOC sub-network comprises the MAT enzymes in the 
met cycle (MAT2B and MAT2A), as well as enzymes within serine-glycine 
metabolism such as phosphoglycerate dehydrogenase (PHGDH) and glycine 
amidinotransferase (GATM) (Figure 3.4H). I generally observed negative associations 
between DNA methylation and expression of PHGDH and GATM, but positive 
associations with expression of MAT enzymes. A cautionary note however is that in 
many disease states, levels of particular metabolites in the methionine cycle 
substantially deviate from physiological ranges, thus activating compensatory 
mechanism and leading to correlation with DNA methylation in directions opposite of 
what would be expected from the biochemistry of the reactions (Jia et al., 2016). 
Therefore, when interpreting the direction of correlations between metabolic enzyme 
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levels and DNA methylation, it is important to note that they not only depend on the 
stoichiometry of the corresponding enzymatic reactions, but also on endogenous 
abundance of the related metabolites.  Together, my results suggest that a particular 
flux configuration through the SGOC metabolic network— which previous studies 
have shown to be predictable from gene expression patterns (Mehrmohamadi et al., 
2014)—may be important for regulation of DNA methylation.  
3.3.5 Cancer pathogenesis of metabolically regulated DNA methylation 
 
Involvement of the met cycle in promoter and gene body methylation at cancer 
genes suggests a potential implication for this metabolic pathway in explaining part of 
the variability in cancer pathogenesis and patient outcome. To further assess this 
relationship, I divided patients in each cancer type into two groups based on overall 
predictability of their cancer loci methylation by the met cycle (see Methods). I then 
compared survival rates between the two groups (“predictable” by met cycle vs. “not 
predictable” by met cycle) in each cancer type using the Kaplan-Meier estimator 
(Kaplan and Meier, 1958) (Figure 3.5A-H). An improved overall survival for the 
“predictable” group was observed, although the magnitude of this trend varied 
depending on cancer type with brain, kidney, liver, and colon cancers showing 
statistically significant differences (log-rank test p-values: brain= 3.92e-05, 
liver=0.0048, kidney=0.0085, colon=0.04) (Figure 3.5A-D). The difference in survival 
between the predictable and non-predictable groups was not significant in the rest of 
the cancers studied here (Figure 3.5E-H), possibly explained by limited power due to 
data censoring at later time points. The overall patterns however suggest that the 
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regulation of DNA methylation by the met cycle may be important in maintaining a 
normal epigenome, and disruption of this relationship in specific subtypes of tumors 
can lead to high epigenetic stochasticity in those tumors that correspond to poor 
clinical outcomes. This is consistent with a previous study that showed DNA 
methylation stochasticity increased across samples with increasing malignancy (from 
normal to adenoma to carcinoma) (Timp and Feinberg, 2013).  
 
Figure 3.5— Implication of metabolic regulation of methylation in patient survival. 
A-D) Kaplan-Meier curves are depicted comparing groups of patients wherein cancer gene 
methylation was predictable (red) or not predictable (black) by the met cycle variables (see 
Methods). Overall survival in days is plotted in each case and censored subjects are shown by 
vertical tick marks (Methods). Log-rank test p-value between the two groups is reported. 
Survival analysis results and log-rank test p-values are shown for brain, liver, kidney, and 
colon cancers respectively.  
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E-H) Survival analysis results as described above are reported for bladder, breast, lung, and 
prostate cancers, respectively. Log-rank test p-values showed no significant difference 
between the “predictable” and “not predictable” groups (“NS”= not significant) (Sample 
sizes: breast=770, lung=450, liver= 374, brain= 534, bladder= 408, kidney=316, prostate= 
424, colon= 198). 
 
To validate the results of my survival analyses, I applied multivariate Cox 
regression models to account for covariates such as mutations and clinical factors that 
are known to be associated with survival rates (Methods). I performed this test in the 
cases of brain, liver, and kidney cancers were the univariate analyses found highly 
significant differences between the predictable and non-predictable groups (Figure 
3.5A-C). The models including covariates still showed a significant difference 
(p<0.05) between the predictable and non-predictable groups of patients even after 
taking mutational and clinical factors into account (see Methods for the list of 
covariates considered in each cancer), suggesting that a unique part of variation in 
survival may be explained by epigenetic regulation. I next tried to further validate my 
results through comparison with independent analyses of the TCGA data by the 
cBioPortal for Cancer Genomics (cBioPortal) (Cerami et al., 2012) and Prediction of 
Clinical Outcome from Genomic profiles (PRECOG) (Gentles et al., 2015). These 
analyses found lower survival in prostate cancer patients harboring tumors with deep 
deletions in the met cycle genes (Figure A2.S12A), and higher survival in kidney 
cancer patients where the met cycle enzymes are over-expressed (Figure A2.S12B), 
respectively. These results confirm a relationship between met cycle and survival in 
the same direction as predicted by my hypothesis.  
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3.4. Discussion 
 
In this study, I conducted a pan-cancer TCGA analysis of the molecular and 
clinical contributions to within-cancer (inter-individual) variation in DNA 
methylation.  Through several lines of integrated analysis, I found the overall 
expression of both the methionine cycle and SGOC network to be strong predictors of 
multiple aspects of DNA methylation and consistently ranked as one of the highest 
contributing factors to cancer-associated DNA methylation such as methylation of 
numerous cancer genes.  Within the methionine cycle, I consistently observed a more 
significant contribution from MAT2B and BHMT2, suggesting that the regulation 
may be occurring at these enzymatic steps. MAT2B is the enzyme that converts 
methionine to SAM, therefore it is expected that this enzyme affects SAM levels more 
directly than other metabolic enzymes.  The significance of BHMT2 but not MTR 
suggests that metabolism of choline and betaine may be more prevalent than folates in 
cases where one-carbon metabolism fuels DNA methylation.  It is important to note 
that given the predictive nature of my models, the results do not prove causal 
relationships. As such, they should not be interpreted as direct evidence for regulation 
of DNA methylation by the model variables, but rather as predictive associations.    
I introduced a novel approach to identify chromatin regions with strong 
correlations between DNA methylation and metabolic enzyme levels. The identified 
regions for the met cycle enzymes significantly overlapped with histone modifications, 
consistent with enzymatic cross-talk between the two epigenetic processes (Cedar and 
Bergman, 2009). The enrichment of gene signatures of repressing histone marks such 
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as H3K27me3 in all cancers points to a possible role for the met cycle in maintenance 
of DNA methylation at silenced loci. Previous studies have reported aberrant 
methylation of transcriptionally repressed genes in cancer (Sproul et al., 2011). In fact, 
heterochromatin instability arising from increased variability in DNA methylation is a 
phenomenon observed in many cancers and is thought to contribute to epigenetic 
plasticity and tumor progression (Carone and Lawrence, 2013; Hansen et al., 2011; 
Landau et al., 2014). My results provide evidence for this model of dysregulated 
cancer epigenome and further suggest that disruption of the regulation of DNA 
methylation by the met cycle—which can be a cause or consequence of 
tumorigenesis— may be one of the sources of methylation stochasticity leading to 
higher malignancy. Survival analyses confirm that tumors with a weaker association 
between their cancer gene methylation and the met cycle expression are more 
malignant in comparison to tumors wherein this relationship is closer to normal. In 
addition to epigenetic overlaps, genes with important tissue-specific functions and 
disease states were also found to fall under the metabolism-DNA methylation peaks. 
DNA methylation at cell-type related disease and lineage-specific genes has 
previously been shown to be dynamic and functionally important (Ziller et al., 2013). 
My results further strengthen the idea that met cycle regulation of methylation is 
strongly associated with normal tissue function.   
Application of the integrative modeling to cancer genes revealed a major role 
for MAT enzymes (MAT2B and MAT2A), as well as PHGDH and GATM— enzymes 
involved in serine and glycine metabolism, respectively. Importantly, MAT2B and 
MAT2A have been shown to co-localize in nuclei and bind DNA through complex 
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formation with chromatin binding proteins providing direct evidence for the role of 
these enzymes in regulation of transcription via methylation (Katoh et al., 2011). My 
results illustrate that higher levels MAT2B are associated with more “regulated” 
methylation and higher survival, suggesting potentials for genetic or dietary 
interventions with methionine cycle intermediates in cancer patients.  PHGDH diverts 
the glycolytic flux into the de novo serine synthesis pathway that allows glycolysis to 
provide methyl units. GATM diverts glycine into the creatine synthesis pathway in 
which SAM is consumed to produce creatine (Brosnan et al., 2011). Creatine synthesis 
is therefore in competition with the methionine cycle over cellular pools of SAM, 
explaining why enzymes within the serine-glycine metabolism generally tend to be 
negatively correlated with the met cycle and DNA methylation.  
Overall, this study provides the first comprehensive quantification of the 
determinants of inter-individual DNA methylation variation in human cancers. The 
activity of the methionine cycle that emerges in these findings could be either sensed 
directly by the DNA, or indirectly through interplay with dynamic histone 
methylation, which itself is tightly regulated by the status of methionine metabolism 
(Mentch et al., 2015).  Due to limitation in the coverage of the DNA methylation 
arrays, it remains to be determined if my findings are generalizable to methylation 
across the entire genome including all non-CpG methylation sites as well as hydroxy-
methylation sites. Nevertheless these findings altogether identify metabolism as a 
major determinant of DNA methylation status in human cancer. It is important to note 
that the current TCGA dataset contains one sample per individual tumor and therefore 
my conclusions do not necessarily explain the variation in clonal populations within a 
		 78	
given tumor.   Future studies using multiple samples per tumor or single cell 
epigenomics are therefore required to characterize the determinants of intra-tumor 
epigenetic heterogeneity. Finally, my study identifies an association between altered 
tumor metabolism and DNA methylation, while the sources of alterations in 
metabolism itself remain to be elucidated but can be addressed using similar 
approaches.  
 
3.5 Methods 
3.5.1 Data curation  
 
Publically available genome-wide mRNA expression and DNA methylation 
data were downloaded from the cancer genome atlas (TCGA) portal (https://tcga-
data.nci.nih.gov/tcga/). In order to increase consistency and minimize unwanted 
variations, only samples processed using RNASEQ-V2 with level-3 gene-normalized 
RNA-seq by Expectation Maximization (RSEM) values for gene expression, and 
level-3 beta-values from Illumina Infinium HumanMethylation450K BeadChip data 
for DNA methylation were included in the study.  I selected the following 8 cancer 
types wherein the number of available samples analyzed on both platforms was 
sufficiently large for machine-learning calculations: 770 samples of breast invasive 
carcinoma (BRCA), 450 samples of lung adenocarcinoma (LUAD), 374 samples of 
liver hepatocellular carcinoma (LIHC), 534 samples of brain lower grade glioma 
(LGG), 408 samples of bladder urothelial carcinoma (BLCA), 316 samples of kidney 
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renal clear cell carcinoma (KIRC), 424 samples of prostate adenocarcinoma (PRAD), 
and 198 samples of colon adenocarcinoma (COAD).  Somatic mutations with a 
frequency of 5% or higher, and Genomic Identification of Significant Targets in 
Cancer (GISTIC) values for copy number alterations with a frequency of 15% or 
higher according to the cBioPortal (Cerami et al., 2012) were obtained and included in 
the models. Clinical and follow-up data were downloaded via the TCGA-Assembler 
(Zhu et al., 2014) .  
 
3.5.2 Assessment of batch effects  
 
I used the TCGA Batch Effects online tool 
(http://bioinformatics.mdanderson.org/tcgabatcheffects) to check for the existence of 
batch effects in the data used in my study. For each cancer types in my study, both the 
DNA methylation and the RNA-seq batch effects were negligible (Dispersion 
Separability Criterion (DSC) score < 0.5 for all sample batches included in the study). 
3.5.3 DNA methylation  
 
The Illumina Infinium Human Methylation450K BeadChip consists of more 
than 450,000 probes across the genome covering CpG sites within and outside of CpG 
islands as well as non-CpG methylation sites identified in embryonic stem cells (see: 
http://www.illumina.com/products/methylation_450_beadchip_kits.html). I first 
filtered all probes with more than 80% missing values across each cancer type. Global 
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DNA methylation was then defined as the average beta-value across all remaining 
probes for each sample (Figure A2.S1A). Sex chromosomes were also excluded from 
all subsequent analyses of DNA methylation. In order to assess local DNA 
methylation, I divided the genome into 10 kb intervals and calculated the average beta 
value across all probes within each bin. I then filtered regions where variation in 
methylation was modest (standard deviation < 0.2 across each dataset). The average 
beta-value across all remaining 10 kb regions was then calculated for each sample 
individually and plotted in Figure A2.S1C. In order to study DNA methylation at 
cancer loci, probes that mapped to each gene according to Illumina annotations were 
identified. Promoter DNA methylation was then defined as the average beta value 
across all probes mapping to a given gene and falling within one of the following 
positional categories based on Illumina chip annotation information: “TSS1500”, 
“TSS200”, or “5’UTR”.  Gene body methylation for each gene was defined as the 
average beta value across all probes mapping to a given gene and falling in “1st exon”, 
“Body”, or “3’UTR” based on the annotation. Promoter and gene body methylation 
were separately modeled for each of the cancer genes in the study (Figure 3.4).  
3.5.4 Gene expression  
 
Log-transformed gene normalized RSEM values were used as expression 
levels and low-expression genes in each dataset were defined as having less than 70% 
of the samples with a count value larger than 3. Such genes were removed from 
further analysis.   
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3.5.5 Gene expression variables included in the integrative models 
 
In addition to the major enzymes in the met cycle (MAT2B, MTR, BHMT2, 
AHCY), four classes of expression variables with potential links to DNA methylation 
were also included in the integrative models . The four classes are described in the 
following: 
“Other SGOC enzymes”: Serine, glycine, one-carbon (SGOC) metabolic genes from 
my previous network reconstruction were included (Mehrmohamadi et al., 2014). In 
order to separately assess the effect of the met cycle from the rest of the network, I 
excluded the met cycle enzymes from this class and treated them as a separate class 
(“Methionine cycle enzymes”).   
“Chromatin Remodelers”: A list of human chromatin remodelers and DNA 
methylation machinery was constructed by combining the Gene Ontology (GO) 
chromatin modifiers list, GO chromatin remodelers list (Ashburner et al., 2000), and 
methylated DNA binding proteins and de-methylases (Marchal and Miotto, 2015). 
“Transcription factors”: For each cancer type, transcription factors important in the 
pathogenesis or subtype specification based on previous literature were included 
(Johnston and Carroll, 2015).  
“SAM-metabolizing enzymes”: DNA methyltransferases and other SAM-consuming 
enzymes (except for MAT enzymes already included in the class “Methionine cycle 
enzymes”) according to Human Cyc (Romero et al., 2005) were included in this class.   
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3.5.6 Mutations included in the integrative models 
 
For each cancer type, genes with frequent somatic mutations (minimum 
frequency of 5%) among the TCGA cohort according to the cBioPortal (Cerami et al., 
2012) summary table (TCGA, Provisional) were obtained. The transposed matrix of 
individual barcodes and mutations in the selected genes was downloaded from the 
cBioPortal for each of the 8 cancers in this study.  
3.5.7 Copy number alterations included in the integrative models 
 
For each cancer type, genes with frequent copy number alterations (minimum 
frequency of 15%) among the TCGA cohort according to the cBioPortal (Cerami et 
al., 2012) summary table (TCGA, Provisional) were obtained. The transposed matrix 
of individual barcodes and putative copy number alteration calls by GISTIC (Mermel 
et al., 2011) for the selected genes was downloaded from the cBioPortal for each of 
the 8 cancers in this study (Values of putative copy number calls determined using 
GISTIC 2.0 : -2 = homozygous deletion; -1 = hemizygous deletion; 0 = neutral / no 
change; 1 = gain; 2 = high-level amplification).  
3.5.8 Clinical factors included in the integrative models 
 
For each cancer type, clinical information was downloaded through the TCGA-
Assembler (Zhu et al., 2014). All clinical attributes were included for each cancer type 
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with the exception of the ones filtered out due to missing data for all samples or 
factors with the same level across all samples.  
3.5.9 Variable ranking using the Random Forest algorithm 
 
The Random Forest is a machine-learning algorithm that generates predictions 
by averaging over a collection of randomized decision trees.  Since successive trees 
are built with bootstrap samples, the algorithm is robust to over-fitting, and also those 
samples that are left out (the out-of-bag (OOB) samples) can be used to quantify the 
contribution that prediction variables make to the overall response. The Random 
Forest method is designed to accommodate nonlinearities between the response and 
prediction variables as well as unknown interactions among the variables (Costello et 
al., 2014; Mentch and Hooker, 2015). I used the R package “randomForest”(Liaw and 
Wiener, 2002) and performed 3-fold cross validation by manually dividing the 
samples in each cancer type into 3 training and test subsets. To build each forest, tree 
size was set to 500 and the “importance” parameter was set to “TRUE” in the R 
function “randomForest” so as to provide estimates for the importance of prediction 
variables. Missing data were imputed using the “na.roughfix” function in the 
“randomForest” package. I obtained separate measures of importance for each variable 
from each Random Forest run. These importance scores are calculated as the percent 
increase in the mean squared prediction error on the OOB samples when a given 
variable is permutated. Variables were ranked based on average importance scores 
across all cross validation folds.  Prediction errors were calculated as the mean 
squared difference between the predicted vs. the observed methylation values for the 
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test set samples. The square root of the mean squared error (MSE) has the same scale 
as the response (DNA methylation beta values in this case), and is therefore a direct 
measure of the accuracy with which predictions were made.  (Figure 3.1C; Figure 
A2.S8A,B).  
3.5.10 Variable selection using the Elastic Net algorithm 
 
Elastic Net is a penalized regression approach for variable selection and 
quantitative inference that identifies linear combinations of unique variables that 
contribute to a response variable such as the amount of DNA methylation. The 
algorithm was developed and benchmarked to avoid over-fitting in statistical modeling 
of high-dimensional data containing collinearity (Waldmann et al., 2013). I applied the 
Elastic Net algorithm using the R package “glmnet”(Friedman et al., 2010). Elastic 
Net performs variable selection by minimizing a regularized cost function using the 
following equation 
𝒎𝒊𝒏𝜷𝟎,𝜷 𝟏𝑵 𝒘𝒊𝒍(𝒚𝒊𝑵𝒊8𝟏 𝜷𝑻𝒙𝒊)+	) +	λ [(1−α) ||𝜷||𝟐𝟐/2 + 𝜶||𝜷||𝟏] 
where lambda is the tuning parameter and alpha is the Elastic Net penalty term. For 
each cancer type, the samples were divided into 3 independent test subsets (3-fold 
cross validation), and separate models were generated using each training subset.  
Using a grid of different tuning parameter values, I found the lambda that minimized 
the mean squared error using 5-fold cross validation within each training set for each 
model separately. The value of alpha was set to α=0.5 to handle potential correlated 
variables. Finally, for each variable, average coefficient across the 3 independent 
		 85	
models was calculated for each region and each cancer type. Due to the existence of 
categorical factors among my variables (for which scaling is not appropriate), I also 
calculated the selection rate as an alternative measure of variable importance referred 
to as “variable usage” in the manuscript. Variable usage was measured as the fraction 
of times across all cross validation folds that a variable was selected by the Elastic Net 
to be included in the final model (Figure A2.S8C; Figure 3.4 F,G; Figure A2.S11A-F). 
Finally, prediction errors were calculated as the squared difference (mean squared 
error (MSE)) between the predicted and measured DNA methylation values for the 
test sets (Figure 3.1C; Figure A2.S8A,B).  
3.5.11 Variable class contributions to DNA methylation 
 
Variables were functionally categorized into the following 8 classes: 
“Methionine cycle enzymes”, “Other SGOC enzymes”, “Chromatin remodeling 
factors”, “Transcription factors”, “SAM metabolizing enzymes”, “Clinical factors”, 
“Copy number variations”, and “Mutations”. Results of the integrative modeling were 
summarized and reported in terms of the average contribution from each of the above 
functional classes in explaining DNA methylation variation. Variable importance 
scores from Random Forest models were averaged across all variables within a given 
class, and an overall class importance score was calculated. In the case of Elastic Net 
models, variable usage as described in the previous section, was averaged across 
variables in each class and an average percentage showing selection rate was 
calculated. Finally, classes were ranked in each cancer type according to their average 
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contribution and the overall class ranks were plotted in Figure 3.2A,B, Figure 
A2.S4A,B, Figure A2.S8E,D.   
3.5.12 Comparison with gene expression controls 
 
A set of 100 randomly selected genes from the genome with similar cross-
sample variation in expression as my original gene expression variables (TFs, SGOC, 
MET-C, SAM, and RMs) were considered. I performed this test on local DNA 
methylations (all variable 10 kb regions) in brain cancer (LGG) as an example and 
repeated the integrative modeling using this set of randomly selected genes in addition 
to all other variables present in the original models.  All gene expression variables 
were then ranked using a similar approach as described above. To compare my 
original gene expression variables with the variance-matched random genes, the ranks 
across all models were averaged (Figure 3.1D), and p-values were obtained from one-
tailed Mann-Whitney non-parametric test between the two groups from Elastic Net 
and Random Forest. To further test my gene expression variables against other gene 
families, 5 popular gene sets were considered: Receptor tyrosine kinases (RTK), 
Receptor serine kinases (RSK), Toll like receptors (TLR), MAPK signaling and WNT 
signaling families. The list of genes in these families were obtained from the HUGO 
Gene Nomenclature Committee (HGNC)( http://www.genenames.org/cgi-
bin/genefamilies/). The same approach as described above for randomly selected 
genes was used to compare these gene sets with my original gene expression variables 
(Figure A2.S3) 
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 3.5.13 Distance to nearest gene transcriptional start site (TSS) 
 
Selected 10 kb regions were converted to genomic range objects using the R 
package “GenomicRanges” (Lawrence et al., 2013). The distance to single nearest 
gene’s transcription start site (TSS) was found using Genomic Regions Enrichment of 
Annotations Tools (GREAT) (McLean et al., 2010). Genomic regions are associated 
with nearby genes by first assigning a regulatory domain to every gene in the genome, 
and then finding genes whose regulatory domains overlap with a given genomic 
region. I set the association rule parameter in GREAT to “Single nearest gene” with a 
maximum extension of 1000 kb for definition of regulatory domains. Density plots of 
distance to TSS are depicted in Supplementary Fig. 2b. The same approach was used 
for annotating peaks obtained from Figure 3.3 (density plots shown in Figure 
A2.S5A,C). To obtain the distribution of Illumina probe densities around the TSS, I 
randomly selected 10000 probes across the arrays and applied the above-described 
approach to measure the distance to nearest gene’s TSS for each probe. Density plots 
were obtained for the purpose of comparison with the distribution of metabolically 
regulated peaks (Figure A2.S5B,D). 
3.5.14 Identification of metabolically regulated genomic regions  
 
To find peaks of strong association between the met cycle and DNA 
methylation, I designed a novel scanning method by applying the idea of Manhattan 
plots from e-QTL analyses to DNA methylation data. In each cancer type, I first 
selected one of the major enzymes in the met cycle with the highest overall Spearman 
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correlation with global and local DNA methylations (BHMT2 in brain, breast, prostate, 
and liver; MAT2B in lung and bladder; and AHCY in colon and kidney cancers), and 
calculated the Spearman correlation between its expression and the beta value of each 
individual probe across the genome. I then sorted the probes according to genomic 
coordinates and aligned the –log10 of the p-values obtained from the Spearman 
correlations along the chromosomes.  Next, I applied a sliding window scan for 
regions of strong association across the genome separately in each cancer type (Figure 
3.3A). For this, probes with the highest correlations (top 10% across the genome) were 
located and a 6 kb window (+3 kb and -3 kb) flanking the genomic coordinate of the 
original probe was scanned. A region was reported as a “peak” if the following criteria 
were met: 1- Region included at least 3 probes with a correlation in the same direction 
as the original probe (positive or negative); 2- At least 80% of all probes within the 
region had a significant (p<0.00001) correlations with met cycle expression. After 
applying these filters, the selected regions were annotated and genes overlapping with 
each of the peaks were used for subsequent pathway enrichment analyses. Given the 
window size and the above criteria, the majority of the identified peaks only 
overlapped with one unique.  
To assess potential bias toward highly methylated regions in the identified 
regions where correlation of methylation with met cycle expression peaks, I tested 
2000 randomly selected probes across the genome. I then evaluated the association 
between methylation of each probe with the value of its Spearman correlation rho with 
met cycle expression— I used AHCY in colon cancer as an example in this test 
(Figure 3.3B).  
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Finally, an additional filter was applied to rank the identified peaks according 
to peak shape. For this, the aligned correlation coefficients in each region were 
assessed with respect to whether they formed a peak according to an information 
theory score calculated by the R function “turnpoints” (refer to R package “pastecs” 
(Grosjean and Ibanez, 2014)). This function finds all turning points (peaks and pits) in 
a series of points (in this case, aligned correlation coefficients), and calculates the 
information quantity of each turning point using Kendall’s information theory. Finally, 
it measures a p-value against a random distribution of the turning points in a given 
series, with smaller p-values corresponding to less random shape and a higher 
probability of a turning point corresponding to a real peak or pit.  I selected regions 
containing turning points with the most significant p-values (lowest 20%) in each 
cancer type and subsequently tested them for specificity for the met cycle as described 
in the following section.   
3.5.15 Test of specificity of peaks for the met cycle 
 
Each of the selected peaks was tested for specificity of their correlations with 
the met cycle expression (vs. gene expression in general). For this, 500 genes were 
randomly selected from the genome in each cancer type, and the Spearman correlation 
coefficient was measured between their expression and the methylation of every probe 
within a given peak. The fraction of significant correlations was calculated for all of 
the 500 genes as well as for the met cycle gene. A randomization q-value was 
calculated for the met cycle gene by comparing it to the distribution of the correlations 
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calculated for the 500 random genes. This procedure was repeated separately for each 
peak in each cancer type and the results are summarized in Figure A2.S8A,B. 
3.5.16 Pathway enrichment analyses 
 
Peaks were annotated according to Illumina information and UCSC Ref gene 
names for genes overlapping with the identified peaks were extracted. Pathway 
enrichment analysis was performed on the resulting gene list for each cancer type 
using Enrichr (Chen et al., 2013). Combined scores from Enrichr were used to rank 
pathways. The Combined score “c” is defined as c=log(p)*z where p refers to the p-
value from the Fisher’s exact test and z is the z-score indicating the deviation from the 
expected rank. Enrichr first calculates Fisher’s exact p-values for many random gene 
sets to generate a distribution of expected p-values for each pathway in their pathway 
library. The z-score for deviation from this expected rank is therefore an alternative 
ranking score and the combined score is considered a corrected form of the enrichment 
score and p-value, which I used to sort pathways in Figure 3.3C-F and Figure A2.S7A-
D. All gene sets in Figure 3.3C-F and Figure A2.S7A-D had Fisher’s exact p-values 
<0.05, and the most highly enriched sets are shown ranked by the combined 
enrichment scores. Gene set names used in Figure 3.3C-F and Figure A2.S7 follow the 
convention used and described by Enrichr 
(http://amp.pharm.mssm.edu/Enrichr/#stats). Briefly, gene ontology (GO) sets are 
shown by GO numbers in parenthesis following their name, epigenetic modifications 
from the ENCODE histone modifications 2015 project are shown by “-hg19” 
following gene set names to be distinguished from those from the Epigenomics 
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Roadmap project, gene sets from the Cancer Cell line Encyclopedia are shown by cell 
line names following cancer type in upper case, disease signatures from the gene 
expression omnibus (GEO) are shown in upper case followed by GSE accession 
numbers, KEGG 2015 and the Human Gene Atlas gene sets are shown in lower case. 
Refer to Enrichr for a complete list of all gene sets included in more than 70 libraries.   
3.5.17 Cancer genes  
 
A list of 12 cancer drivers common in multiple human cancers was considered 
(Tamborero et al., 2013) (tumor protein p53 (TP53), phosphate and tensin homolog 
(PTEN), neuroblastoma RAS viral oncogene homolog (NRAS), epidermal growth 
factor receptor (EGFR), isocitrate dehydrogenase 1(IDH1), isocitrate dehydrogenase 2 
(IDH2), CCCTC-binding factor (CTCF), von Hippel-Lindau tumor suppressor, E3 
ubiquitin protein ligase (VHL), catenin beta 1 (CTNNB1), nuclear factor erythroid-2 
like 2 (NFE2L2), phosphoinositide-3-kinase, regulatory subunit 1 (PIK3R1), and ms-
related tyrosine kinase 3 (FLT3)). These genes were consistently identified as 
candidate cancer drivers by 4 independent positive selection detection algorithms in a 
comprehensive pan-cancer analysis of thousands of TCGA tumors (Tamborero et al., 
2013). I added to this list, well-known cancer drivers not included in the above list 
(Kirsten rat sarcoma viral oncogene homolog (KRAS), B-Raf proto-oncogene, 
serine/threonine kinase (BRAF), phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha (PIK3CA), and breast cancer 1, early onset (BRCA1)). In 
addition to these common cancer drivers, I also considered a number of cancer type-
specific genes including receptors important in specific subtypes of cancers (estrogen 
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receptor 1(ESR1), androgen receptor (AR), erb-b2 receptor tyrosine kinase 2 
(ERBB2)). Finally, cancer genes frequently aberrantly methylated in human cancers 
were also considered (Heyn and Esteller, 2012) (RAS association domain family 
member-1 (RASSF1), glutathione S-transferase pi 1 (GSTP1), adenomatous polyposis 
coli (APC), and O-6-methylguanine-DNA methyltransferase (MGMT)),  together 
constructing a list of 23 cancer genes for detailed analysis of DNA methylation shown 
in Figure 3.4.  
3.5.18 Evaluation of model performance using randomized responses 
 
In order to test the reliability of the variable contribution results obtained from 
my gene-specific DNA methylation models, I built two different randomized data sets 
as control responses, each with the same dimensions as the original response dataset 
(i.e. the cancer gene DNA methylations). In the first case, I permuted the DNA 
methylation values of each cancer gene, and repeated the modeling using the met 
cycle variables. In the second case, I generated random beta-values (from uniform 
distribution in the range of 0-1) and used those as the response variables in the 
calculations.  I then compared average met cycle variable importance (Random Forest) 
and variable usage (Elastic Net) from prediction of true cancer gene methylations vs. 
permuted methylations and randomly generated responses. The Kolmogrov-Smirnov 
test p-values were calculated between the distributions as illustrated in Figure A2.S9B. 
3.5.19 Evaluation of model performance using randomized predictors  
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Using prostate cancer as an example, Lucas Mentch performed simulation tests 
to determine whether the Random Forest as a methodology is able to utilize the 
information in the prediction variables beyond what could be expected if the 
predictors were only random noise and unrelated to the response. To investigate this, 
he modeled methylation in the prostate cancer dataset at 3 example cancer loci 
(GSTP1, RASSF1, and PITX2). These genes were selected based on previous evidence 
indicating the critical importance of their aberrant methylation in prostate cancer 
(Heyn and Esteller, 2012; Litovkin et al., 2014). As controls, he generated 3 additional 
datasets. For the first dataset, he copied the exact response as the GSTP1 methylation, 
but randomly generated a predictor variable set of the same dimensions as the original 
variable set by sampling from a standard normal distribution. That is, each observation 
on each variable is a sample from a normal distribution of unit variance and should 
therefore have no relationship to the response. The other two datasets were generated 
in the same fashion, using RASSF1 and PITX2 methylation as responses and randomly 
generated variable sets as predictors. To assess the performance of the Random Forest 
computations, Lucas Mentch compared the mean squared error (MSE) from 
predictions made using the original data with those made by the datasets consisting of 
random variables unrelated to the responses. For each of the three responses, he 
randomly divided the data into training and test sets, generated a total of 100 
simulations consisting of 500 decision trees, and compared the resulting MSEs of the 
predictions made on the test points. Results are summarized in Figure A2.S10A-D. 
To quantify the improvement in the Random Forest algorithm by using the 
original variables over the randomly simulated variables, Lucas Mentch defined an 
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improvement metric (MSE-Imp), describing the relative improvement in prediction 
accuracy: 
MSE-Imp :=  𝐌𝐒𝐄C𝐫𝐚𝐧𝐝𝐌𝐒𝐄C𝐨𝐫𝐢𝐠  
where MSE-rand is the average MSE calculated using the random simulated variables 
and MSE-orig is the average MSE calculated using the original variables. 
In this test, another simulated dataset of the same dimensions as the original dataset 
was generated where the variables and response were linearly related via the following 
equation: 
Y= 𝜷𝒊𝑿𝒊𝑷𝒊8𝟏 + 	𝜺 
To generate this linear dataset, he sampled the value of each prediction variable Xi 
from a standard normal distribution and the noise ε from a normal distribution with 
mean 0 and standard deviation 0.05. The values of the coefficients βi were selected 
uniformly at random from the interval [0,1]. He then measured the MSE improvement 
(MSE-Imp) for the linear dataset using the same approach as MSE improvements for 
the original datasets were calculated (explained in the previous paragraph). This 
allowed us to compare a linearly simulated dataset to my real dataset. Results are 
shown in Figure A2.S10E-F. 
 
3.5.20 Network construction 
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Genes in the serine, glycine, one-carbon (SGOC) network (including the met 
cycle genes) that were among the most highly ranked variables (top 15%) in at least 4 
of the cancer datasets according to the Elastic Net models and at least 3 of the cancer 
datasets according to the Random Forest models were selected. A metabolic network 
consisting of these enzymes was then constructed using MetScape (Gao et al., 2010)  
where nodes represent genes and metabolites, and edges represent biochemical links. I 
fixed the node size for metabolites but adjusted node sizes for genes to correspond to 
the number of cancers in which each variable was highly ranked (among the top 15% 
of all variables) (Figure 3.4G). For nodes not directly connected to the rest of the 
network, I manually added dashed lines where appropriate.  
3.5.21 Survival analyses 
 
In each cancer type, the average error of prediction of DNA methylation at 
cancer loci was measured for each patient across all Elastic Net models using only met 
cycle variables for prediction. Patients were then divided into 2 groups based on 
predictability of their methylation by the met cycle activity (“predictable”= below-
median prediction error, “not predictable”= above-median prediction error). To 
estimate overall survival time, “days-to-death” was used with vital status information 
and last follow-up date used to right-censor subjects (subjects alive at last follow-up 
were censored from the analysis beyond their last follow up date). The relationship 
between survival and predictability was then analyzed using the “survfit” function in 
the R package “survival” (Therneau, 2015) and visualized by Kaplan-Meier curves. 
Log rank test p-values were calculated by fitting models of overall survival to patients’ 
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“predictability” group assignments using the “survdiff” function in the survival 
package for each cancer type separately. Results are depicted in Figure 3.5. 
3.5.22 Multivariate Cox regression  
 
In the three cancer types (brain, liver, and kidney) where univariate analysis 
showed a highly significant difference in survival between the predictable and non-
predictable groups as described above, and also the sample size allowed for sufficient 
power to perform multivariate analysis, I used relevant clinical and mutational factors 
as covariates and repeated the survival analysis. The following factors were 
individually tested as covariates in separate models of overall survival along with 
“predictability” status as the fixed effect: Brian cancer: all frequent somatic mutations, 
histological diagnosis, age, gender, and initial weight; Liver cancer: all frequent 
somatic mutations, tumor stage, history of other malignancies, and residual tumor; 
Kidney cancer: all frequent somatic mutations, age, and race.  In each case, the results 
of regression using the “coxph()” function in R provided the p-value for the 
significance of the predictability status when modeling overall survival in the presence 
of covariates.  
3.5.23 Software  
 
All computational and statistical analyses were done using R 3.1.2 (R-Core-
Team, 2014). Distribution plots, box-plots, scatter-plots, and bar-plots were made in 
GraphPad Prism version 6 (GraphPad Software, San Diego California USA, 
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www.graphpad.com). Circular plots were generated using Circos (Krzywinski et al., 
2009). 
3.5.23 Code availability 
 
R script is available through the following Github repository 
(https://github.com/mahyam/DNA-methylation-and-metabolism-R-code).  
3.5.24 Data availability 
 
All data used in this study was obtained from the TCGA data portal available 
online at: https://gdc.nci.nih.gov/. 
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CHAPTER 4: INVESTIGATING THE DETERMINANTS OF METHIONINE 
IN THE HUMAN SERUM 4 
 
4.1 Abstract 
 
Methylation of DNA and histones are two of the major epigenetic mechanisms 
known to regulate gene expression. A direct link between epigenetics and the activity 
of the methionine cycle as the source of the methyl donor for methylation reactions 
has previously been established. In order to assess the validity of this relationship in 
humans for potential dietary interventions, it is critical to quantitatively assess inter-
individual variation in methionine levels. In this work, I design a computational model 
to characterize variation in serum methionine in healthy human subjects and identify 
its determinants. I show that methionine variability in fasting serum is commensurate 
with concentrations needed for epigenetic changes and can be partly explained by diet 
and clinical factors. 
4.2 Introduction 
 
The one-carbon (1-C) metabolic network is considered the cellular source of S-
adenosyl-methionine (SAM) — the universal methyl donor in all methylation 
reactions (Crider et al., 2012). Methionine is converted to SAM through the action of 
																																								 																				
4 Some of the text was published in: Mentch S.J., Mehrmohamadi M, Huang L., Liu X., Gupta 
D., Mattocks D., Gómez Padilla P.,  Ables G.,  Bamman M.M., Thalacker-Mercer A.E., 
Nichenametla S. , Locasale J.W., Histone Methylation Dynamics and Gene Regulation Occur 
through the Sensing of One-Carbon Metabolism. Cell Metabolism 22, 861-873 (2015). 
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methionine adenosyl transferase (MAT) enzymes and this provides an important 
regulatory link between 1-C metabolism and epigenetics (Locasale, 2013).  Studies in 
human pluripotent stem cells have demonstrated that a depletion of methionine, which 
is the precursor to SAM could lead to changes in histone and DNA methylation 
(Shiraki et al., 2014).  However, these changes are also accompanied by widespread 
induction of stress response pathways and cell death confounding the interpretation of 
whether the epigenetic changes occurred directly through the sensing of SAM status.  
Furthermore, previous studies have provided evidence that under pathological 
conditions, aberrant expression of nicotinamide N-methyltransferase (NNMT)—an 
enzyme that metabolizes SAM— has profound biological consequences resulting from 
changes in histone methylation (Kraus et al., 2014; Ulanovskaya et al., 2013). 
Previous work from our group has provided evidence for the regulatory role of 
1-C metabolism in epigenetics. We have reported a significant contribution from 
expression levels of methionine cycle enzymes in predicting DNA methylation status 
in human tumors (Mehrmohamadi et al., 2016). Furthermore, we have performed 
methionine restriction experiments in cell lines as well as in mice to assess the link 
between the methionine cycle and epigenetics (Mentch et al., 2015). Mentch et al. 
found that both SAM levels and the SAM/SAH ratio can be quantitatively tuned 
through changes in the metabolic flux of the methionine cycle to affect histone 
methylations to control numerous physiological processes including direct feedback 
regulation for the maintenance of homeostasis in 1-C metabolism and the activity of 
genes involved in cancer and cell fate (Mentch et al., 2015). She further illustrated this 
link by dietary restriction of methionine in mice and reported alterations in histone 
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methylation in the liver (Mentch et al., 2015). However, whether 1-C metabolism’s 
relationship with methylation also occurs in humans at physiological conditions 
requires further investigation. 
Here, I use computational modeling and integrate clinical and environmental 
information including diet records to determine the contribution of different factors in 
explaining variation in human serum methionine levels. I identify specific dietary 
sources that may have a significant impact on serum methionine levels. Together, my 
results complement Mentch’s findings and confirm that the regulation of epigenetics 
through 1-C metabolism occurs at physiologically relevant concentrations of 
methionine, and diet explains a significant portion of overall variation in serum 
methionine levels. The results of this work have been published as a separate section 
in the same manuscript (Mentch et al., 2015). 
 
4.3 Results 
4.3.1 Humans exhibit variability in methionine levels  
 
I asked whether variability in methionine metabolism exists in humans and 
how it can be regulated.  Standard clinical parameters and a record of dietary intake 
over four days was considered to reflect variations in habitual diet as is standard 
practice in clinical nutrition (Levine et al., 2014) across a cohort of healthy human 
subjects.  Fasting serum was collected and subjected to a metabolomics analysis 
(Figure 4.1A).  We then performed an unsupervised hierarchical clustering of the 
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nutrient intake for each subject and found sets of defined modules that were able to 
classify the subjects into discrete dietary behaviors such as groups that are high in 
fruits and vegetables or carbohydrates (Figure 4.1B).  We next measured the 
concentration of methionine along with a panel of amino acids in these subjects 
(Figure 4.1C).  Strikingly, the concentration of methionine exhibits substantial 
variation with values ranging from 3 to 30 μM, and of all amino acids, methionine 
exhibited the largest variation (Figure 4.1.C).  This variation in concentration is on the 
same order as that needed to induce changes in histone methylation in cells and in 
mice (Mentch et al., 2015).   
 
Figure 4.1 – Methionine and metabolic variation in human subjects.5  
A) Measurement of serum methionine and clinical and dietary variables in human subjects.   
B) (left) Hierarchical clustering of the distance matrix diet variables. (right) k-means 
clustering of subjects and diet variables (N=24).   
C) Absolute concentrations of amino acids in fasting serum in 38 human subjects.  
																																								 																				
5 Credit goes to Samantha J. Mentch:  Mentch, S.J., Mehrmohamadi, M., Huang, L., Liu, X., 
Gupta, D., Mattocks, D., Gomez Padilla, P., Ables, G., Bamman, M.M., Thalacker-Mercer, 
A.E., et al. (2015). Histone Methylation Dynamics and Gene Regulation Occur through the 
Sensing of One-Carbon Metabolism. Cell metabolism 22, 861-873.  
		 106	
 
We next considered the correlations among various serum metabolites that 
were quantified (Figure 4.2A), and observed that levels of metabolites in the taurine 
and glutamine metabolic pathways correlate with the methionine metabolism 
intermediates in the serum (Figure 4.2B). In addition, methionine in the serum 
correlated with N,N,N-trimethyllysine and N-methylglycine (sarcosine), both of which 
are methylated by the transfer of methyl groups from SAM, suggesting that 
methionine levels in the serum are indicative of cellular methylation status (Figure 
4.3A) with clear patterns of food consumption that corresponded to both high and low 
methionine intake (Figure 4.3B).  
 
      Figure 4.2— Serum metabolic profiles in human subjects. 6 
A) Measurement of a metabolomics profile across the human cohort (N=38).  Results of 
unsupervised clustering of a distance matrix for metabolites are shown.   
B) Pathways that correspond to clusters observed in (A).  Pathways were identified from 
consideration of the highest pathway impacts of all metabolites contained in the specified 
cluster denoted by different colored boxes.  
 
																																								 																				
6 Credit goes to Samantha J. Mentch.  
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Vegetable-based nutrients such as fiber correlated with low methionine levels and 
age, body weight and fat intake correlated with high methionine levels.  Surprisingly, 
protein intake exhibited no correlation with methionine.  An analysis of the 
metabolites and pathways that correlated with methionine levels revealed pathways 
related to ketogenesis and amino metabolism (Figure 4.3C).  Taken together, these 
findings demonstrate that the variability in methionine concentration in humans is on 
the same scale as that needed to induce alterations in histone methylation and that 
these differences correlate with changes in diet and health status.   
 
Figure 4.3— Analysis of methionine-correlated serum metabolites. 7 
A) Correlation of methionine in the serum with methylated serum metabolites, N,N,N- 
trimethyllysine and sarcosine.  
B) Correlation of methionine concentrations with dietary variables obtained from habitual 
diet records.   
C) Correlation of methionine concentrations with fasting serum metabolite levels.    
 
4.3.2 A computational model identifies factors that determine methionine levels                        
 
																																								 																				
7 Credit goes to Samantha J. Mentch.  
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Having identified associations of methionine with diet and other factors, I next 
built a computational model to identify the direct influences on methionine 
concentration.  I considered a mixed effects model that aims to identify causal features 
in high dimensional data and thus identifies factors that give rise to the variation in 
methionine levels (see Methods).  I considered dietary intake variables, clinical 
variables such as age, gender, and body composition measured by Dual X-ray 
Absorptiometry (DEXA).  To reduce the dimensionality of the data matrix, I filtered 
the variables first according to their correlations with methionine, and then carried out 
a principle components analysis on the DEXA variables (Figure 4.4A), and finally 
checked the resulting twelve variables for collinearity (Figure 4.4B). I then carried out 
a regression with maximum likelihood estimation (Methods) using least squares to 
obtain a model with good fit (P < 10-4, F test) to the experimentally measured 
methionine concentrations (Figure 4.5A,B).   
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Figure 4.4— A computational model identifies determinants of methionine variability. 
A) Eigenvalue spectrum form principal components analysis of DEXA variables.   
B) Calculation of variance inflation factor for each variable.    
 
An analysis of the coefficients revealed several contributions to methionine 
variation including age, body composition and gender (with maleness contributing to a 
positive influence) and diet including variables known to be associated with 
methionine such as zinc and tocepherol (Figure 4.5C).  Using established guidelines 
(Methods), we was found that the diet variables could be related to major sources of 
food intake (Figure 4.5D) with for example, fats, seafood and meat contributing to 
higher concentrations of methionine.   
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Figure 4.5— A computational model identifies determinants of methionine variability. 
A) Overview of variable selection for the computational model.   
B) Predicted versus measured methionine levels in human subjects (model fit).   
C) Regression coefficients.  Error bars are obtained from maximum likelihood estimates.   
D) Schematic of dietary factors that contribute to each modeled variable.   
E) Results from variance partitioning.   
 
4.3.3 Variance partitioning quantifies relative contributions of factors explaining 
methionine variation 
 
Finally, my collaborator Lei Huang and I calculated the proportion of variance 
explained by each of the categories of variables in the study using variance 
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partitioning (Methods).  We found that about thirty percent of the variation in human 
serum methionine is explained by diet, about thirty percent explained by clinical 
variables including gender and age and the remaining unaccounted variance is likely 
due to genetic differences (Figure 4.5E).  These results indicate that physiological 
methionine concentrations observed in humans are determined by several factors 
including diet, suggesting potential for dietary intervention in cases of pathological 
states where methionine is implicated to play a role.  
4.4 Discussion 
 
Previous in silico, in vitro, and in vivo experiments have provided evidence for 
the contribution of 1-C metabolism to cellular epigenetics through the activity of the 
methionine cycle. The goal of the present work was to assess the relevance of these 
findings in humans under physiological concentrations of methionine. The variation of 
methionine in the serum of healthy individuals was found to be largest across a panel 
of serum amino acids.  Although these measurements are by no means exhaustive of 
human population dynamics, concentrations in many individuals in our cohort were 
found to be far lower than the concentration required for inducing changes in 
methylation levels.  Computational modeling of diet and clinical variables found that 
about thirty percent of the variation could be due to fundamental clinical variables 
such as age, body composition, and gender, and about thirty percent was explained by 
variations in individuals’ diets.  Approximately 20% of the variation remained 
unexplained by our models, which we speculate to be at least in part due to genetic 
factors. In the future, the results from these models could further be integrated with 
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genomics data to specifically define the genetic contributions as have been identified 
to associate with serum metabolite levels (Suhre et al., 2011).  Nevertheless it is 
tempting to speculate that the intake of basic dietary factors such as vegetables and fat 
could mediate human epigenetics through modulation of methionine metabolism. 
Previous studies have demonstrated a wide range of physiological responses to dietary 
methionine restriction, the most well known example of which is extension of lifespan 
(Ables et al., 2016). However, detailed molecular and cellular mechanisms through 
which methionine restriction acts remain largely unknown. Our results suggest 
potentials for epigenetic alterations through dietary intervention experiments using 
varying levels of methionine in both normal and pathological conditions.  
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4.5 Methods 
4.5.1 Human Subjects  
 
Serum samples, 4-day diet records, and body composition results (via DEXA 
scan) on 24 de-identified healthy older adults were provided by Marcas Bamman at 
the University of Alabama at Birmingham (UAB).  As part of the UAB Institutional 
Review Board-approved parent project, all 24 subjects agreed to have their samples 
and data used for future research.  
4.5.2 Clinical Nutrition Studies  
 
A four-day diet record was collected according to previous standards of 
recording diet to reflect habitual behaviors as has been previously described (Levine et 
al., 2014).  Surveys were converted into nutritional variables according to previously 
described procedures using standard software (Levine et al., 2014).  Nutrition data 
system for research (NDSR) dietary analysis software (University of Minnesota), a 
comprehensive food and nutrient database, was used to determine the average macro- 
and micronutrients consumed over the four-day period as previously described 
(Thalacker-Mercer et al., 2009).  Before serum was collected, each subject was 
subjected to overnight fasting.  Metabolites from serum were extracted using a 
previously described protocol(Shestov et al., 2014).  All additional clinical variables 
were recorded according to previously described methods(Thalacker-Mercer et al., 
2013; Thalacker-Mercer et al., 2009).  
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4.5.3 Metabolite Extraction 
 
For culture from adherent cells, the media was quickly aspirated and cells were 
washed with cold PBS on dry ice.  Then, 1mL of extraction solvent (80% 
methanol/water) cooled to -80°C was added immediately to each well, and the dishes 
were transferred to -80°C for 15 min.  Plates were removed and cells were scraped 
into the extraction solvent on dry ice.  For tissue, the sample was homogenized in 
liquid nitrogen and then 5 to 10 mg was weighed in a new Eppendorf tube.  Ice-cold 
extraction solvent (250μL) was added to each tissue sample and homogenized using a 
tissue homogenizer.  The homogenate was incubated on ice for 10 min.   For plasma 
or serum, 20 μL was transferred to a new Eppendorf tube containing 80 μL HPLC 
grade water.  Next, 400 μL of ice-cold methanol was added to the sample for a final 
methanol concentration of 80% (v/v).  Samples were incubated on ice for 10 min.  All 
metabolite extracts were centrifuged at 20,000g at 4°C for 10 min.  Finally, the solvent 
in each sample was evaporated in a Speed Vacuum for metabolomics analysis.  For 
polar metabolite analysis, the cell extract was dissolved in 15 μL water and 15 μL 
methanol/acetonitrile (1:1 v/v) (LC-MS optima grade, Thermo Scientific).  Samples 
were centrifuged at 20,000g for 10min at 4°C and the supernatants were transferred to 
Liquid Chromatography (LC) vials.  The injection volume for polar metabolite 
analysis was 5 μL. 
4.5.4 Liquid Chromatography  
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An Xbridge amide column (100 x 2.1 mm i.d., 3.5 μm; Waters) is employed on 
a Dionex (Ultimate 3000 UHPLC) for compound separation at room temperature. The 
mobile phase A is 20 mM ammonium acetate and 15 mM ammonium hydroxide in 
water with 3% acetonitrile, pH 9.0 and mobile phase B is acetonitrile. Linear gradient 
as follows: 0 min, 85% B; 1.5 min, 85% B, 5.5 min, 35% B; 10min, 35% B, 10.5 min, 
35% B, 14.5 min, 35% B, 15 min, 85% B, and 20 min, 85% B. The flow rate was 0.15 
ml/min from 0 to 10 min and 15 to 20 min, and 0.3 ml/min from 10.5 to 14.5 min.  All 
solvents are LC-MS grade and had been purchased from Fisher Scientific.  
4.5.5 Mass Spectrometry  
 
The Q Exactive MS (Thermo Scientific) is equipped with a heated electrospray 
ionization probe (HESI), and the relevant parameters are as listed: evaporation 
temperature, 120 °C; sheath gas, 30; auxiliary gas, 10; sweep gas, 3; spray voltage, 3.6 
kV for positive mode and 2.5 kV for negative mode. Capillary temperature was set at 
320°C, and S-lens was 55. A full scan range from 60 to 900 (m/z) was used. The 
resolution was set at 70,000.  The maximum injection time was 200 ms. Automated 
gain control (AGC) was targeted at 3,000,000 ions. 
4.5.6 Metabolomics and Data Analysis 
 
Raw data collected from LC-Q Exactive MS is processed on Sieve 2.0 
(Thermo Scientific). Peak alignment and detection are performed according to the 
protocol described by Thermo Scientific.  For a targeted metabolite analysis, the 
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method “peak alignment and frame extraction” is applied. An input file of theoretical 
m/z and detected retention time of 263 known metabolites is used for targeted 
metabolites analysis with data collected in positive mode, while a separate input file of 
197 metabolites is used for negative mode. M/Z width is set at 10 ppm.  The output 
file including detected m/z and relative intensity in different samples is obtained after 
data processing.  Dot plots and other quantitation and statistics were calculated and 
visualized with the Graphpad prism software package. 
4.5.7 Computational Modeling 
 
In brief, a set of 12 predictor variables were obtained after a variable selection 
process that incorporates methionine correlations, a dimensional reduction of the 
Dual-energy X-ray Absorptiometry (DEXA) data using principal components analysis, 
and a collinearity assessment using the variance inflation factor.  I next fitted a mixed 
effects linear model including the set of predictor variables, a random effect term and 
noise.  Model selection was carried out using exhaustive sampling and optimization of 
the Akaike information criteria.  Variance contributions for each variable and random 
effect were summed to define the total contribution of variance for each variable and 
unexplained factor.  The full details of the modeling are contained in the Supplemental 
Information. 
4.5.7.1 Detailed Description 
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The dataset consists of 24 samples of serum methionine concentration (SMC) 
and 233 predictor variables. To understand what factors determine SMC, I develop a 
linear mixed model (a type of linear regression analysis) following the steps: 
The final model: 
𝒚𝒊 = 𝜷𝟎 + 𝜷𝒌𝑿𝒊,𝒌	𝒌 + 𝒁𝒊 + 𝜺𝒊 
 
where 𝒊 = 𝟏,… , 𝟐𝟒 indexes the samples, 𝒚𝒊 denotes SMC for the i-th sample, 𝑿𝒊,𝒌	 	(𝒌 =𝟏,… , 𝟏𝟐) represent the 12 predictor variables that I model as fixed effect (intercept, 
alpha carotene, galactose, gamma tocopherol, gadoleic acid, arachidic acid, synthetic 
alpha tocopherol, vitamin E, zinc, age, gender, height, body composition), 𝒁𝒊 denotes 
the i-th sample that I model as random effect, and 𝜷𝟎, 𝜷𝟏, 𝜷𝟐, 𝜷𝟑 and 𝝐𝒊 are the standard 
parameter and noise terms in linear regression. 
4.5.7.2 Variable Selection 
 
Since the number of predictors vastly outnumber the sample size and 
presumably only a small subset of the predictors are related to SMC, I first have a 
filtering step to pick out the predictors that significantly correlate with SMC. To do 
this, each of the 233 predictors is individually fit to the following linear mixed model.  
A p-value cutoff of 0.05 for the significance of correlation is used, after which 34 
variables are left; no correction for multiple testing is conducted in order to include as 
many potentially relevant variables as possible.  I mention that a linear mixed model, 
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rather than an ordinary linear model, is chosen to account for the fact that some 
samples are not independent but come from the same individuals. 
21 of the 34 variables are Dual-energy X-ray absorptiometry (DEXA) 
variables that measure bone mineral density. An inspection of the correlation matrix 
and the principal components analysis (PCA) spectrum revealed that they are highly 
correlated with each other. Therefore, I condensed each of the 21 variables into a 
single one by using the first principal component.  Large gaps between the leading and 
following eigenvalues in the PCA spectrum suggests that little information is lost in 
such a condensation. 
I performed a standard procedure of variable selection using the remaining 14 
variables to achieve a good balance of model predictive power and simplicity. I follow 
the suggestion of Faraway and use the Akaike information criterion (AIC) as my 
criterion for model selection: the model with the lowest AIC is selected. With only 14 
candidate variables, I performed an exhaustive evaluation of the AIC of all possible 
models. This lead to the selection of a model with 12 variables.  
Among the final 12 variables, it is important to assess whether there is 
collinearity.  Collinearity refers to the situation in which some predictors contain 
heavily redundant information and causes problems for parameter identifiability and 
model interpretation. None of the variables was significantly correlated with any of the 
others (corresponding to an often-suggested threshold of 10 for variance inflation 
factor), confirming a lack of collinearity among my 12 variables. 
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4.5.7.3 Model Analysis 
 
For a multiple linear regression 𝒚 = 𝑿𝜷 + 𝜺, a common interpretation is of a 
geometric kind: given vector 𝒚, find a linear combination of the column vectors of 𝑿, 𝒚 = 𝑿𝜷, such that 𝒚 − 𝒚  is the smallest, or equivalently, 𝒚 − 𝒚 is orthogonal to 𝒚 . 
When the set of predictors has a natural partition, such as diet vs. non-diet variables in 
my case, the model can be written as 𝒚 = 𝑿𝜷 + 𝒁𝜸 + 𝜺, where 𝑿𝜷 and 𝒁𝜸 
correspond to the two groups of predictors. 
The goodness-of-fit by the linear model is often measured by the so-called 
coefficient of determination, 𝑹𝟐, which also has a geometric interpretation: let 𝑺𝑺𝑻 =(𝒊 𝒚𝒊 − 𝒚)𝟐 = 𝒚 − 𝒚 𝟐 be the total sum of squares (variation), it can be shown that 𝒚 − 𝒚 𝟐 = 𝒚 − 𝒚 𝟐 + 𝒚 − 𝒚 𝟐 = 𝑺𝑺𝑬 + 𝑺𝑺𝑹, where SSE and SSR stand for the 
explained and residual sum of squares, respectively; 𝑹𝟐 is then the proportion of 
explained sum of squares (variation) out of the total variation, 𝑺𝑺𝑬𝑺𝑺𝑻 = 𝒚C𝒚 𝟐𝒚C𝒚 𝟐 . When the 
predictors have two groups, 𝒚 = 𝒙 + 𝒛 = 𝑿𝜷 + 𝒁𝜸 and 𝒚 = 𝒙 + 𝒛 . Hence SSE can 
be partitioned into three parts: 𝑺𝑺𝑬 = 𝒚 − 𝒚 𝟐 = (𝒙 + 𝒛) − (𝒙 + 𝒛) 𝟐 =(𝒙 − 𝒙) + (𝒛 − 𝒛) 𝟐 = 𝒙 − 𝒙 𝟐 + 𝒛 − 𝒛 𝟐 + 𝟐 𝒙 − 𝒙, 𝒛 − 𝒛 ; plugging it into the 
definition of 𝑹𝟐, I have 
𝑹𝟐 = 𝑆𝑺𝑬𝑺𝑺𝑻 = 𝒚 − 𝒚 𝟐𝒚 − 𝒚 𝟐 = 𝒙 − 𝒙 𝟐 + 𝒛 − 𝒛 𝟐 + 𝟐 𝒙 − 𝒙, 𝒛 − 𝒛𝒚 − 𝒚 𝟐
= 𝑺𝑺𝑬𝒙𝑺𝑺𝑻 + 𝑺𝑺𝑬𝒛𝑺𝑺𝑻 + 𝑺𝑺𝑬𝒙𝒛𝑺𝑺𝑻 = 𝑹𝒙𝟐 + 𝑹𝒛𝟐+𝑹𝒙𝒛𝟐  
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which I interpret as the proportions of total variation explained by the first group of 
predictors, the second, and their interactions, respectively. 
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CHAPTER 5: IDENTIFYING GENE EXPRESSION SIGNATURES OF 
RESPONSE TO ANTIMETABOLITE CHEMOTHERAPIES8 
 
5.1 Abstract 
 
Chemotherapeutic agents that target cellular metabolism are widely used in the 
clinic and are thought to exert their anti-cancer effects mainly through non-specific 
cytotoxic effects. However, patients vary dramatically with respect to survival and 
cancer outcome in response to treatment with these antimetabolite agents. Specific 
sources of this heterogeneity remain largely unknown. A deeper understanding of the 
extent that molecular information encoded in the metabolic pathways targeted by 
antimetabolite agent can explain variability in response is lacking. Here, I introduce a 
method for identifying gene expression signatures of response to chemotherapies and 
apply it to human tumors as well as cancer cell lines. This approach to analyzes 
genome-wide expression in an unbiased manner and identifies distinct favorable and 
unfavorable metabolic expression signatures. Importantly, metabolic pathways 
targeted by antimetabolites are enriched in the expression signatures. Finally, I 
characterize seventeen antimetabolite agents in various contexts and demonstrate that 
unlike common notion about their non-specific cytotoxicity, in fact specific metabolic 
factors explain variation in sensitivity to these agents.  
																																								 																				
8 Manuscript under preparation for publication. Authors: Mehrmohamadi M, Jeong S.H., 
Locasale J.W. 
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5.2. Introduction 
 
Cancer cells adapt their metabolism to meet the requirements of inappropriate 
growth, survival and proliferation (Pavlova and Thompson, 2016; Schulze and Harris, 
2012). Since these demands are often not present in non-neoplastic cells to the same 
extent, there is considerable interest in exploiting these alterations for therapeutic 
advances. Antimetabolite chemotherapies are one of the most commonly used 
therapeutic strategies for the treatment of neoplastic disease (Chabner and Roberts, 
2005).  Historically, some of the first successful chemotherapeutic agents were derived 
from intermediates in the synthesis of folates (Farber, 1949; Farber and Diamond, 
1948). Subsequently, there are now at least seventeen agents approved in the United 
States that target a specific metabolic enzyme (Cheung-Ong et al., 2013).  These 
agents can often be tolerated and can achieve remarkable responses in advanced stage 
cancers leading to complete remission in many cases.  However, the clinical responses 
to these agents are heterogeneous with some patients exhibiting resistance.  
There is little molecular level information that is used clinically for 
prognostication.  For instance, 5-fluorouracil (5-FU) is a widely used antimetabolite 
chemotherapy that interferes with pyrimidine biosynthesis by targeting the enzyme 
thymidylate synthetase (TYMS). Previous studies of association between cellular 
levels of TYMS and tumor response to 5-FU have been controversial, and currently 
TYMS expression is not used as a biomarker in clinical decision-making (Showalter et 
al., 2008). Other studies have found TP53 mutational status as the only strong 
predictor of 5-FU outcome (Iorio et al., 2016; Kandioler et al., 2015). However, it 
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remains unclear whether the activity of the specific pathway that is targeted by 5-FU 
has any association with its impact on tumors.  Other agents such as Methotrexate and 
Gemcitabine also have specific targets within one-carbon metabolism and nucleotide 
metabolism, but no successful biomarkers of response to these agents within the 
metabolic network are known.  
The wealth of genomic information on annotated tumors now publically 
available through the cancer genome atlas (TCGA) allows these questions to be 
addressed in a more systematic way than previously possible. One study applied an 
unbiased analysis of genomic data on the TCGA ovarian cancer tumors and 
specifically looked for prognostic markers of response to Cisplatin using progression 
free survival of recipients, and was able to identify novel genetic and epigenetic 
subgroups with variable outcome (Hsu et al., 2012). Despite difficulties in studying 
drug response in human patients in the presence of numerous confounding factors and 
heterogeneity in therapeutic regimens, the unbiased framework introduced in that 
study provided useful insights (Hsu et al., 2012). This motivated us to apply a similar 
approach to identify gene expression subgroups of response to antimetabolite 
chemotherapies.   
Unlike limitations associated with studying drug response in patients, cell line 
studies of drug response are more straightforward in some ways as cells are cultured in 
highly controlled laboratory environments, and dose-response analysis allows for 
careful quantification of sensitivity.  A recent study used a large panel of cell lines 
from the catalog of somatic mutations in cancer (COSMIC) collection and 
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characterized molecular markers of response to hundreds of different drugs (Iorio et 
al., 2016). This drug panel included a number of antimetabolite chemotherapies 
including MTX, 5-FU, and Gemcitabine, together with a number of other agents 
grouped as “cytotoxic drugs”. This study comprehensively evaluated thousands of 
molecular features in their ability to act as predictive markers of sensitivity and found 
the TP53 mutational status as the most dominant marker for antimetabolite agents 
mentioned above. For 5-FU, a handful of copy number variants (CNVs) were also 
found to be predictive of cell line resistance (Iorio et al., 2016). However, this study 
did not explore gene expressions beyond expression of only 11 popular pathways, 
which found no significant predictors. It remains to be investigated whether any 
differences among antimetabolite agents can be captured in gene expression signatures 
of response to each, and whether such gene expression signatures can add to our 
power of distinguishing subtypes with heterogeneous outcome.  
Here, I carry out an investigation of a set of antimetabolite compounds that 
target metabolic enzymes for use in cancer therapy.  These agents target different 
pathways including folate synthesis, nucleotide metabolism, and glutathione 
biosynthesis.  I first develop an unbiased approach to identify gene expression 
signatures of response in patients. Subsequently, I consider cell line analysis as a 
complementary approach to assess markers of cell line sensitivity to antimetabolite 
agents. Together, my results demonstrate specificity in molecular markers and identify 
metabolic determinants of response to these agents.    
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5.3. Results 
5.3.1 Gene expression signatures of response to antimetabolite chemotherapy in 
patients are enriched for metabolic pathways 
 
To identify gene expression signatures associated with response to 
chemotherapies in patients, I undertook an unbiased genome-wide approach based on 
step-wise filtering adapted from the framework previously introduced by Hsu et al. 
(Hsu et al., 2012) (Fig. 5.1A). I used the TCGA for the source of my clinically 
annotated human tumor genomic data. Progression free survival (PFS) was used as a 
measure of patient response to chemotherapy. TCGA cancer types in which patients 
were treated with a common antimetabolite agent were considered if both RNA-seq 
gene expression and follow-up data were available for a large enough cohort of 
patients (N>50). Since my goal was to identify subtypes of cancer patients with “good 
response” and “poor response”, I considered each cancer type separately. These 
criteria limited my analyses of human data to 5-FU response in colon cancer and 
Gemcitabine response in pancreatic cancer.  
5.3.1.1 Response to 5-FU in colon cancer 
 
A total of 109 colon cancer patients were considered who received adjuvant 5-
FU therapy as part of their chemotherapy combination. To avoid bias in my analysis of 
gene expression, I considered all of the genes in the genome after filtering out low-
count mRNA expressions (Methods). I first calculated association between expression 
of each gene with PFS using univariate Cox regression (Methods), and filtered out 
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genes that did not show a significant (p<0.05) association. Next, I looked at the 
remaining 446 genes and further filtered out stage, age, TP53 mutation, and nodal 
status associated genes to eliminate confounding factors that might affect association 
of genes with 5-FU response (see Methods). This lead to a final set of 299 genes that 
were each individually significantly associated with patient response to 5-FU in colon 
cancer, and their relationship to PFS was independent of stage, age, TP53 mutation, 
and nodal status of the tumors (Figure 5.1A). Notably, this set included TYMS—the 
direct target of 5-FU. Next, I assessed the power of TYMS expression alone in 
distinguishing response subgroups. For this, I divided tumors into two groups based on 
their TYMS expression level: “low-TYMS” and “high-TYMS” (see Methods). I then 
compared PFS between the two groups using Cox regression and found a modestly 
significant difference in response between the low-TYMS and high-TYMS groups 
(p=4.9e10-2; Figure A3.S1A). Given that adjuvant 5-FU therapy is usually 
administered in stage III colon cancer, I repeated this analysis in stage III tumors only 
(N=59), and found a slightly stronger association (p= 6e10-3; Figure A3.S1B). In both 
analyses, I found that higher expression of TYMS is associated with poorer response 
to 5-FU therapy, consistent with previous reports (Hu et al., 2003; Wakasa et al., 
2015), possibly explained by higher resistance of these tumors to TYMS inhibition. 
I next set out to assess the combined power of all 299 genes in separating 
response subgroups. For this, I used a scheme previously proposed by Hsu et al. for 
DNA methylation (Hsu et al., 2012), and modified the method to apply to gene 
expression analysis (Methods). First, I converted the gene expression matrix into a 
discretized matrix of “favorability scores”, where a gene with high expression in a 
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patient in the better prognosis subgroup was assigned a score of 1 (favorable), and a 
gene with high expression co-occurring with poorer prognosis subgroup was assigned 
a score of -1 (unfavorable), and all other cases were assigned a score of 0 (neutral) 
(see Methods for details). The clustering heatmap of the favorability scores discovered 
distinct subsets of genes (favorable vs. unfavorable) as well as distinct subgroups of 
patients (Figure 5.1B). To assess the functional relevance of the favorable and 
unfavorable gene signatures, I performed gene set enrichment analysis using the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The unfavorable gene 
set was enriched for the following KEGG pathways: Circadian entrainment (p=7e10-
3); Nucleotide sugar metabolism (p=7e10-3); Notch signaling (p=7e10-3); and One-
carbon metabolism (p=1e10-2). TYMS, SHMT2, GALT, RENBP, and AMDHD2 
were among the metabolic genes that had an unfavorable expression in colon cancer, 
meaning that their high expression in patients treated with 5-FU was associated with 
poorer prognosis. Consistent with my results, one-carbon metabolic fluxes have 
previously been shown to correlate with sensitivity to 5-FU in vitro and in mice (Ser et 
al., 2016). These observations illustrate the importance of specific metabolic target 
pathways of 5-FU in explaining part of the variability in patient response to this drug. 
Enrichment analysis on the favorable gene cluster showed enrichment of lipid 
metabolic KEGG pathways (Synthesis of unsaturated fatty acids (p=4e10-4); and Fatty 
acid metabolism (p=2e10-3)), with SCD and ACOX1 fatty acid de-saturases being 
among the metabolic genes in this group. Lipid synthesis has long been known to 
increase upon carcinogenesis, producing cellular membrane subunits for rapidly 
proliferating cells (Beloribi-Djefaflia et al., 2016). However, lipidome analyses have 
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shown that the role of fatty acids in cancers are more complex, with an enrichment of 
saturated fatty acids causing the loss of membrane fluidity, increase in drug resistance, 
and increase in malignancy of cancer cells (Rysman et al., 2010). My results confirm 
previous studies by identifying fatty acid oxidases and de-saturases SCD and ACOX1 
as favorable enzymes, implicating a role for fatty acid metabolism. 
To compare the two patient subgroups identified by this approach, I performed 
k-means clustering on the matrix of favorability scores and identified a distinct 
subgroup enriched with favorable genes (Group 1 in Figure 5.1B), and a second 
subgroup enriched with unfavorable gene expression (Group 2 in Figure 5.1B) (see 
Methods; Figure 5.1B). When PFS was compared between these two subgroups, I 
found a highly significant difference (Cox p= 3.46e-07; Figure 5.1C). This result is 
interesting as it shows that my scheme of discretizing combined gene expression 
signatures followed by favorability scoring and clustering is able to identify prognosis 
subgroups that are significantly more distinct than the subgroups identified based on 
TYMS expression alone, despite TYMS being the direct target of 5-FU. Importantly, 
my gene expression signatures are not associated with other prominent clinical 
predictors of prognosis (e.g. age, stage, nodal status, and TP53 mutation), as I 
controlled for these confounding factors in the gene selection step (Methods; Figure 
5.1A). This suggests that the gene expression signatures identified here offer 
additional information about prognosis beyond what is already captured by commonly 
used clinical metrics. Results also suggest that metabolism is an interconnected 
network of reactions that work in concert together; thus the combined activity of 
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multiple connected genes and pathways is a better reflection of the biological state of a 
tumor than the activity of individual enzymes.  
 
Figure 5.1— Combined gene expression signatures of response to 5-FU in colon cancer 
identify novel subgroups.  
A) Schematic of the step-wise filtering used for gene selection in colon cancer (TCGA COAD).  
B) Hierarchical clustering of heatmap of the discretized gene favorability scores. Columns 
represent genes and rows represent individuals. Favorable scores are shown by the color red 
(F=1), unfavorable by blue (F= -1), and neutral by yellow (F=0) (see Methods).  
C) Kaplan-Meier plot showing progression free survival in the two tumor subgroups identified 
in part B.  
 
5.3.1.2 Response to Gemcitabine in pancreatic cancer 
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I next set out to apply my gene expression analysis method to an independent 
TCGA cohort consisting of pancreatic cancer patients (N=100) who were treated with 
adjuvant Gemcitabine chemotherapy as part of their chemotherapy regimen. 
Gemcitabine is another chemotherapeutic agent that targets nucleotide and glutathione 
metabolism. My gene selection and filtering steps resulted in a set of 665 genes 
associated with PFS in this cohort after controlling for patient age, tumor grade, and 
TP53 mutational status (Figure 5.2A). Visualization of a discretized expression 
heatmap made apparent subsets of favorable and unfavorable genes (Figure 5.2B). 
Pathway analysis of the favorable gene set showed Glycerophospholipid metabolism 
(p=1e10-4) pathway being enriched, while the following KEGG pathways were 
enriched in the unfavorable expression signature: Mitotic cell cycle and nuclear 
division (p<10e-9), Viral carcinogenesis (p=2e10-4), Mismatch repair (p=2e10-4), 
Apoptosis (p=8e10-3), and Pyrimidine metabolism (p=1e10-2) (Figure 5.2B). Notably, 
the unfavorable gene set included ribunucleotide reductases RRM1 and RRM2— 
direct targets of Gemcitabine— as well as DTYMK and TK1 in thymidine metabolism 
and NT5E in purine degradation pathways, demonstrating a role for specific target 
pathways of Gemcitabine in explaining response to this agent. The favorable gene 
signature included the following metabolic genes: PLA2G2D, PLA2G4A, PLA2G4C, 
and PLD2 phospholipases, LPGAT1, PNPLA6, AGPAT1, and AGPAT4. This 
observation further supports previous cancer profiling studies that have established 
important structural and signaling roles for phospholipids in the pathogenesis and 
malignancy of cancer cells (Beloribi-Djefaflia et al., 2016).  
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I next performed k-means clustering on the matrix of favorability scores across 
these 665 genes and identified clear subgroups of patients. Comparison of the 
subgroup enriched with unfavorable gene expression with that of the favorable 
subgroup showed a significant difference in PFS (Cox p=1.8e-4; Figure 5.2C). 
Notably, when considered individually, RRM1 and RRM2 each had far less distinctive 
power (Cox p=6e10-3 for RRM1 and p=5e10-3 for RRM2; Figure A3.S2A,B) than the 
combined gene sets, further confirming the advantage of my approach by considering 
pathways rather than individual genes. Together, these results confirm the 
generalizability of this approach for identifying clinically distinct subgroups of cancer 
patients using gene expression signatures.  
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Figure 5.2— Combined gene expression signatures of response to Gemcitabine in 
pancreatic cancer identify novel subgroups.  
A) Schematic of the step-wise filtering used for gene selection in pancreatic cancer (TCGA 
PAAD).  
B) Hierarchical clustering of heatmap of the discretized gene favorability scores. Columns 
represent genes and rows represent individuals. Favorable scores are shown by the color red 
(F=1), unfavorable by blue (F= -1), and neutral by yellow (F=0) (see Methods).  
C) Kaplan-Meier plot showing the progression free survival in the two tumor subgroups 
identified in part (B). 
 
5.3.2 Specificity in gene expression signatures of cell line sensitivity to 
antimetabolite drugs  
 
Due to limitations in the availability of sufficiently annotated human data with 
gene expression and follow-up information, I next turned to cancer cell lines to further 
test the applicability of my method. I used the catalog of somatic mutations in cancer 
(COSMIC) cell line set as the largest collection of annotated cancer cell lines and 
obtained microarray gene expression data as well as drug sensitivity information in the 
form of 50 percent of maximal inhibition of cell proliferation (IC-50) for the same 
agents I had previously tested in human samples (i.e. 5-FU and Gemcitabine). In the 
case of cell lines, I considered a gene favorable if its high expression co-occurred with 
higher sensitivity to drug treatment (lower IC-50), and unfavorable if its high 
expression co-occurred with lower sensitivity (higher IC-50) (see Methods).   
5.3.2.1 Response to 5-FU in colon cancer cell lines 
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A set of 44 cell lines from colorectal origins was considered. For the gene 
selection step, I calculated correlation between expression of every gene in the 
genome with IC-50 value for 5-FU, and selected genes with a Kendall’s tau value of 
0.2 or larger and a corresponding p-value of 0.01 or smaller. A total of 364 genes 
passed this filter (Figure 5.3A). Subsequently, the discretization and favorability 
scoring approach as described in the previous section was applied to this matrix and 
the clustering heatmap was visualized (Figure 5.3B). Distinct subsets were 
immediately obvious, with favorable genes enriched in Protein processing (p=4e10-5), 
Arginine and proline metabolism (p=7e10-3), and glutathionie metabolism (p=8e10-
3), while the unfavorable genes were not significantly enriched in any of the KEGG 
pathways. Dihydropyrimidine dehydrogenase (DPYD) was the only metabolic gene 
identified in the unfavorable set, consistent with its biological function and previous 
reports of its predictive power in 5-FU treated rectal cancers (Huang et al., 2013).  
Next, I compared response to 5-FU between the two subgroups of cell lines 
identified by k-means clustering of the favorability matrix. The subgroup of cells 
enriched with the unfavorable gene expression signature had a significantly higher IC-
50 for 5-FU (higher resistance), than the subgroup enriched with the favorable 
signature (Wilcox test p= 1.96e-11; Figure 5.3C). Together, these results confirm the 
generalizability of this method for identification of novel subgroups with distinct 
response to 5-FU, and also find a specific metabolic target (DPYD) as a marker of cell 
line sensitivity.  
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Figure 5.3— Combined gene expression signatures of response to 5-FU across colon 
cancer cell lines identify novel subgroups.  
A) Schematic of the step-wise filtering used for gene selection in colon cancer (COSMIC 
COAD-READ).  
B) Hierarchical clustering of heatmap of the discretized gene favorability scores. Columns 
represent genes and rows represent individuals. Favorable scores are shown by the color red 
(F=1), unfavorable by blue (F= -1), and neutral by yellow (F=0) (see Methods).  
C) Box-plots comparing the resistance to 5-FU (log IC-50 values) between the two cell line 
subgroups identified in part (B) (error bars show the range of the data points in each group). 
 
5.3.2.2 Response to Gemcitabine in pancreatic cancer cell lines 
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I next considered all COSMIC cell lines derived from pancreatic origins 
regarding their sensitivity to Gemcitabine. This set included only 17 cell lines, limiting 
the statistical power of this analysis. Only 201 genes passed my initial filtering (Figure 
A3.S3A). A visualization of the favorability heatmap illustrated two distinct clusters 
of genes, one with a mostly favorable expression score, but the second one with 
heterogeneous scores across the cell lines (Figure A3.S3B). Pathway analysis of the 
favorable set identified Chemical carcinogenesis (p=7e10-3), glutathionie metabolism 
(p=2e10-2), and Drug metabolism (p=4e10-2) KEGG pathways significantly enriched, 
while the unfavorable set was enriched in Adherens junctions (p=5e10-3), Bacterial 
invasion (p=6e10-3), and Glycophospholipid synthesis (p=7e10-3). Finally, 
comparison of sensitivity to Gemcitabine between two of the cell line subsets with 
distinct signatures found a significant difference in IC-50 (Wilcox p-value= 8e10-4; 
Figure A3.S3C), showing the power of this approach even when applied to such small 
data sets.  
5.3.3 Analysis of metabolite profiles of cell lines identifies variability in metabolic 
markers 
 
So far my results have shown considerable contribution from the metabolic 
gene expression network in distinguishing drug response subsets within human tumors 
as well as cancer cell lines. Careful consideration of two nucleotide metabolism 
inhibitors — 5-FU and Gemcitabine —revealed subtle differences in gene expression 
signatures associated with favorable and unfavorable response in each case, suggesting 
that even closely similar cytotoxic agents may act through different cellular pathways 
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and therefore be explained by different markers. My approach used gene expression 
levels of metabolic enzymes as surrogates for metabolic fluxes or enzyme activities. 
Next, to gain a more direct measure of metabolic states, Seong H. Jeong — an 
undergraduate student that I supervised— attempted to complement my analyses by 
taking advantage of direct metabolite consumption and release measurements across a 
panel of 60 cancer cell lines. The metabolic activities in the form of consumption or 
release rates (CORE) (Jain et al., 2012) were correlated with IC-50 values of 17 
antimetabolite compounds (see Methods for the complete list; Figure 5.4A). 
Interestingly, the release rate of phosphocholine showed a strong negative correlation 
with sensitivity to 6 of the antimetabolite agents tested (Figure 5.4A). This result 
suggests that cells that have a higher rate of phosphocholine production are less 
sensitive to drug treatments, consistent with my gene expression results showing the 
enrichment of phospholipid metabolic genes in response signatures. Similarly, 
previous studies have shown that an increase in phosphatidylcholine affects cancer cell 
membrane dynamics and correlates with higher tumor malignancy and poorer overall 
survival (Beloribi-Djefaflia et al., 2016). Jeong’s results agree with previous reports 
suggesting that increased amounts of phosphatidylcholine in the membrane of cancer 
cells may protect them from the uptake and toxicity of drugs, while high activity of 
enzymes that degrade phosphatidylcholine renders cells more sensitive to drug 
treatments, potentially contributing to a more favorable outcome for chemotherapy 
(Beloribi-Djefaflia et al., 2016). An example of a specific interaction that was detected 
at the level of metabolite consumption and release is sensitivity to Fludarabine— a 
purine analog— that was significantly associated with CORE of 2-deoxycytidine 
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(Figure 5.4A). Together, these results identify relationships between directly measured 
metabolic signatures of cancer cells and their sensitivity to antimetabolite 
chemotherapies, and also demonstrate variability among the 17 antimetabolites tested 
regarding their interaction with cellular metabolism.  
 
Figure 5.4— Analysis of additional determinants of sensitivity to antimetabolite agents 
demonstrate variability among these agents. 9 
A) The significance of association between metabolic profiles (consumption and release rates 
(CORE)) and sensitivity to drugs (-log (IC-50)) was assessed using spearman correlations 
(SC) across the NCI-60 cell line panel. The y-axis shows negative log-10 of the corresponding 
correlation p-values for only the significant associations found (q-value < 0.05).   
B) Hierarchical clustering of the Pearson similarity matrix between the IC-50 values of 17 
antimetabolite agents across the NCI-60 panel. The diagonal shows correlation of each drug 
with itself (=1). The yellow boxes show three distinct clusters of drugs.  
																																								 																				
9  Credit goes to Seong H. Jeong. 
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C) Spearman correlation coefficient (SCC) between proliferation rate (kp) and sensitivity to 
each drug (-log (IC-50)) is shown. Solid bars show significant correlations (FDR-corrected q-
value <0.05).  
D) Spearman correlation coefficient (SCC) between cell volume (V) and sensitivity to each 
drug (-log (IC-50)) is shown. Solid bars show significant correlations (FDR-corrected q-value 
<0.05).   
E) Spearman correlation coefficient (SCC) between growth rate (kg) and sensitivity to each 
drug (-log (IC-50)) is shown. Solid bars show significant correlations (FDR-corrected q-value 
<0.05). 
 
5.3.4 Sensitivity to antimetabolite agents is more specific than previously 
appreciated 
 
The gene expression results suggest that despite common cytotoxic effects of 
antimetabolite agents, they might have distinct biological markers in cells that are 
specific to the target metabolic pathways. Also, the analysis of metabolic CORE 
profiles in cell lines suggested that markers of sensitivity to antimetabolite agents 
might be more variable than previously appreciated. This motivated us to further 
assess specificity of determinants of response across a larger set of antimetabolite 
agents. We considered a set of 17 antimetabolite chemotherapeutic compounds (see 
Methods for the complete list).  These agents target enzymes involved in a number of 
metabolic pathways including de novo nucleotide metabolism, amino acid 
metabolism, and glutathione metabolism. To assess the extent of correlation in the 
sensitivities of cell lines to these compounds, Jeong computed a similarity matrix of 
pairwise Pearson correlations between the IC-50 values for antimetabolite.  Three 
distinct clusters were identified by hierarchical clustering: a cluster including 
Thiopurine and Thioguanine, a cluster for an anti-folate Methotrexate (MTX) and 
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pyrimidine analogs (5-FU and 5-FUDR), and a cluster for other purine analogs (Figure 
5.4B). The antimetabolite compounds in the second cluster shared TYMS as a target 
enzyme.  This analysis suggests that in general, compounds with common mechanisms 
of action tend to have similar sensitivity profiles across cell lines.   
A common notion is that cytotoxicity of antimetabolite chemotherapies occurs 
in all rapidly dividing cells and thus lacks specificity. It has also been proposed that 
cell size, cell proliferation, and cellular metabolism are invariably coupled (Dolfi et 
al., 2013).  Given that data on proliferation rate, cell size, and metabolic profiles are 
readily available for the NCI-60 cell lines, we sought to re-investigate these 
relationships in the context of association with cell line sensitivities to antimetabolite 
agents.  Spearman rank correlations between IC-50 and proliferation rate were 
computed and revealed significant positive correlations (q-values< 0.05 in all cases 
except Capecitabine and Fluodarabine phosphase; Figure 5.4C). When the cell 
volumes were correlated with responses to antimetabolites, all compounds except for 
Capecitabine showed a negative correlation (four compounds had q-value<0.05) 
(Figure 5.4D). Together, these results confirm that cytotoxicity, as defined as the 
concentration of drug needed to achieve toxic dosages, is lower with smaller cells that 
also tend to divide more rapidly due to their size (Dolfi et al., 2013). The significant 
negative correlation between proliferation rate and cell volume suggested that to 
obtain an overall growth rate corresponding to the rate of synthesis of 
macromolecules, the proliferation rate should be corrected for cell volume (see 
Methods). Jeong next correlated dose responses with the volume-corrected 
proliferation rate, referred to hereinafter as the “growth rate” (Figure 5.4E). The strong 
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correlations that were observed between IC-50 values and proliferation rate were 
absent when considering the growth rates (Figure 5.4E).  Thus, although cytotoxicity 
of antimetabolite agents appears highly non-specific with selectivity pertaining only to 
proliferation rate, these effects are completely removed when considering an overall 
growth rate. This suggests that unlike the common notion, variation in sensitivity to 
antimetabolite agents is not explained by differences in the actual rates of production 
of macromolecules in cells.  
 
5.4 Discussion 
 
The specificity of antimetabolite chemotherapeutic agents has long been 
questioned and previous reports have not reached a consensus about a prognostic 
value for expression levels of target enzymes for most of these agents. Given that the 
metabolic network is composed of complex interactions between multiple enzymes 
and pathways, we hypothesized that perhaps by defining gene signatures instead of 
individual enzyme markers, we would gain power in distinguishing subgroups of 
tumors with differential response to therapy.  
Here, I introduced an unbiased approach for the assessment of combined 
prognostic power of expression of multiple genes and used this platform to define 
favorable and unfavorable signatures. Notably, I showed that these signatures allow 
for distinguishing novel poor prognosis (high progression rate) from good prognosis 
(low progression rate) subgroups far more robustly than individual target genes. 
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Importantly, since the gene selection steps control for expression differences related to 
other important clinical and genetic attributes of response, I am assured that the gene 
signature analysis captures information about response subgroups beyond the already 
established markers. 
In both studied cases of 5-FU in colon cancer and Gemcitabine in pancreatic 
cancer, I found that expression of metabolic pathways related to direct targets of the 
drugs are enriched in the unfavorable gene set. This confirmed that tumors with higher 
activity of target pathways require higher doses of drug to elicit the inhibitory 
response and are therefore more resistant to treatment.  However, my results 
discovered that metabolic state of cells are not fully reflected in the expression levels 
of individual target enzymes, but rather captured more robustly in the collection of 
functionally and chemically linked enzymes in pathways. Although I was only able to 
illustrate the applicability of my method in two independent cohorts of human tumors 
due to data limitations, results suggest generalizability of this method to other 
antimetabolite agents as well.  
Gene signatures associated with favorable and unfavorable response for 5-FU 
and Gemcitabine exhibited functional similarities overall, but distinct markers for each 
drug were also discovered. In both cases of 5-FU and Gemcitabine, high expressions 
of the target metabolic pathways (i.e. nucleotide metabolism) were associated with 
unfavorable outcome, while high expression of lipid metabolizing pathways were 
associated with favorable outcome. These point to common general mechanisms of 
cellular response to these drugs. However, a deeper look into specific genes and 
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pathway within the signatures for 5-FU and Gemcitabine identified some differences. 
For instance, while One-carbon metabolism and Nucleotide sugar metabolism were 
identified as the unfavorable signature for 5-FU, Pyrimidine metabolism was 
discovered in the case of Gemcitabine. Furthermore, TYMS was among the 
unfavorable genes for 5-FU, while RRM1 and RRM2 were among the unfavorable 
genes for Gemcitabine. Together, these results suggest that despite similarities in 
overall mechanisms of action, antimetabolite agents have specific biological markers 
that have not been very well characterized and appreciated in the past.  
My parallel analyses of cancer cell line sensitivities to the same 
chemotherapeutic agents also proved useful in identifying distinct subgroups using the 
gene signature approach. Other than lipid metabolic genes, the gene sets identified as 
favorable and unfavorable signatures in cell lines did not completely match that 
identified from the analysis of PFS in human tumors.  The main sensitivity predictor 
in vitro seemed to be Glutathione metabolism and Drug metabolism that were found in 
both cases of 5-FU and Gemcitabine to be associated with favorable outcome (i.e. 
higher sensitivity of cells to drug treatment). This observation is consistent with 
previous reports showing a critical role for glutathione metabolism in detoxification 
and protection against drugs in vitro (Traverso et al., 2013). These results illustrated 
that despite the availability and convenience of using cell lines as models of human 
tumors for drug response studies, analysis of patient tumors is advantageous in that it 
provides insights that are not fully reflected in cancer cell lines, potentially due to 
unwanted effects of culture media.   
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Together, our analyses of human tumors and cancer cell lines elucidated 
considerable variability among different antimetabolite agents, as well as specificity in 
metabolic markers of sensitivity to them. These demonstrate that despite the common 
notion, different classes of antimetabolite agents vary according to their distinct 
cellular functions.  Our results suggest that potentially important biological markers of 
response to antimetabolite compounds exist, and a better understanding of these 
factors will provide useful insights for clinical decision-making. Notably, we showed 
that gene expression signatures have significant power to capture part of the 
previously unexplained variation in patients’ responses to 5-FU and Gemcitabine in 
colon and pancreatic cancers, respectively. Future studies using larger cohorts of 
human tumors with well-annotated patient follow-up information can provide valuable 
additional insights about antimetabolite response signatures.  
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5.5 Methods 
5.5.1 Survival analyses  
5.5.1.1 Individual genes 
 
TCGA progression free survival (PFS) across COAD and PAAD were 
obtained through the cBioPortal for cancer genomics. Level-3 RNA-seq RSEM gene-
normalized counts were also downloaded through the GDC portal 
(https://gdc.cancer.gov/). The values were log2 normalized and in each data set, genes 
with a count of 2 or smaller in over 80% of the samples were removed as low-count 
genes. I used cancer progression as the “event” in Cox models and last day of follow-
up to right censor the data in cases where no progression was documented. R packages 
“survival” was used for univariate survival analyses independently for all genes 
(Figure 5.1A and Figure 5.2A).  
5.5.1.2 Gene signatures 
 
When considering survival analysis for subgroups identified by my favorability 
scoring method (described in the following), I used the subgroup assignments based 
on the k-means clustering of favorability matrix in each case to label samples as 
“favorable signature group” and “unfavorable signature group”. Subsequently, Cox 
regression was performed to assess the significance of the difference between PFS of 
the two groups as shown in Figure 5.1C and Figure 5.2C.  
5.5.2 Cell line sensitivity analyses 
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For the COSMIC cell lines, RMA-normalized gene expressions were obtained 
through the Sanger Institute (http://cancer.sanger.ac.uk/cosmic). Genes with a 
coefficient of variation of 0.05 or smaller were removed. To test association with drug 
response, inhibitory concentration (IC-50) values were correlated with gene 
expression values and a Kendal tau was calculated. Genes with a correlation of over 
0.2 and an associated p-value of 0.01 or less were selected for subsequent 
discretization step (Figure 5.3A and Figure A3.S3A).   
5.5.3 Gene selection approach 
 
Genes that passed my first filter i.e. showed a significant association with PFS 
(Cox p-value<0.05), were subsequently evaluated by additional clinical and genetic 
attributes. To eliminate genes whose expression levels were significantly affected by 
TP53 mutational status, I compared expression levels in TP53 mutant with TP53 wild-
type samples and a Wilcox non-parametric test was used to assess statistical 
difference. This test allowed filtering out genes significantly associated with TP53 
mutation. For other clinical attributes such as cancer stage, patient age, tumor grade, 
and nodal status, the Spearman correlation was used to test associations between gene 
expression and these clinical factors across samples. Finally, genes that passed all of 
the above filters were used for subsequent discretization analyses.  
5.5.4 Survival analysis using expression of target enzymes 
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To assess the strength of direct target enzymes of 5-FU and Gemcitabine as 
markers of PFS, I considered expression levels of TYMS and RRM1 (RRM2), 
respectively.  I first used the function “cutp” in the R package “survMisc” to find the 
best cutting point in the continuous gene expression. I the used this cutting point as a 
threshold to divide the samples into two groups of “low” and “high” expression for 
samples below and above the cut-point, respectively.  
5.5.5 Discretizing gene expressions and defining favorability scores 
 
I used the following criteria to discretize the signature gene expression matrix 
and label expressions “favorable” or “unfavorable” based on their relationship with 
PFS. A gene was assigned a value of 1 and was considered favorable if its high 
expression (higher than median plus half of the standard deviation for that gene) co-
occurred with better prognosis, and a value of -1 (unfavorable) if its high expression 
co-occurred with poor prognosis in univariate Cox regression: 
 
, where Eij represents expression of gene “i” in individual tumor “j”.  
For discretizing cell line expression data, the following modified scheme was 
used where cell lines were labeled either “sensitive” or “resistant” to a drug if their IC-
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50 value was at either extremes of the distribution of IC-50 values for that given drug 
across all cell lines.  
 
, where Eij represents expression of gene “i” in cell line “j”.  
5.5.6 Pathway enrichment analyses 
 
Pathway enrichment analysis was performed on the resulting gene list for each 
cancer type using Enrichr (Chen et al., 2013).  P-values from the Fisher’s exact test are 
reported for significant (p<0.05) KEGG pathways.  
5.5.7 Analyses of non-gene expression cell attributes 
 
Jeong obtained IC-50 values for the 17 antimetabolite compounds across a 
panel of 60 cell lines from the National Cancer Institute (NCI-60) (Dolfi et al., 2013). 
To complement my gene expression analyses, we took advantage of the NCI-60 cell 
line panel where in addition to the comprehensive annotation of cell lines, a previous 
study has quantified the consumption and release rates (CORE) of hundreds of 
metabolite by each of these cell lines. Jeong obtained cell volumes, proliferation rates, 
CORE values, and dose response sensitivity information (IC-50 values) for 17 
antimetabolite drugs across this cell line panel 
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(https://dtp.cancer.gov/discovery_development/nci-60/). CORE values are positive if a 
metabolite is released into the media by cancer cells and is negative if the metabolite is 
consumed. The list of these antimetabolic agents is as follows: Gemcitabine, 
Methotrexate, Pemetrexed, Thioguanine, Thiopurine, Fluorouracil, 5-Fluorouracil 
deoxyriboside, Hydroxyurea, Ara-C, Azacytidine, Cladribine, Decitabine, Pentostatin, 
Cytarabine, Fluodarabine phosphate, Clofarabine, and Capecitabine.  
5.5.8 Growth rate calculations 
 
We obtained growth rate by correcting proliferation rates for volumes. At time 
zero - right after the cell division, the cell volume (V0) is the minimum. At time T1, the 
cell gets bigger to V1. If we define growth rate (kg) as the increase of cell volume per 
time it takes, we can come up with the equation below: 
 
!𝟏 = 𝑽𝟎 + 𝑻𝟏𝒌𝒈 
 
At doubling time (Td), the cell will divide into two and we assume two divided cells 
will have the same volume as the initial volume, V0.  
 
𝑽𝟐 = 𝟐𝑽𝟎 = 𝑽𝟎 + 𝑻𝒅𝒌𝒈 
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𝑽𝟎 = 𝑻𝒅𝒌𝒈 									− (𝟏) 
 
𝑻𝒅 = 𝐥𝐧𝟐𝒌𝒑 											− (𝟐) 
 
𝑽𝟎 = 𝐥𝐧𝟐𝒌𝒑 𝒌𝒈 −	 1 , (𝟐) 
 
Jeong then solved the above equation to obtain the following equation for growth rate: 
 
𝒌𝒈 = 𝑽𝟎𝒌𝒑𝐥𝐧𝟐  
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CHAPTER 6: CONCLUSIONS 
 
6.1. Cancer as a heterogeneous disease 
 
 Due to instability and substantial heterogeneity, cancer is not 
considered one disease but a collection of multiple diseases.  Variation exists between 
and within cancer types, between cancer subtypes, and even among clonal populations 
of cells within an individual tumor (McGranahan and Swanton, 2015). Such multi-
level heterogeneity makes treatment of cancer exceptionally complex and challenging.  
 Though promising, personalization of therapy strategies for cancer 
patients requires a deeper understanding of various aspects of the heterogeneity in 
cancer (Chin et al., 2011). Altered metabolism is one of the relatively newly 
recognized features of cancer that is not yet fully characterized across different human 
cancers (Pavlova and Thompson, 2016).  In this dissertation, I focused on the study of 
a specific metabolic network —one-carbon (1-C) metabolism— and provided insights 
on the heterogeneity with respects to various functions of 1-C metabolism in human 
cancers.  
6.2. Summary of results 
 
 The main goal of my thesis was to characterize some of the important 
roles of one-carbon metabolism across human tumors in an unprecedented systematic 
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and quantitative manner.  Findings from this work have significance in providing 
molecular insights about cancer metabolism, novel computational tools for analysis of 
high dimensional multi-layer genomic and epigenomic tumor data, and clinical and 
translational information toward personalized medication and dietary intervention in 
cancer patients.   
 In chapter 2, I studied the amino acid serine and its utilization across 
hundreds of human tumors. First, using a computational framework that I introduced, I 
estimated pathway activities from gene expression profiles of tumors. Comparative 
analyses at this level revealed significant heterogeneity among cancer types with 
respect to how they metabolize serine. Furthermore, co-regulation analysis revealed 
significant correlation between nucleotide and glutathione synthesis in all cancer types 
in the study, suggesting a common feature of cancers.  I next used a panel of cancer 
cell lines to directly test the computational flux predictions. I used serine tracing in 
vitro followed by metabolomics. The experimental flux calculations agreed with my 
computational predictions in illustrating that the bulk of the serine flux is shunted 
toward nucleotide and glutathione synthesis in colon cancer. Furthermore, this study 
introduced a novel approach for estimating metabolic fluxes from pathway-level gene 
expression profile of tumors. This is significant as measuring metabolic fluxes in 
human tumors experimentally is not simple with current technology, especially for 
larger sample sizes. I showed that although expression levels of individual enzymes do 
not accurately reflect actual enzyme activities, combined gene expression information 
across metabolic pathways provide a reasonable estimate of pathway activities in 
tumors. Another important feature of flux distribution through one-carbon metabolism 
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that was identified by my computations and in vitro analyses was the de-coupled folate 
and methionine cycle fluxes. Together, my results revealed common as well as cancer-
specific utilization of serine through one-carbon metabolism in a quantitative manner.   
 In the 3rd chapter, my main goal was to investigate the biochemical link 
between one-carbon metabolism and methylation by quantifying the extent that cancer 
DNA methylation profiles are predictable by the activity of one-carbon metabolism. 
To this end, I obtained multiplatform information on thousands of human tumors 
through the cancer genome atlas (TCGA) and applied computational modeling and 
machine-learning algorithms to quantify determinants of variation in DNA 
methylation between individual tumors of the same cancer type (inter-individual 
variation). I was able to show that a number of one-carbon metabolic enzymes— 
especially methionine adenosyl transferase (MAT) in the methionine cycle— have a 
significantly large predictive power of DNA methylation at multiple levels studied. 
Furthermore, my results illustrated that this relationship between one-carbon 
metabolism and DNA methylation exists at functionally important chromatin regions 
and overlaps with important cancer genes. Finally, I performed survival analyses and 
provided evidence for the clinical relevance of metabolic regulation of the DNA 
methylome by showing that loss of regulation of DNA methylation by the methionine 
cycle is associated with poorer overall survival. This is consistent with the model of 
cancer as a dysregulated epigenome that suggests loss of epigenetic stability provides 
cancer cells with higher plasticity and adaptive advantage (Timp and Feinberg, 2013).  
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 In chapter 4, I assessed the physiological relevance of potentials for 
dietary intervention with the amino acid methionine in humans. Using dietary records 
as well as serum metabolomics on a cohort of human subjects, I studied methionine 
levels in the serum. Results confirmed that the physiological range of methionine 
encompasses the methionine concentrations previously shown to affect epigenetics. 
Furthermore, I used computational modeling to identify the determinants of serum 
methionine. My models showed a ~30% contribution from diet in explaining overall 
variation in serum methionine, ~30% for clinical factors (e.g. age, gender, etc), and 
~20% unexplained, probably due to genetic differences between individuals. I also 
further identified the main food categories of dietary determinants of methionine in the 
serum. Together, these results confirm the relevance of potential epigenetic 
modifications through one-carbon metabolism using dietary intervention with 
methionine.  
 Finally in chapter 5, I focused on translating my findings about the 
important roles of 1-C metabolism in cancer into more clinically relevant discoveries 
by investigating patient response to antimetabolite chemotherapies.  I introduced a 
novel approach for identifying gene expression markers of prognosis in an unbiased 
manner and showed that this approach can successfully separate novel poor prognosis 
from good prognosis subgroups of patients beyond the power of features already used 
in the clinic (e.g. tumor grade, stage, TP53 mutation, etc). Furthermore, I illustrated 
that although the expression levels of individual enzyme targets of antimetabolite 
agents do not strongly associate with prognosis subgroups, the combined activity of 
multiple enzymes within a metabolic pathway is a strong predictor of therapy 
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outcome. Furthermore, using multiple independent datasets on primary human tumors 
as well as cancer cell lines, I showed that despite the common notion about the non-
specific cytotoxic nature of most antimetabolite chemotherapies, there is considerable 
variability among different classes of such agents, and response to these agents 
strongly correlates with specific metabolic features of tumors suggesting potentials in 
utilizing these metabolic signatures as biomarkers for clinical decision-making in 
cancer therapy.  
6.3. Limitations and future directions 
  
 My work provides a framework for the study of inter- and intra- cancer 
type metabolic heterogeneity using genomic profiles of tumors. I have analyzed over 8 
different human cancer types and thousands of individual tumors within each type for 
the work presented in this thesis. In the future, larger datasets including additional 
cancer types and subtypes can be analyzed using the tools developed and described 
here, to fully represent the complete collection of human cancers and complement our 
current understanding of this field.  
 Furthermore, it is known that individual tumors are composed of 
multiple clonal populations that typically exhibit great variability. This is an important 
aspect of what makes cancer such a complex condition to understand and treat. The 
work presented here was performed using data on bulk tumor samples from individual 
patients, and therefore did not have sufficient resolution for analyzing within-tumor 
heterogeneity.  In the future, by taking advantage of the analyses of multiple section 
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sub-sections from the same tumor or the novel technology of single cell genomics 
(Gawad et al., 2016), similar analyses can be performed with higher resolution using 
information about sub-clonal and cell-to-cell variability within a tumor. Understanding 
this level of heterogeneity is crucial for personalized medicine and informed decision-
making, as well as understanding tumor evolutionary dynamics. 
 
 The bulk of the work presented here involved computational analyses 
and modeling of cancer using high dimensional multi-platform data on human tumors. 
In most cases, computational validation of models was reached using independent test 
sets. In the case of the serine fate study presented in chapter 2, the computational 
results were also complemented by experimental validation in cancer cell lines. 
Though rigorous computational cross-validation was used to assure the accuracy of in 
silico findings throughout the thesis, future experimental procedures that would 
directly test some of the main results presented here would provide further support for 
the role of 1-C metabolism in human cancers. Future studies on mechanistic details of 
the relationship between epigenetics and one-carbon metabolism, as well as potentials 
for dietary intervention with methionine in humans are needed to directly and 
mechanistically test some of my predictions.  
 Finally, the clinical translation of my findings in the area of 
identification of patient subgroups that would benefit from antimetabolite 
chemotherapies is a critical aspect. Current practice in the clinic does not involve use 
of metabolic markers for making decisions about prescribing antimetabolite 
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chemotherapies. I have provided evidence for potential advancements that can be 
made in this area. However, an important limitation in modeling drug response using 
the TCGA data is the lack of uniformity in therapy regimens as most patients received 
combination of multiple treatments. Furthermore, given that all TCGA samples had 
undergone adjuvant chemotherapy, progression in this group remains an indirect 
measure of response of the tumor to drug treatment with the assumption that 
remaining tumor cells after surgery represent the original tumor in patients. Although I 
was able to obtain interesting results in spite of these limitations and confounding 
factors inherent in the data, the field would benefit greatly from the availability of 
larger datasets with neo-adjuvant as well as adjuvant therapy cohorts and a more 
uniformly controlled chemotherapy combination since the unwanted variability in the 
current TCGA data substantially compromises the analysis and discovery power.  
 Despite limitations in the availability and types of data on human 
tumors, my thesis provides valuable computational framework and tools for studying 
complex human diseases using genomic information, sheds light on the biology of 
one-carbon metabolism in cancer, characterizes how different human cancers utilize 
this metabolic network toward their needs, quantifies the contribution from this 
metabolic network in cellular epigenetics, elucidates potentials for dietary intervention 
therapies using the intermediates in one-carbon metabolism, and demonstrates how 
these findings can be translated into clinically useful information.  
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APPENDIX 1: SUPPLEMENTARY INFORMATION FOR CHAPTER 2 
 
Supplementary Methods. 
Contingency table comparing mitochondrial vs. cytosolic isoforms in the 
context of tumor/normal over-expression (combined across all cancer types in study). 
This test was done only on enzymes that have both mitochondrial and cytosolic 
isoforms included in the SGOC network (6 mitochondrial and 5 cytosolic enzymes, 4 
cancer types). Fisher’s exact p-value = 0.02 
 
  Over-expressed in tumor Not over-expressed in tumor 
Mitochondrial isoforms 12 12 
Cytosolic isoforms 3 17 
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Figure A1.S1— Clustering of individual tumors based on gene expression profiles.  
 
A) Principal component analysis on 100 randomly picked samples from each cancer 
type (400 samples total). The second principal component (PC2) is plotted against the 
first principal component (PC1). B) Principal component analysis on 100 randomly 
picked samples from each cancer type (400 samples total). Different cancer types are 
shown by letters (B:Breast, O:Ovary, C:Colon, L:Lung). The second principal 
component (PC2) is plotted against the first principal component (PC1). Fraction of 
variation explained by each PC is shown as R^2. 
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Figure A1.S2— Steady state labeling distribution on serine and glycine.  
 
Schematic showing the mass isotopomer distribution (MID) patterns observed for 
serine and glycine in my 13C-serine tracing experiment (right) along with the 
chemical reactions explaining the patterns observed (left). 
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Figure A1.S3— Clustering of metabolite MIDs.  
 
Heatmaps of abundance ratios of some of the labeled isotopomers from the 13C 
experiment. On the right, hierarchical clustering is shown for the 8 colon cancer cell 
lines in the columns and the labeled metabolites in rows. The left heatmap shows the 
similarity matrix of pairwise Spearman correlations across labeled isotopomers. 
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Figure A1.S4— Association between nucleotide synthesis and redox metabolism. 
 
Scatterplots of average pathway expressions in TCGA colon cancer samples. A 
significantly positive association (regression p-value<0.0001) is seen in all three cases 
between NADPH pathway and glutathione, purine, or thymidine pathways.  
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Table A1.S1— Calculated SGOC network fluxes across 8 cell lines.  
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8 
SW
48 
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48 
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C-
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+ 
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Estimated fluxes and associated fitting errors are listed. All fluxes are fitted or 
calculated based on flux balance (exceptions are gcs, shmt2-, x_methf- and dil_methf 
that were fixed).  Results from a Monte-Carlo simulation using parameters that reflect 
HCT116 cells are also shown (MC-ave: average flux from 500 iterations; MC-sd: 
standard deviation; MC-cv: coefficient of variation).  
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APPENDIX 2: SUPPLEMENTARY INFORMATION FOR CHAPTER 3. 
 
Figure A2.S1—Pan-cancer analysis of global and local DNA methylation variation. 
 
A) Variations in global DNA methylation are shown as measured by averaging the 
genome-wide value per sample. Values range between 0 and 1, with 1 indicating 
maximum methylation. Each point represents a unique tumor.  
B) Schematic summarizing the approach used for dividing the genome into 10 kb 
intervals and calculating local DNA methylations.  
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C) Variations in local DNA methylation. Each point represents a unique sample, and 
local DNA methylation is calculated as the average value across all selected 10 kb 
regions. 
D) Total number of 10 kb bins across the genome with variable DNA methylation (sd 
> 0.2) is shown for each cancer type.  
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Figure A2.S2— Assessing models of local DNA methylation. 
 
A) The y-axis shows the fraction of regions where DNA methylation was predicted 
with MSE smaller than 0.04 using the integrative models in each cancer.  
B) Density plots resulting from positional annotation of regions where DNA 
methylation was most predictable (smallest MSEs) by the integrative models. Distance 
to nearest gene’s transcription start site (TSS) is shown on the x-axis in kilobases.  
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Figure A2.S3— Comparison of my gene expression variables with popular gene 
families. 
 
Comparison of original gene expression variables with 5 popular gene sets was 
considered: Receptor tyrosine kinases (RTK), Receptor serine kinases (RSK), Toll like 
receptors (TLR), MAPK signaling (MAPK) and WNT signaling (WNT) families. The 
y-axis shows the average rank of each gene expression category based on average 
variable importance score across all Random Forest models of local DNA methylation 
in brain cancer (Error bars show the minimum and maximum value in each group). 
Significance of p-values associated with the Mann-Whitney test between the ranks 
across all models is shown (***: <0.0001; see Methods).  
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Figure A2.S4— Results of modeling local DNA methylation. 
 
A) Contributions of variable classes to local DNA methylation are shown according to 
Elastic Net average variable usage (see Methods). The width of a given ribbon 
represents the relative value for the contribution of the corresponding variable class in 
the corresponding cancer type, with thicker ribbons showing higher relative 
contributions. 
B) Contributions of variable classes to local DNA methylation are shown according to 
Random Forest average variable importance (see Methods). 
C) The relative contributions of met cycle variables to local DNA methylation were 
calculated according to the Elastic Net integrative models with MSE<0.04. The y-axis 
shows the fraction of the 10 kb regions wherein each variable was selected for 
prediction of DNA methylation (variable usage). 
D) The relative contributions of met cycle variables to local DNA methylation were 
calculated according to the Random Forest integrative models with MSE<0.04. The y-
axis shows average variable importance score across all models. 
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Figure A2.S5— Annotation and evaluation of metabolically regulated regions. 
 
A) Density plots resulting from positional annotation of peaks identified in each 
cancer type by the genome-scanning algorithm described in Figure 3.3 are depicted. 
Distance to nearest gene’s TSS is shown on the x-axis in kilobases. 
B) Density plots of the distribution around nearest gene’s TSS for 10000 randomly 
selected probes along the Illumina Infinium HumanMethylation 450K BeadChip 
arrays are shown. 
C) Zoomed-in view from part “A” to visualize the distribution of peaks immediately 
surrounding the TSS region.  
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D) Zoomed-in view from part “B” to visualize the distribution of probes immediately 
surrounding the TSS region.   
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Figure A2.S6— Test of specificity of the metabolically regulated regions for 
correlation with met cycle expression. 
 
A) Diagram describing the method used for testing specificity of correlation peaks for 
the met cycle genes vs. random genes. A p-value is calculated for each peak by 
comparison to 500 random genes (see Methods). 
B) Density plot of the distribution of randomization p-values for all peaks. Shaded 
area shows significant p-values (<0.05) indicating peaks that were specifically and 
non-randomly correlated with the met cycle genes.  
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Figure A2.S7— Functional annotation of metabolically regulated regions of the 
epigenome. 
 
A-D) Pathway enrichment analyses results in cancers of breast, kidney, bladder, and 
prostate. Functional annotation analyses were performed on lists of genes located 
within peaks of correlation between met cycle and DNA methylation in corresponding 
cancers.  
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Figure A2.S8— Modeling DNA methylation at cancer gene promoters and gene 
bodies. 
 
A) Fraction of cancer genes that were predictable by met cycle genes alone with test 
set prediction error (MSE) of 0.01 or smaller. 
B) Fraction of genes that were predictable by the integrative models with test set 
prediction error (MSE) of 0.01 or smaller.  
C) Fraction of Elastic Net models in which the met cycle variables was selected by the 
integrative approach in each cancer type. 
		 178	
D) Contribution of variable classes to cancer gene DNA methylation according to 
Random Forest average variable importance of each class (see Methods). The width of 
a given ribbon represents the relative value for the contribution of the corresponding 
variable class in the corresponding cancer type, with thicker ribbons showing higher 
relative contributions. 
E) Contribution of variable classes to cancer gene DNA methylation according to 
Elastic Net average variable usage of each class (see Methods).  
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Figure A2.S9— Evaluation of modeling performance using randomized responses. 
 
A) Diagram summarizing the approach used for testing the reliability of models by 
comparing cancer gene methylation values with randomized responses.   
B) Average contribution of met cycle variables to prediction of cancer gene 
methylation vs. permutated methylation values and randomly generated numbers (see 
Methods). The y-axis shows the fraction of Elastic Net models wherein met cycle 
variables were selected. Kolmogorov-Smirnov non-parametric p-values were 
calculated between the variable usage values obtained using the original methylations 
vs. permutated or random responses separately. (Significant p-values (<10e-16) were 
also obtained by comparing the Random Forest variable importance scores across the 
models in all cases (not shown). Error bars show the standard error of mean (SEM) in 
each category). 
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Figure A2.S10— Evaluation of modeling performance using randomized predictors.  
 
A) Comparison of glutathione S-transferase pi 1 (GSTP1) methylation prediction error 
by the original variables vs. random simulated variable sets of the same dimensions in 
prostate cancer (see Methods). 
B) Comparison of RAS association domain family member-1 (RASSF1) methylation 
prediction error by the original variables vs. random simulated variable sets of the 
same dimensions in prostate cancer. 
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C) Comparison of paired-like homeodomain transcription factor 2 (PITX2) 
methylation prediction error by the original variables vs. random simulated variable 
sets of the same dimensions in prostate cancer. 
D) Average MSE across 100 simulations of random predictors is shown for each of 
the responses. 
E) Comparison of prediction errors for a simulated response by variables linearly 
related to the response vs. random variable set of the same dimensions.  
F) Improvement of predictions by original variables vs. random variable (MSE-Imp= 
MSE-rand / MSE-orig) is plotted for the three example responses from my original 
dataset and also a simulated linearly-related dataset (see Methods). (MSE-rand= 
average MSE calculated using the randomly simulated variables, MSE-orig= average 
MSE calculated using the original variables) 
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Figure A2.S11— Summary of predictive modeling of DNA methylation at cancer 
gene loci. 
 
A-F) Variables that were most predictive of cancer gene methylation on average (top 
15%) are listed and ranked in order of increasing contribution (variable score= percent 
variable usage by Elastic Net averaged across all models of cancer gene body and 
promoter methylation). Variables in the serine, glycine, one-carbon (SGOC) network 
(including the met cycle genes and other SGOC genes) are shown in red and all other 
variables are shown in black. Green arrows point to previously published factors 
associated with variations in DNA methylation in each cancer type (positive controls). 
(Variable names: official gene symbols are used to show gene expression variables 
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(including “Methionine cycle enzymes”, “Other SGOC enzymes”, “Transcription 
Factors”, “Chromatin Remodelers”, and “ SAM-metabolizing enzymes”), while 
“_mut” and “_cn” suffixes following gene symbols denote “Mutations” and “Copy 
Number Variations”, respectively. For “Clinical factors”, variable names match the 
descriptors used in the TCGA clinical data files). 
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Figure A2.S12— Independent analyses of survival in TCGA cases by cBioPortal and 
PRECOG. 
 
A) Comparison of disease-free survival between patients with deep deletions in 
MAT2B or BHMT2 genes and other patients in the TCGA prostate cancer cohort. The 
plot and the log-rank test p-value were adopted from the cBioPortal.  
B) Comparison of overall survival between TCGA kidney cancer patient groups 
exhibiting high expression vs. low-expression of the met cycle genes. Plots and log-
rank test p-values were adopted from Prediction of Clinical Outcome from Genomic 
profiles (PRECOG). (MAT2B= methionine-adenosyltransferase 2B, MAT2A= 
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methionine-adenosyltransferase 2A, BHMT2= betaine-homocysteine S-
methyltransferase 2) 
Note A2.S1—Variation in DNA methylation.  
I considered an analysis of a large set of DNA methylation arrays from the 
TCGA that were collected and processed according to a standardized procedure that 
results in an estimate of the relative amount of DNA methylation at each 
oligonucleotide probe (the beta-value).  This value ranges from 0 to 1 with 1 
indicating that each allele is completely methylated(Cancer Genome Atlas, 2012).  
Arrays were used over bisulfite sequencing because of the higher availability of these 
data in a standardized format allowing for an integrative analysis.  I considered several 
tumor types with large sample sizes where both RNA-seq and DNA methylation data 
was available on each tumor (breast invasive carcinoma (BRCA), colon 
adenocarcinoma (COAD), lung adenocarcinoma (LUAD), liver hepatocellular 
carcinoma (LIHC), brain lower grade glioma (LGG), bladder urothelial carcinoma 
(BLCA), kidney renal clear cell carcinoma (KIRC), and prostate adenocarcinoma 
(PRAD).   
Upon analysis of global DNA methylation levels (average per tumor), I 
observed that variation in global methylation across tumors from the same cancer type 
is higher than the between-cancer-type variation (between-cancer-type sum of squares 
(SS)= 44%, within-cancer-type SS= 56%) (Figure A2.S1A).  This differs from what is 
typically seen in normal tissues where between-tissue type variability in DNA 
methylation exceeds within-tissue type variability by an order of magnitude(Lokk et 
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al., 2014; Ziller et al., 2013).  Thus, my results confirm increased inter-individual 
variation in DNA methylation among tumors from the same tissue of origin, consistent 
with methylation hypervariability in cancer(Hansen et al., 2011).  It is important to 
note however, that due to the nature of the current TCGA data (one sample per tumor), 
I were unable to further parse this inter-individual variation to distinguish between 
variations caused by differences between individual patients vs. differences between 
clonal populations of cells within a given tumor.  
 Since the biological function of DNA methylation occurs at specific regions of 
genomic DNA, I considered a local analysis of DNA methylation. I partitioned the 
genome into 10 kilobase (kb) regions and calculated average methylation in each 
region (Figure A2.S1B; Methods).  Notably, a previous study showed that DNA 
methylation at genomic regions with high inter-individual variation is more likely to 
be associated with expression of nearby genes, suggesting that variable regions are 
enriched for functionally active DNA methylation(Gutierrez-Arcelus et al., 2013).  I 
therefore focused only on regions with standard deviation (sd) of 0.2 or higher for the 
subsequent integrative analyses (Figure A2.S1C).  The number of such regions 
differed substantially among cancer types, with liver and bladder cancers exhibiting 
the largest number of variable DNA methylation regions (Figure A2.S1D). 
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APPENDIX 3: SUPPLEMENTARY INFORMATION FOR CHAPTER 5. 
 
Figure A3.S1—Relationship between target enzyme expression and response to 5-FU 
in colon cancer.  
 
 
A) Kaplan-Meier plot compares progression free survival in high-TYMS expression 
vs. low-TYMS expression subgroups of TCGA COAD patients.  
B) Kaplan-Meier plot compares progression free survival in high-TYMS expression 
vs. low-TYMS expression subgroups of stage III TCGA COAD patients. 
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Figure A3.S2—Relationship between target enzyme expression and response to 
Gemcitabine in pancreatic cancer.  
 
 
 
A) Kaplan-Meier plot compares progression free survival in high-RRM1 expression 
vs. low-RRM1 expression subgroups of TCGA PAAD patients.  
B) Kaplan-Meier plot compares progression free survival in high-RRM2 expression 
vs. low-RRM2 expression subgroups of TCGA PAAD patients. 
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Figure A3.S3— Identifying gene expression signatures of sensitivity to Gemcitabine 
in pancreatic cancer cell lines.  
 
A) Schematic of the step-wise filtering used for gene selection in pancreatic cancer 
(COSMIC PAAD).  
B) Hierarchical clustering heatmap of the discretized gene favorability scores. 
Columns represent genes and rows represent individuals. Favorable scores are shown 
by the color red (F=1), unfavorable by blue (F= -1), and neutral by yellow (F=0) (see 
Methods).  
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C) Box-plots comparing the resistance to Gemcitabine (log IC-50 values) between the 
two cell line subgroups identified in part B (error bars show the range of the data 
points in each group). 
